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SUMMARY 
DETERMINANTS OF VENTURE CAPITAL SUPPL Y IN THE 
CANADIAN BIOTECHNOLOGY SECTOR: FINANCING ISSUES, 
PERFORMANCE AND EVALUATION 
This doctoral dissertation contributes to the existing literature an in-depth analysis of the 
major fmancing issues and difficulties of Canadian biotechnology flillls , an estimation 
of the capacity of Canadian suppliers of capital to meet the predicted demand of 
Canadian fmns, and fmally, an evaluation of the adequacy of capital supply and demand 
in the sub-therapeutic segment of the Canadian biotech sector. 
Analysis of the financing issues and problems encountered by biotech comparues is 
based on in-depth interviews with supply stakeholders operating in Canada (the 
Montreal, Toronto, and Vancouver areas) and in the U.S. (the Boston, New York, and 
San Francisco areas). Seventy in-depth interviews were conducted between February 
and October 2001. The methodology used is similar to th at used in Bergeron, 
Kryzanowski, Gadoum, and Beaulieu, 2001-a (Bergeron et al. (2001-a) hereafter) and 
identifies the financing issues and difficulties by stage of product and company 
development for the bio-pharmaceutical, ag-biotech, and bioenvironmental segments of 
the biotechnology industry. Our study extends the Bergeron et al. (2001-a) study by 
examining the observations and perceptions of the other primary party to each fmancial 
transaction, namely the supplier of funds. We built an interview guide used to collect 
general supply stakeholders' information and a semi-structured questionnaire in which 
six main dimensions that are relevant to biotechnology fmancing, retained from the 
existing literature, were systematically explored. This is the first study to examine, on 
the ground, the financing process of a biotech firm and to analyse the issues and 
problems surrounding it. 
Capital supply estimates are obtained using a probabilistic madel that we consider the 
most appropriate to capture the supply generating process that results from the complex 
interactions between the vanous relevant factors affecting supply. The estimation 
involves simulations using initial values of key relevant variables, retained from the 
existing literature and validated through the interviews, that are expected to affect the 
flows of funds to biotech companies along with hypotheses about their mean and 
volatility and on their future behaviour as explicitly modeled by two stochastic 
processes. The variables used in the model are macroeconomie variables, market and 
sector variables, finn-specifie variables and the global availability of funds in past years. 
We contribute to the existing literature by identifying the main fmancing sources, direct 
and indirect, to the biotech sector and their proportions in the Canadian economy. We 
also innovate in using a probabilistic model to capture the stochastic nature of the 
fundamental factors affecting the supply of funds. We believe this can be extended to 
other areas in the high-tech sector. 
In order to evaluate the adequacy of capital supply and demand, we first estimate the 
capital requirements for the Canadian therapeutics sub-segment which, according to 
interviewees, shares over 80% of the total capital allocated to biotech activities, and is 
the only segment with available data about development costs and attrition rates, and a 
more complete and updated state of the pipeline of molecules for Canadian firms. Initial 
estimates of aggregate capital requirements are presented in Bergeron, Kryzanowski, 
Beaulieu, and Zorgati, 2001-b (Bergeron et al. (2001-b) hereafter). We re-estimate total 
capital requirements using an irnproved estimation method, new and updated data about 
development costs and attrition rates, and a more complete and updated state of the 
pipeline of molecules for therapeutics biotechnology fmns. In addition, unlike Bergeron 
et al. (200 1-b ), we pro vide initial estimates of the aggregate external capital 
requirements of our Canadian sample. Second, we estimate the capacity of Canadian 
suppliers of capital to meet the predicted demand of Canadian firms, and fmally we 
produce a matching of expected demand and supply of funding and evaluate the volume 
of external funding likely to come from the U.S. and other financial markets . To our 
knowledge, it is the first attempt to characterize the adequacy of supply and demand in 
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the biotech sector in Canada. Such an effort is Iikely to prevent from any wrong effect of 
a shortfall of supply of capital on reasonable tenns and costs that could impede 
Canadian firms to fully exploit their future growth opportunities. 
111 
--------- -------------- --------------------
TABLE OF CONTENTS 
CHAPTER 1: INTRODUCTION ................................................................................. 1 
CHAPTER 2: REVIEW OF THE LITERATURE ...................................................... 8 
CHAPTER 3: FINANCING-RELATED ISSUES AND DIFFICULTIES FROM 
THE POINT OF VIEW OF SUPPY SIDE ST AKEHOLDERS .. 16 
3.1 Methodology ... .. ........... .. ................ .... .. ... .................. ... ...... ... ... ... .... ............. ............ 16 
3 .1.1 Company commercialization pro cess and development stages ..... ......... .. 17 
3 .1.2 Relevant dimensions of the anal y sis and discussion guide used .. ............. 18 
3.2 Description of the interview sample of supply stakeholders .... .... ....... ...... .... .. ......... 18 
3.3 Synthesis and analyses offmancing-related issues and difficulties .... .. ................... 21 
3.3.1 Type ofproject to fmance ... ..... .. .... ... ..... ... ...... ..... .. .. .... ...... ....... ... ..... .. .. .. .. 21 
3.3.2 Perceptions ofrisk and retmn ..... ............. .......... ..... .. ..... .... ....... ... .............. 33 
3.3.3 Difficulty in valuing biotech firms .... .................. .. ...... .. ... .. .. ....... ...... ........ 36 
3.3.4 Level of owner commitment and financial participation in the project .. .. 43 
3.3.5 Disclosure of infonnation .......... .... ........ ..... ....... ....... .... .. .. ......................... 43 
3.3.6 Strategie alliances and mergers & acquisitions ........ ... ...... .... .. .................. 43 
3. 3. 7 Govemment commitment and guarantees for managing risk ... .... ....... ..... 4 7 
3.3.8 Other relevant dimensions ................... .... ... ............................................... 49 
CHAPTER 4: CAPITAL REQUIREMENTS FOR THE THERAPEUTICS SUR-
SEGMENT OF THE CANADIAN BIOTECHNOLOGY 
INDUSTRY ...... ............................................................................. ..... . 54 
4.1 General methodology for estimating capital requirements ...................................... 54 
4 02 Capital requirement estirnates 0000000000 000 0000000000 00 OOOOOOOoOOOOOOOOOOOOO OOOOOOOO o OOOo o oooo o ooooooooooooooooo 58 
4.2 0 1 Capital requirement estirnates using scenarios with no new molecule entry 
ooo oo oo o ooooo oo oooooo o ooooo oo o oo o o oooooooO o Oo OO oO O OOOOO OOOOOOOOOO O OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOoOOOOoo oo ooooooooooooOOo 58 
40202 Capital requirement estimates assuming new molecule entry into the pre-
clinical development stage 0 00 0 0 0 0 00 0 0 00 0 0 0 00 00 0 0 0 0 0 00 0 0 00 00 0 0 0 0 0 00 0 0 0 00 0 0 0 00 00 0 0 0 00 0 0 0 0 0 0 0 0 0 00 0 00 0 0 0 0 00 00 00 60 
402 03 Capital requirement estima tes for the Canadian pipeline of molecules 
public! y signalling the need for external fmancing 00 00 00 00 00 00 00 00 00 00 00 00 00 00 00 00 00 00 00 00 00 00 66 
403 Concluding remarks oooooooooooooo ooo oooo o ooooooo o oooo oo ooooooo oooo oooo oo oooo o oo oo ooooo ooooooo oo o oooooooo o ooooooooooo 68 
CHAPTER 5: CAPITAL POTENTIALLY AVAILABLE TO CANADIAN 
COMP ANIES ..................................................................................... 70 
501 Evaluation of recent capital supply to Canadian biotech firms 00 000000000000000000000000000000 70 
5 01 0 1 Main fmancing sources 00 0 0 00 0 0 0 00 0 0 0 0 00 0 0 0 0 00 0 .. .. 0 00 ... 00 0 0. 00 .. .. 0 00 0 0 00 0 0 0 0 0 0 0 00 00 0 0 0 0 0 00 0 0 0 0 00 0 70 
5 01. 2 Capital obtained by Canadian firms from each of the main sources of 
fmancing 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 73 
5 02 Evaluation based on a probabilistic mode! for the supply of funds 00 00 00 00 00 00 00 00 00 00 00 00 0 81 
5 0201 Context 00 00000 00 0 0 00 0 0 0 00 0 0 0 00 0 00 00 0 000 0 0 0 0 00 0 0 0 00 0 0 0. oo oo 00 0 0 0 0 0 00 0 0 0 00 0 0 00 0 0 0 0 00 0 00 0 0 0 0 0 0 00 0 00 0 0 0 0 00 0 .. 00 0 0 81 
5 0202 Selection and behaviour of the key variables affecting the supply of fimds 
and valuation pro cess 00 0 0 0 0 0 00 00 00 0 0 00 0 0 0 00 0 0 0 00 00 0 0 0 0 00 0 0 0 00 0 0 00 0 00 0 0 00 00 0 0 00 00 00 0 00 00 0 00 0 0 0 0 0 0 0 00 00 0 0 00 0 0 00 0 82 
5.2 03 Identification and specification of the supply of funds 0000 00 00 00 00 00 00 00 0000 0000 000 84 
5 0 2.4 Mode! constmction and calibration and initial values of the key variables 
and hypotheses 0 0 0 00 0 0 0 00 00 0 0 0 00 0 0 0 00 0 0 0 00 0 00 00 0 0 00 0 0 00 0 0 0 0 00 0 0 0 00 0 0 0 0 0 00 0 0 0 0 00 0 00 00 0 0 00 0 00 0 0 0 0 0 0 00 0 00 0 0 0 00 0 0 0 00 0 0 0 85 
5 020 5 Supply simulation results 000000000000000000000000000000000000000 0 000000000000000 0 000000000000000000 90 
CHAPTER 6: PAIRED SCENARIOS OF CAPITAL SUPPLY AND DEMAND 91 
601 Scenario construction and presentation 0 0 000 0 0 00 0 00 000 0 000 00 0 0 00 0 0 0 00 0 0 0 0 00 0 00 00 00 00 0 0 00 0. 00 000 0 0 0 0 000 0000 0 91 
602 Analysis of the most relevant paired scenarios 00 00 00 0000 00 00 00 00 00 00 00 0000 00 00 .00 .. 000000 00 00 00 0000 00 0 93 
v 
6.3 Evaluation of the adequacy of capital supply and demand ... ... .. .......... ............ ..... .. . 97 
CHAPTER 7: CONCLUDING REMARKS ............................................................ 100 
7.1 Deficiencies in our knowledge about the fmancing of Canadian biotechnology 
co1npanies ..... ...... .. .. .. .... .... ............. ......... ........... ... .. .. .... .......... ... .......... .... ...... ...... 104 
APPENDIX A: Input variables and their quantification ...... ...... .......... .. .. ........ ........ .. 107 
APPENDIX B: Description and comparative analysis of the financial data of Canadian 
and U.S. public firms ... ............. ... ... .. .... .. .. ..... ... ... ... ........ .... .... .. .... .... 112 
APPENDIX C: Interview guide ..... .... ....... ....... ..... ...... ... ..... ...... .. .. ........ ................ ... .. 121 
APPENDIX D: List of suppliers interviewed ... .... ...... ....... ....... ... ...... .. .. ... ... ..... ..... .... 135 
REFERENCES .. ........... ........ ..... ....... ... ................. .. ........ ... ............... ...... .... .. .... ... ........ 138 
Vl 
LIST OF TABLES AND FIGURES 
TABLES 
3.1 Quantitative information gathered from the Canadian and U. S. interviewees ... 20 
3.2 Quo tes of interviewed supply si de stakeholders ............ .. ...... .. .. .. ...... ...... .. .. .. .... . 52 
4.1 The development process for a pharmaceutical drug ........ .. .. .. ............................ 55 
4.2 Estima tes of the capital required to bring the current Canadian pipeline of 
molecules up to market Entry assuming no new molecule entry into the pre-
clinical development stage ............. .. ... ... .. .... .. ..... .... ... ....... ..... ............ ... .. ... .. .... .. . 59 
4.3 Capital requirement estimates for the current Canadian pipeline of molecules for 
various new molecule entry rates into the pre-clinical development stage ......... 62 
4.4 Scenario 4: Breakdown of capital requirements per stage of development for 
various new molecule entry rates into the pre-clinical development stage .... .. ... 63 
4.5 Sensitivity of the capital requirement estimates for the cwTent Canadian pipeline 
of molecules to various changes in development duration for various new 
molecule entry rates into the pre-clinical development stage .. .... .. ............ .. .. .... . 66 
4.6 Capital requirement estimates for the current Canadian pipeline of molecules 
publicly signalling the need for external fmancing for various new molecule 
entry rates into the pre-clinical development state ........ .. .... .... .. .. .. .. .. .. .... .... .. .. .... 67 
5.1 VC investments in Canada .... .. .... ........ .... .. .......................... ...... .. .................. .... .. 74 
5.2 Federal government science and technology (S&T) expenditures on 
biotechnology by activity and perfonner ($000s) ........ .. .... .. .. .. .. .. ...... .. .. ....... ...... 78 
5.3 Federal government R&D expenditures on biotechnology activities by selected 
department or agency, and by performer, 1999-2000 ($000s) .......... .... .. .. .. .. .. .... 79 
5.4 Financing in the Canadian biotech sector: An evaluation($ million) ........ .. .. .... 80 
5.5 Initial values of the key variables and hypotheses ...... ............... .. .... ................... 89 
5.6 Canadian cumulative and average supply estimates over the period 2001-2006 
(Biotechnology sec tor and therapeutics sub-segment, billions of CAN$) ... ...... . 90 
6.1 First set of pairing of scenario estimates of Canadian supply and demand of funds 
over the period 200 1-2006 (Therapeutics sub-segment, billions of CAN$) ...... . 95 
6.2 Second set of parings of scenario estima tes of the Canadian supply and demand 
of funds over the period 200 1-2006 (Therapeutics sub-segment, billions of 
CAN$) .... ... ..... ... .... ... .... .... .. ..... .. ... ........ .. ........ ........ ... ... ......... ..... ... .. ..... ... ... .. .... ... 95 
FIGURES 
3.1 Breakdown of the Canadian sample by type of stakeholder.. ........ ........ .. ...... .. .. . 19 
3 .2 Breakdown of the U. S. sample by type of stakeholder .. .. .. ...... .. .................... .. .. . 19 
3.3 Sources of funds of Canadian suppliers interviewed ...... .. .... .. .... .. ............ .... .. .. .. 21 
4.1 Capital requirement estimation procedure ....... ... .... .... ..... .... ........ ... ... .. ........ .... ... 56 
5.1 Successful IPOs in the life sciences industry in Canadian markets .... .... .... .. ...... 77 
Vlll 
RÉSUMÉ 
DÉTERMINANTS DE L'OFFRE DE CAPITAL DE RISQUE DANS LE . 
DOMAINE DE LA BIOTECHNOLOGIE : ENJEUX ET DIFFICULTÉS, 
PERFORMANCE ET MODÈLES D'ÉVALUATION 
Cette thèse contribue à la littérature financière par une analyse des enjeux et difficultés 
de fmancement des entreprises canadiennes de biotechnologie, une estimation de la 
capacité des investisseurs canadiens à rencontrer la demande anticipée de capital des 
fim1es canadiennes et enfm, une évaluation de l'adéquation de l'offre et de la demande 
de capital dans le sous-segment thérapeutique du secteur de la biotechnologie au 
Canada. 
L'analyse des points de vue des investisseurs sur les enJeux et difficultés liés au 
financement des firmes canadiennes de biotechnologie repose sur des entrevues 
approfondies réalisées avec des intervenants oeuvrant au Canada (régions de Montréal, 
Toronto et Vancouver) et aux États-unis (régions de Boston, New York et San 
Francisco). Un total de 70 entrevues ont été effectuées entre février et octobre 
2001. L'étude vise à dégager la configuration structurelle de la problématique soulevée 
et ne vise donc pas une validation statistique de la population des investisseurs (directs 
et indirects) dans le domaine de la biotechnologie. La démarche adoptée est inspirée de 
Bergeron, Kryzanowski, Gadoum et Beaulieu (2004-a) et consiste à analyser un nombre 
suffisant de cas jusqu'à saturation, au sens d'une méthode d'analyse de cas, c'est-à-dire 
suffisamment pour qu'aucune autre dimension significative n'émerge. À cette fin, un 
guide d'entrevue comprenant six dimensions majeures retenues de la littérature 
fmancière est utilisé. Ce guide sert à faciliter l'analyse détaillée du contenu des 
entrevues et permet la construction de profils types des enjeux et difficultés liés au 
financement des fmnes du domaine. C'est la première fois qu'une étude examine, sur le 
terrain, le processus de financement des entreprises de biotechnologie et les enjeux qui 
lui sont associés 
L'estimation de l'offre de capitaux a été réalisée à travers tm modèle probabiliste qui 
permet de capturer le processus générateur de l'offre résultant d' interactions complexes 
entre différents facteurs déterminants de l'offre. L'estimation requiert l'utilisation de 
variables exogènes que nous avons retenues à partir de la littérature économique et 
fmancière et validées à travers les entrevues. Aussi, 1 'utilisation de modèles 
probabilistes nécessite un état initial représenté par des valeurs initiales des variables 
pertinentes affectant l'offre de capital ainsi que l'adoption d'hypothèses quant à leurs 
moyenne, volatilité et leur comportement futur tel que spécifié par deux processus 
stochastiques. Les variables exogènes du modèle sont macroéconomiques, de marché, 
spécifiques aux entreprises et au secteur, et enfin l'historique de l'offre de capital dans 
le domaine de la biotechnologie. Notre contribution à la littérature financière est réalisée 
à travers 1' effort d'identification des principales sources de fmancement, direct et 
indirect, dans le secteur de la biotechnologie ainsi que leurs proportions respectives. 
Nous avons aussi innové en utilisant un modèle probabiliste pour modéliser le 
comportement stochastique des variables clés affectant l'offre de fonds. Nous croyons 
que cette méthodologie peut être appliqué dans d'autres secteurs de la haute de 
technologie. 
Dans le but d'évaluer l'adéquation entre l'offre et la demande de capital, nous avons 
estimé en premier lieu les besoins en capitaux nécessaires pour compléter les composés 
en place dans l' ensemble des firmes canadiennes appartenant au sous-segment 
thérapeutique. Plus spécifiquement, les capitaux nécessaires sont estimés selon deux 
types d'analyses : une analyse statique et une analyse dynamique. L'analyse statique 
porte sur les capitaux requis pour compléter les molécules thérapeutiques en cours de 
développement, c'est-à-dire pour, en quelque sorte, compléter le développement du 
« pipeline » actuel de composés dans les firmes. L'analyse statique et 1' analyse 
dynamique portent sur les capitaux nécessaires, en faisant abstraction des réserves 
financières présentes des firmes . Cette estimation repose sur des scénarios tenant 
compte, entre autres, des estimations disponibles relativement aux coûts de 
développement à chaque étape ou phase, des taux d'attrition (taux d'échec ou taux de 
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passage d'une phase de développement à l'autre) et des caractéristiques propres au sous-
segment thérapeutique. En deuxième lieu, nous avons évalué la capacité des offreurs 
canadiens de capitaux à rencontrer les besoins des entreprises canadiennes pour enfm 
produire des scénarios d'adéquation entre 1' offre et la demande de capital ainsi qu'une 
estimation du volume de fmancement étranger pouvant être en besoin pour combler un 
éventuel manque de fmancement. À notre connaissance, cette étude constitue la 
première tentative de caractérisation de l'adéquation de l'offre et de la demande de 
capital dans le secteur de la biotechnologie au Canada. Cet effort est d'autant plus 
valorisé puisqu'il constitue une base de réflexion et de prévention contre tout manque de 
fmancement susceptible d'entraver la croissance de ce secteur. 
Mots clés : Capital de nsque, investissement, fmancement de la biotechnologie, 
demande de capital, offre de capital. 
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CHAPTERl 
INTRODUCTION 
A more in-depth knowledge of biotechnology financing-related issues and problems is 
important for many reasons. Small and medium-size enterprises represent a large 
proportion of the Canadian biotechnology firms in number. Many of them have already 
entered, or are in the process of entering, the pre-clinical and/or commercialization 
stages in which capital requirements are larger. Furthermore, the number of products in 
the product pipeline is growing rapidly. It is reasonable to assume that the aggregate 
capital requirements of Canadian biotechnology comparues will increase significantly. 
Although financing is considered a key development dimension, there is relatively little 
information available on how much capital is required, and on the difficulties 
encountered by companies when seeking financing. Inadequate capitalization affects the 
competitiveness of Canadian biotechnology comparues and makes them potential 
acquisition targets. Strengthening competitiveness is also a major issue given the 
significant economie advantages associated with production and commercialization. 
Therefore, a better understanding of the financing issues and concems faced by 
Canadian biotechnology companies is a pre-requisite for evaluating whether Canadian 
financial markets can provide sufficient access to capital, and for implementing policies 
to encourage the development stages with the greatest profit potential to be undertaken 
in Canada. 
Biotechnology industry players are unanimous that their research-focused industry must 
do a strategie about-face and focus on commercializing products. Therefore, facilitating 
access to capital is a priority. Many existing companies are entering or will soon enter 
the development and commercialization stages where financing is particularly critical. 
Paradoxically, little information is available on stage-related financing issues and 
difficulties. Specifie questions that need to be answered include: What are the capital 
requirements? Can Canadian financial markets provide sufficient access to capital? 
What types of financing problems are encountered in this respect? What are the 
significant concems oftypical supply-side stakeholders? 
This study provides answers and tools for though on the issues mentioned above and 
extends the literature by characterizing the supply of capital for Canadian biotechnology 
firms and evaluating the adequacy of capital supply for funding Canadian companies by 
estimating the capacity of Canadian su pp liers of capital to meet the predicted demand of 
Canadian firms. 
Our work has two main components. The first of these is a detailed analysis of the 
viewpoints of various suppliers of capital about the financing-related issues and 
difficulties facing Canadian biotechnology companies. Given the structure of the biotech 
sector in Canada with small and medium-size enterprises representing a large proportion 
of the Canadian biotechnology firms in number and that many of them are in the process 
of entering, the pre-clinical and/or commercialization stages in which capital 
requirements are larger, it is reasonable to assume that the aggregate capital 
requirements of Canadian biotechnology comparues will increase significantly. 
Although financing is considered a key development dimension, there is relatively little 
information available on the difficulties encountered by companies when seeking 
financing. Inadequate capitalization affects the competitiveness of Canadian 
biotechnology companies and makes them potential acquisition targets. Our analysis 
allows us to address such questions as whether Canadian financial markets can provide 
adequate access to capital and provides us with descriptive evidence on the problems 
and concems faced by suppliers of capital. To our knowledge, this is the first attempt to 
examine the financing process of a biotech firm and to analyse the issues and problems 
surrounding it. 
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The methodology used in this part of the study is based on the pioneering work of 
Bergeron et al. (200 1-a) 1 and identifies the financing issues and difficulties by stage of 
commercialization and company development. The approach is similar to that used in 
analyzing cases (i.e. , a sufficient number of cases is analyzed until no other significant 
dimension emerges). For this purpose, we use an interview discussion guide based on 
the commercialization and development stages in JoUy (1997). This facilitates interview 
analysis, and the construction of the profiles for the financing-related issues and 
difficulties encountered by a typical biotechnology firm. Following Bergeron et al. 
(2001-a), the purpose of this study is to determine the structural configuration of the 
financing issues discussed, rather than to attempt a statistical validation of the 
importance ofthese issues for the population of supply-side stakeholders. 
The issues and challenges ofbiotechnology investing in Canadian markets are identified 
using in-depth semistructured interviews with a sarnple of 70 specialists from both 
American and Canadian capital supply stakeholders. These participants include: 
• Venture capitalists involved in seed financing and the subsequent stages of 
development; 
• Investment bankers involved in IPO and subsequent stock issues; 
• Capital market specialists from the Montreal, Toronto and Canadian stock 
exchanges, NASDAQ, and the New York Exchange; 
• Alliance specialists from large pharmaceutical firms; 
• Bank and public entities that are involved in biotech financing; and 
• Canadian government officers involved with grants, fiscal assistance and tax 
credits. 
A total of 70 in-depth, semi-structured interviews were conducted in Canada and in the 
U.S. between February and October 2001. In accordance with the methodology, six of 
these interviews were performed prior to the study to validate and finalize the interview 
1 See also Bergeron, Kryzanowski, and Zorgati (2002) 
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guide. Of the 63 retained interviewees, 37 are supply stakeholders operating in Canada 
and 26 in the U.S . Each interview was taped, and a corresponding verbatim written 
record was prepared to assure the quality of the detailed analysis. The participants 
identified severa! issues and challenges, which were categorized according to the 
investment's technological opportunity, the firms' management expertise, and its 
financial potential. 
The second main component of this study presents an evaluation of how adequately 
capital supply meets capital demand for the Canadian therapeutics sub-segment of the 
industry. This effort is made in two steps. 
First, we estimate the capital requirements for the Canadian therapeutics sub-segment 
which, according to interviewees, shares over 80% of the total capital allocated to 
biotech activities, and is the only segment with available data about development costs 
and attrition rates, and a more complete and updated state of the pipeline of molecules 
for Canadian firms. The stream of estirnated capital requirements for the biotechnology 
sector in Canada and what these estimates imply in terms of the development of this 
sector were initially presented in Bergeron et al. (2001-b ). These estimates strongly 
indicate an unprecedented increase in capital requirements in the therapeutics sub-
segment. They also clearly stress the importance of adequate planning on the part of 
users and providers of capital if the capital appetite of this segment is to be adequately 
satisfied in the foreseeable future. We re-estimate total capital requirements using an 
improved estimation method, new and updated data about development costs and 
attrition rates, and a more complete and updated state of the pipeline of molecules for 
therapeutics biotechnology firms . In addition, unlike Bergeron et al. (2001-b), we 
provide initial estimates of the aggregate extemal capital requirements of our Canadian 
sample. 
The capital required is estimated usmg both static and dynamic analyses with no 
adjustment made for the financial reserves currently held by firms in the sample. The 
4 
static analysis generates estimates of the capital required to bring products currently in 
the product pipeline up to market entry. These estimates are based on estimated 
development costs at each stage, estimated attrition or failure rates (i.e., the rate of not 
passing from one development stage to the next), and on certain factors specifie to the 
therapeutics sub-segment. Estimates of the products currently in the product pipeline are 
elicited from the 2001 pipeline portrait of 171 Canadian public and private comparues 
(Industry Canada, April 2001). Despite the inherent limitations of this estimation 
approach (particularly for the basic or discovery phase), we are able to objectively 
quantify capital requirements for the scenarios used. 
The dynamic analysis extends the static analysis. By assuming growth in the number of 
products entering the pipeline annually over the initial five years, we analyze the 
evolution of capital requirements for various growth rate assumptions. Estimates of 
capital requirements for the other two segments (ag-biotech and bioenvironmental) are 
not provided herein. First, only limited information is available on the state of the 
pipeline for the ag-biotech segment. Second, cost and attrition rates are not available for 
these two segments, or for any other biopharmaceutical sub-segment other than 
therapeutics (i .e., diagnostics, drug delivery, systems or companies providing 
specialized scientific services). 
Second, we estimate the capacity of Canadian suppliers of capital to meet the predicted 
demand of Canadian firms, and finally we produce a matching of expected demand and 
supply of funding and evaluate the volume of extemal funding likely to come from the 
U.S. and other financial markets. For this purpose, we use a probabilistic madel that we 
consider the most appropriate to capture the supply generating process that results from 
the complex interactions between the various relevant factors affecting supply. The 
estimation involves simulations using initial values of key relevant variables, retained 
from the existing literature and validated through the interviews, that are expected to 
affect the flows of funds to biotech companies along with hypotheses about their mean 
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and volatility and on their future behaviour as explicitly modeled by two stochastic 
processes. 
The variables used in the madel are macroeconomie variables, market and sector 
variables, film-specifie variables and the global availability of funds in past years. We 
contribute to the existing literature by identifying the main financing sources, direct and 
indirect, to the biotech sector and their proportions in the Canadian economy. We also 
innovate in using a probabilistic madel to capture the stochastic nature of the 
fundamental factors affecting the supply of funds . We believe this can be extended to 
other areas in the high-tech sector. To our knowledge, it is the first attempt to 
characterize the adequacy of supply and demand in the biotech sector in Canada. Such 
an effort is likely to prevent from any wrong effect of a shortfall of supply of capital on 
reasonable terms and costs that could impede Canadian firms to fully exploit their future 
growth opportunities. 
In its most general goals, our study is related to the large private equity financing 
literature that studies the investrnent schemes and the potential agency problems related 
to them. Theoretical models such as Holmstrom (1982), Gompers, Blair and Hellman 
(1998), and Ireland (2003) examine the distortions in managerial behaviour that arise 
when the market is trying to leam the ability of a decision maker. Because direct 
observation of investment contracts in the technology industry, especially for start-up 
and early-stage ventures, is rare, there is only a small empirical literature on issues 
surrounding the investment process, the potential agency problems and the ways private 
equity investors address them. While this study may improve understanding of 
investment stakes in the biotech sector in Canada it is more generally considered as part 
of a large problematic for corporate insiders and outsiders dealing with different 
perceptions on investment terms and conditions. 
The main goal of our research is to characterize the supply of capital for Canadian 
biotechnology firms . The study has two main objectives. The first objective is to 
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identify the issues and difficulties from the viewpoint of the suppliers of capital by using 
a methodology similar to the one used to characterize demand. The second objective is 
to evaluate the adequacy of capital supply for funding Canadian companies (therapeutics 
sub-segment) by estimating the capacity of Canadian suppliers of capital to meet the 
predicted demand of Canadian firms, and to evaluate the volume of fmancing from the 
US. and other countries needed to satisfy any shortfall in the financing requirements of 
Canadian biotechnology companies. 
The remainder of the study is orgaruzed as follows. The next section presents a 
comprehensive revww of the literature on the financing of biotechnology firms , 
especially with regard to the relevant dimensions to the decision to finance a given 
project or firm. Section 2 presents a synthesis and analysis of financing-related issues 
and difficulties based on comments elicited from the interviewees. We discuss the 
important concems, and what concems should be analyzed in more depth in subsequent 
studies to better understand the financing-related issues and their relevance. The 
methodology used to collect the interview data and a description of the sample precedes 
this synthesis and analysis. Section 3 presents general methodology for estimating 
capital requirements and updated scenarios presenting estimates of the capital required 
to bring products currently in (or expected to enter into) the pipeline of products up to 
market entry for the sample of Canadian comparues in the therapeutics sub-segment. 
Two sets of estimates of the capital potentially available to Canadian comparues follow 
in Section 4. One set is based on evaluations from a probabilistic model and the other 
from an empirical documentary approach. In Section 5 various scenarios matching the 
demand and supply estimates complete this important step of the study. Finally, Section 
6 presents our conclusions as well as suggested areas for further research. 
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CHAPTER2 
REVIEW OF THE LITERA TURE 
This literature review examines the financing-related issues and concerns of biotech 
firms as they are addressed in the existing financial literature. Dimensions that may be 
relevant for characterizing the supply of capital to Canadian biotech's from the 
viewpoint of capital supply siders are examined. 
The financial literature dealing with biotech financing issues is very lirnited for two 
major reasons. First, the biotech domain is fairly new and has highly distinctive features 
that limit the relevance of the more traditionalliterature on firm fmancing. For example, 
the development stages of biotechnology firms are fairly long, capital intensive, and are 
subject to high failure rates. Second, the capital-intensive biophannaceutical segment, 
which is the most important, is highly regulated compared to other technology sectors. 
A more detailed and relevant literature exists for venture and technology finn financing. 
Technology firms in the earl y stages of theil: development exhibit general characteristics 
that are sirnilar to biotech fmns . These characteristics are a high proportion of intangible 
assets like R&D and patents, the highly strategie role of human resources in the fmn's 
value creation process, and the high volatilities and expected retums that characterize 
many investments of hi-tech fmns . Though the distinctive features of biotech fmns 
constitute an important challenge, the fmancialliterature facilitates our effort to identify 
the relevant issues in biotech financing. 
During the last two decades, the biotechnology revolution has resulted in phenomenal 
advances in the understanding and treatment of many diseases (Oliver, 1999). The 
Canadian biotechnology industry is a key sector with an important number of small 
fi1ms that are short of equity but are keen on selling in specialized markets around the 
world. Biotech companies in the nascent stages of developing products, such as drug 
discovery fmns, have not yet had the opportunity to sell these products in the market. 
Managers of these earl y stage companies are still faced with the challenge of attracting 
and retaining investors in the absence of sales revenues. Thus, as the Canadian 
biotechnology industry moves further into the uncharted territory of drug discovery, it 
must make convincing arguments to interest investors. 
Biotechnology is a very capital-intensive business (Robbins-Roth, 2000). It follows that 
a major challenge for biotech fi.rm is the timely and ongoing acquisition of adequate 
funding. This activity requires careful assessment of the fi.rm ' s ongoing needs along 
with a clear understanding of the various options for accessing capital. The purpose of 
the present study is to characterize the supply of capital for Canadian biotechnology 
fi.rms . Our objective is to identify the issues and diffi.culties encountered by suppliers of 
capital when dealing with Canadian biotech fi.rms . Characterization of demand has 
already been completed by identifying the fi.nancing-related issues and diffi.culties from 
the viewpoint of Canadian Biotechnology company executives (Bergeron et al. 2001 -a), 
and by estimating the capital requirements for the therapeutics sub-segment of the 
Canadian biotechnology industry (Bergeron et al. 2001-b). 
The supply of funds for biotechnology fi.rms is not well documented in the literature but 
sorne authors have documented the supply of venture capital. Gompers et al. (1998) 
suggest sorne critical variables to explain the supply of funds in venture capital. At the 
macroeconomie level, these variables include the state of the economy, interest rates, the 
expected rate of return in the biotech segment, fi.nancial institution regulations, which 
prohibit or restrict investment in the segment, and capital gains taxes. 
The development of a start-up investment in biotechnology is likely to go through 
severa! phases (Hall, 1992; Gompers, 1995). In the beginning stages, the venture 
consists essentially of the founders. These people with ideas may have sorne assets (a 
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working system, or a patent) but often little or no money for equipment and expenses. 
Therefore, they need an initial injection of funds (seed investment) to help them get 
started and to both develop their ideas and build the business to the point at which it 
becomes more attractive to outside investors. Working capital is generally very scarce at 
the beginning of a company's life (a few hundred thousand dollars) . The initial 
investment is indeed very risky since a large percentage of seed funding ends in failure 
(Prager, 1999; Clements, 1996; Dawson and Collons, 1986). 
Within about one year, the seed investment will be exhausted but probably with no 
product or service yet ready for the market place. The finn will need more money. The 
team will have prepared a business plan that will map out the next stage of the 
company's development and prepare for first round venture capital funding (Fried, 
1994). At this point, funding requirements may be several times greater than the original 
seed-funding amount (Feen, Liang, and Prowse, 1995; Ehrlich, De Noble, Moore, and 
Weaver, 1994; Wright, 1998). 
By the second or third year, the product(s) or service(s) being developed may be nearer 
the market but a second round of funding is needed. In the fifth or sixth year, the 
company may become a public corporation by offering shares for sale to the public. The 
principal motivation for going public is to obtain capital on terms more favourable and 
in amounts that are greater than may be available through other channels. Substantial 
amounts can be raised in public equity markets to fund working capital, research, 
development, marketing and manufacturing activities, as well as facilities (Rabbins-
Roth, 2000). 
The availability of venture capital to support biotechnology ventures is crucial to the 
continued vitality of Canadian biotechnology firms . Venture capital funds invest money 
in these enterprises because they provide an opportunity to partake in unusually high 
retums as compensation for the unusually high risks involved in biotechnology ventures 
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(especially start-up ventures) but their role is open to discussion (Neidorf and Writer, 
1999). 
The Canadian venture capital industry has considerable financial and management 
resources . According to the Canadian Venture Capital Association (CVCA), Canadian 
venture capitalists financed more than 800 firms and invested almost $4.9 billion by the 
end of year 2001. They have sorne $20.2 billion under management and about $6.2 
billion available for investment. The industry disbursed about $1.1 billion in life science 
companies, with biotechnology receiving more than half ($842 million). As reported by 
the CVCA, there was an upward trend favouring early stage companies with 
investments in company start-ups and seed financings totalling over $2.9 billion. Given 
that a large number ofbiotechs in Canada are early stage companies, this tendency must 
be considered as being encouraging for the expansion of the sec tor. 
The transformation of science into technology is mediated by business forces and brings 
together two sets of people whose outlooks, specialized knowledge, and professional 
languages are very different and often out of touch with each other. Many of those 
charged with making financing decisions regarding science and technology have little or 
no understanding of scientific process or the culture in which it operates. On the other 
hand, many people who do understand technological development are poorly informed 
about fmancial and business matters . A chasm of knowledge and interest di vides these 
two communities and hinders the progress they both seek. Whether the demand for 
funds by Canadian biotechs has been and will be satisfied appropriately needs to be 
explored further. 
V enture capital investments are made on the basis of the investor ' s assessment of the 
business prospects of the venture and the ability of its management team. Doucet (2000) 
suggests that managers of earl y stage companies must have a good story to tell potential 
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shareholders. The story must include good quality science and technology, a winning 
management, and fine intellectual property. 
Scientific due diligence is required to assess the quality of the sc1ence and the 
technology. It is a crucial step for investors to make a decision about a biotech project. 
Also, products (drugs) under development should have clear advantages over those 
already available at the neighbourhood pharmacy. They must address a commercially 
viable market that is both sufficiently large and has the potential to grow. 
Another critical requirement of investors is the presence of a strong management team, 
particularly if the original founders are scientists without business experience (Barney, 
Spencer, and Reve, 1994). Investors will be very keen to ensure that their investrnent is 
in the hands of somebody who knows how torun a business, especially a start-up. 
Investors place an equally great emphasis on the intellectual property (IP) that the 
company may own. They make a careful review of the IP before investing (Narin, 1995; 
Lemer, 1994). Biotech companies must retain the rights to manufacture and market at 
least some of the products that emerge from their research laboratories in order to build 
stockholder value and justify a healthy market valuation for the company. Without 
strong patents and li censes governing the composition and use of the compounds under 
development, competitors who could make off with their "meal" can outrnanoeuvre a 
biotech firm! Investors follow when the IP is "rock-solid", well-protected, covers a wide 
geographie base, and extends weil into the future. This suggests that issues and 
difficulties that capital supply siders may encounter when considering or declining 
biotech projects need to be explored. 
Another investment consideration is the perception by the potential investor of the 
risklreward consequences of investment. Evaluation of risk and putting together a 
financial structure to deal with it are both important. Venture capital investment must 
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aim for high rates of return over a relatively short time period because the investors 
know that, in spite of their best efforts to spot a success, they will often be wrong. 
Because the risk of failure is so high, the return on the successful project must more than 
compensate for the losses or the whole business of investing in high-risk ventures if 
such investing is going to be worthwhile. There follows an important question. How is 
the increased value of the investment to be realized? In the parlance of the industry, 
"what will be the exit route? Thus, the perception that investors have about risk and 
retum when dealing with Canadian biotech firms is a second dimension of the biotech 
investment decision that needs to be explored further. 
As suggested by Chidley (2000), the biotech sector is unpredictable and risky. Whether 
to invest in biotech depends on whether the investor knows what he is doing, how 
patient he is, and whether he has a strong tolerance for volatility. The unpredictability of 
the biotech sector, the gestation time (time to get products or drugs to market) and the 
possibility of failure to reach the critical mass necessary for public funding, are factors 
of risk that may be disadvantageous and may affect the motivation of suppliers to fund 
and support Canadian biotech companies. 
A third dimension of the biotech investment decision is the difficulty in valuing bio tech 
firms. Large, established comparues with earnings track records in stable business 
sectors are easier for investors to assess than growth companies. Biotechnology 
companies are, in a sense, all "potential" and have little or no track record. Therefore, it 
is more difficult for investors to assess their prospects (Hull, 1999; Trigeorgis, 1996). 
Real options models offer potential avenues to value biotechnology projects (Kellog and 
Chames, 2000; Amram, and Kulatilaka, 1998), but they are often seen as complex and 
difficult methods to implement by practitioners. One way to understand how values are 
determined in this "marketplace" is to ask practitioners about their valuation methods, 
and to what extent the difficulties to value biotech projects may be the cause of funding 
in stages as mentioned by the biotech company executives in Bergeron et al. (2001 -a) . 
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Boer (1999) suggests that a simple approximation of value is possible by simply 
examining the R&D funds the company has spent and the amount contributed by 
founders (Chan, Lakonishok, and Sougiannis, 1999). Thus, the level of owner 
commitment and financial participation in the project is a fourth dimension of the 
biotech investment decision that needs to be further examined. 
Asking for funding also requires a biotech company to disclose information relating to 
its science, technology, business and financial conditions. These requirements may force 
a company to suffer the competitive disadvantage that results from disclosure of 
sensitive information such as the identity of products in research (molecules and drugs) 
and the methods and costs of research. Company executives interviewed in the first 
phase of this study mentioned that the disclosure of information could be an impediment 
to funding. Biotech founders may be hesitant or wary of disclosing information because 
of their fear of losing exclusivity or failing to retain control over their project. This is a 
fifth dimension of the biotech investrnent decision that needs to be explored further. 
Until recently, the financial health of a biotech finn was largely measured in terms of 
the interest and funding from venture capitalists and public markets. Oliver (1999) and 
Rabbins-Roth (2000) note that big pharma assets, loans, and even intellectual property 
have forced a re-evaluation of the market value of biotech firms . Alliances between 
small biotech start-ups and big pharmas are now an important form of industry 
financing. Small biotechs need such alliances with big pharma companies for survival. 
The big pharmas need different alliances with the biotechs to hedge their bets and to 
ensure a steady flow of innovations. Usually, a small R&D finn partners with an 
international pharmaceutical company. Big pharmas have deep pockets and considerable 
experience in R&D, marketing, manufacturing, regulatory know-how and other 
resources. Furthermore, Champsi (1998) suggests that for companies that win the 
support of investors, the opportunity for mergers and acquisitions could be used as a 
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catalyst to rmse additional capital more easily. Champsi notes that investors are 
concentrating their holdings in companies with "critical mass", requiring them to pursue 
mergers and acquisitions as a requisite to future financing and liquidity. Thus, the sixth 
dimension of the biotech investment decision that needs to be explored is strategie 
alliances/mergers and acquisitions. 
Government commitments and/or guarantees are used to manage risk (Lemer, 1999; 
Fox, 1996; Eisenger, 1993; Irwin and Klenow, 1994). Federal and provincial 
governments in Canada have industrial policies and regulatory frameworks that may 
support or even favour the biotech sector. Thus, the final dimension of the biotech 
investment decision that needs to be explored is the perceptions of govemment policies 
and tax structure in Canada. 
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CHAPTER3 
FINANCING-RELATED ISSUES AND DIFFICULTIES FROM THE POINT OF 
VIEW OF SUPPY SIDE ST AKEHOLDERS 
3.1 METHODOLOGY 
The methodology used to satisfy the first objective consists of creating profiles of the 
issues and difflculties perceived by the main stakeholders. These issues and difficulties 
are identified and described through the use of semi-structured interviews and an 
analysis chart revised interactively with suppliers of capital. In this respect, the 
methodology is similar to the one used previously to establish the viewpoint of users of 
capital. 2 
The approach involves a characterization of the viewpoints of capital supply 
stakeholders. To identify, document, and analyze financing-related issues and 
difflculties, we begin with a thorough analysis of the detailed verbal record from each 
interview. This facilitates the selection of the issues retained for subsequent analysis . 
The detailed anal y sis of the perceptions of the interviewed supply stakeholders provides 
the raw data upon which we evaluate the measures that could be implemented to 
improve access to capital. 
The completion of case studies helps to determine qualitatively the structural 
configuration of the financial issues discussed. This approach involves analyzing 
additional cases until saturation (i.e., until no other new significant dimension emerges). 
In order to ensure a sufficiently detailed analysis, we select a relatively large number of 
supply stakeholders to interview. 
2 See Bergeron, M.Y., Kryzanowski , L., Beaulieu, P. and Gadoum, Y., 200 1-a, Financing-related issues 
and difficulties for Canadian biotechnology companies, Intern ational Journal of BiotechJ1ology, Vol. 3, 
Issue 3. 
3.1.1 COMPANY COMMERCIALIZATION PROCESS AND DEVELOPMENT 
STAGES 
We use Jolly's (1997) classification of the commercialization process (see Appendix C). 
This classification of the value creation process includes five sub-processes that are 
similar to the conventional stages of technological innovation. These five sub-processes 
are: 1) imagining, 2) incubating, 3) demonstrating, 4) promoting, and 5) sustaining. 
Jolly (1997) argues that these five sub-processes oftechnological innovation correspond 
quite weil to the main categories of sources of funds and financing methods used by 
technology-based fmns. Therefore, it is relevant to use this approach as a backdrop for 
analyzing the evolution of financial requirements in the various sectors of the 
biotechnology sector, and for building a typical profile by sub-process and/or stage of 
commercializati on. 
Our case analysis procedure consists of the following stages: 
1) Conduct an in-depth literature review ofbiotechnology financing issues. 
2) Design a semi-structured discussion guide of financing-related issues that is 
superimposed over each of the sub-processes of Jolly's model, and is pre-
validated with severa} target firms. 
3) Select a representative sample of supply-side stakeholders in each of the three 
previously mentioned segments. 
4) Conduct the field interviews. 
5) Conduct an in-depth analysis of the interview content. 
6) Construct the typical profiles. 
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3.1.2 RELEVANT DIMENSIONS OF THE ANAL YSIS AND DISCUSSION 
GUIDE USED 
The six main dimensions, which were retained following the literature rev1ew, are 
systematically explored in the interviews. Interviewees were also free to suggest other 
relevant dimensions. The main dimensions used include: 
• Types ofprojects 
• Differences in perceptions of risk and retum 
• Degree of founder commitment and financial participation in the project pipeline 
• Disclosure of information 
• Rel ev ance and use of strategie alliances as a source of fmancing 
• Govemment commitments and/or guarantees for managing risk 
• Other dimensions 
The interview guide used to collect general supply stakeholders' information and the 
semi-structured questionnaire are presented in Appendix C. 
3.2 DESCRIPTION OF THE INTERVIEW SAMPLE OF SUPPL Y 
ST AKEHOLDERS 
Seventy in-depth, semi-structured interviews were conducted in Canada and in the U.S. 
between February and October 2001. In accordance with the methodology, six of these 
interviews were performed prior to the study to validate and finalize the interview guide. 
Since these interviews were not considered for analysis purposes, the interviewees are 
not included in the list presented in Appendix D. The interview guide presented in 
Appendix C is used to identify the financing-related issues and difficulties of Canadian 
biotech comparues from the viewpoint of the capital suppliers. Other information 
gathered in the course of the interviews is also combined with secondary data sources to 
evaluate the capital raised by the biotech sector during the last two years, and to estimate 
the amount likely to be invested during 2001 and 2002. 
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Of the sixty-three retained interviews, 37 involved supply stakeholders operating in 
Canada and 26 in the U.S. They involved a representative sample of supply siders: 
venture capitalists, institutional investors, investment bankers, banks and Para public 
entities involved in biotech financing, and other stakeholders including capital markets 
and biotech analysts, alliances and M&A specialists, and public officers. Each interview 
was taped, and a corresponding verbatim written record was prepared to assure the 
quality of the detailed analysis. The average length of an interview was 50 to 60 
minutes. 
Interviews conducted in Canada involved stakeholders from Montreal, Toronto and 
Vancouver. U.S. interviews involved a representative sample of capital suppliers from 
the main U.S. biotech clusters, namely, San Francisco, Boston and New York. As shown 
in Figures 3.1 and 3.2 below, the Canadian sample contains nineteen venture capitalists, 
five investment bankers, five institutional investors and eight others. The U.S . sample 
includes fourteen venture capitalists, eight investment bankers and four others. 
Figure 3.1: Breakdowm of 
the Canadian sample by 
type of stakeholder 
8 
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Figure 3.2: Breakdowm of 
the U.S. sample by type of 
stakeholder 
4 
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Canadian venture capitalists interviewed during the study have about $6.5 billion under 
management, as of December 31, 2000. Over 40% of this amount or $2.6 billion is 
invested in biotechnology, mostly within Canadian firms . This amount in biotechnology 
is expected to increase by about $800 million over the next two years. Pive Canadian 
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interviewees were institutional investors with capital under management of over $4.5 
billion, and 18% of this amount is allocated to biotech investments in Canada. These 
interviewees alone intend to invest an additional $400 million in the Canadian sector 
over the next two years. 
The U.S. sample mainly consists of venture capitalists and investment bankers. 
Interviewed U.S . venture capitalists have $9.5 billion under management, ofwhich 63% 
is invested in biotechnology. Only 2% of the $9.5 billion is invested in Canadian firms. 
Table 3.1 surnmarizes the quantitative information gathered from Canadian and U.S. 
interviewees. 
Table 3.1. Quantitative information gathered from the Canadian and U.S. 
interviewees 
Intention to 
Capital Percentage Percentage invest over Desired 
un der invested in the next one rate of Number 
management bio tech invested in to two years Canada retum (millions) (average) (additional, (average) 
millions) 
Canada 
vc 19 6,494 40 92 800 25% 
Inst. Inv. 5 4,650 18 100 400 20% 
u.s. 
vc 14 9.443 63 2 978 50% 
As shown in figure 3.3, banks, pension funds and governments are the most important 
potential sources of capital for investment in the biotech sector. Corporations and 
individual investors are second (with a proportional share of 22%), and retail and 
foreign investors, foundations and other sources account for the remaining 8% of the 
total capital potentially available for investment. 
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Figure 3.3: Sources of funds of Canadian suppliers 
interviewed 
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3.3 SYNTHESIS AND ANALYSES OF FINANCING-RELATED ISSUES AND 
DIFFICULTIES 
This section identifies the main financing-related issues and difficulties addressed by the 
interviewees. The profiles contain representative sumrnaries of the perceptions of the 
interviewees as identified by the detailed content analyses of the interviews in order to 
provide a concise description and a preliminary analysis of financing-related issues and 
difficulties. This preliminary analysis considers information for every relevant 
dimension identified in the review of literature presented in section 2. 
3.3.1 TYPE OF PROJECT TO FINANCE 
The type of project is an important determinant in the relative difficulty encountered in 
obtaining financing. The fund requester needs to demonstrate a clear competitive 
advantage for the promoted project. Financing is almost impossible to obtain if the firm 
does not own the intellectual property rights to the promoted project. 
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• Quality science and technology 
The vast majority of capital supply siders agree that the quality of science is very good 
in Canada. Very good ideas and very good science come from all Canadian universities. 
The U.S. obviously has more scale, a factor of about ten times, but Canada defmitely 
has sorne leading cutting-edge technologies. According to a few interviewees, 
productivity in terms of product development and relative weight of R&D activities 
conducted in the Canadian research facilities of the big pharmaceutical companies 
confirms the credibility of Canadian science. Sorne companies spend as much as 10% of 
their R&D expenditures in Canada, although the Canadian share of the global market is 
only 2%. For these interviewees, this relative over-weighting of the Canadian share of 
R&D expenditures constitutes a direct validation of the quality of Canadian science. In 
R&D activities, Canada is seen as being very competitive. Without a more probing 
analysis, this may be related to a weak Canadian dollar and not to a real productivity or 
comparative advantage. 
Other interviewees stress that in spite of the high credibility of Canadian science, not 
many Canadian firms have a dominant position in terms of size and pipeline 
development. Some U.S. VC capital supply siders feel that Canadian firms have a lower 
quality of science and technology compared to U.S. fmns, even if they believe that the 
quality of the scientists is probably comparable. These perception differences rnight be 
explained partly by the fact that other important determinants are at play during each 
stage of development. Quality of science does not necessarily mean that the critical mass 
of talent is available. For example, moving a finn to the Boston area might make sense 
from a critical mass point of view in that shopping for additional talent for expansion 
may be easier in this new setting. 
Although science and technology rarely constitute a problem as such, they are important 
criteria in project evaluation and rejection, especially in connection with the depth of the 
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market (the so-called technology-market couple). Even when the technology addresses 
real medical needs, the market niche is often too small. 
Although most interviewees agree that the quality of science is not a problem in Canada, 
at least two observations are advanced about this important financing issue. First, many 
venture capital firms are actively looking for the best projects at the discovery phase. 
Most of the time, they are pre-selecting the most potentially interesting projects at the 
very earl y stages of their development. These capital supply siders have the capability to 
handle the science issue and their rejection rate is very high if we consider earl y phase 
projects. Specifically, more than nine projects out of ten asking for financing are 
rejected. Put differently, the quality of science is not a financing issue at the venture 
capital level because it has been handled properly by the other capital supply siders 
working at the discovery phase (seed and pre-seed) and by the venture capital firms 
themselves. The interviewees at the discovery phase mention that the quality of science 
is an important problem at the very earl y stages of development. The evaluation of the 
potential commercial value of the science being developed represents, quite naturally, 
the biggest issue at later stages of development. 
The second observation put forward by some interviewees is that the technology pool in 
Canada is wearing thin, and that some time might be necessary to regenerate the quality 
of the technologies in the reservoir. For them, the best technologies are already financed 
and few good teclmologies are available to be financed. Even if this point of view is not 
unanimously shared, a few capital supply siders express serious doubt about Canada's 
capacity to keep up the pace. This observation is important because, as we will see later, 
the vast majority of the interviewed venture capital firms clearly express an intention to 
invest more and more abroad in the coming years (mainly in the U.S. and in Europe). 
Only state-linked or labour-owned institutional capital supply siders do not express such 
intentions, probably because they are not allowed to invest abroad. However, they do 
represent an important player given their high level of investment in Canadian biotech 
projects. 
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Other important investment determinants, such as the liquidity of Canadian financial 
markets and diversification considerations, might explain this increased emphasis to 
invest in foreign technology. Whether these intentions should be considered as being 
purely hypothetical possibilities, or as real and potentially threatening determinants, is 
open to discussion. However, if intentions were realized, then such a major erosion of 
the technology pool of capital would certainly constitute an aggravating factor. 
Three or four principles are at play with regard to the decision to invest in a project. 
They are technological advance, market, management and intellectual property. Thus, 
although the quality of science is an important factor, it is far from being sufficient for a 
"go" investment decision. 
• Management team with a record of successful commercialization 
Most capital supply siders consider that the management team, together with technology 
and market, are the major issues when they analyze a company. Management is 
considered as being at least as important as technology. Capital supply siders consider 
lack of management as being one of the major difficulties in Canada not only in terms of 
limited numbers of good managers, but also in terms of the extent and variety of 
experiences and skills. A few cases of recycled management are emerging where 
someone decides to move on and start another venture. They generally do a better job 
during the second and third times than they did during the first round. A majority of 
capital supply siders mention that hiring a CEO abroad is often a necessity in spite of the 
difficulties involved. For a few capital supply siders, the relative scarcity of good 
management teams in Canada is not a major issue since many Canadian firms are 
already prepared to face difficulties in this respect. 
Although the situation is improving, lack of management will probably continue to be 
one of the biggest issues in investing in biotech companies in the near future. Because of 
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the protracted life cycle of a biotech company, a long period of time elapses without 
generating management. There are no mentors and managers basically have to come up 
through the ranks. The managers can be recycled in the community later, but Canada is 
still going through the first generation of on-the-job management training. We have 
sorne good management talent in Canada. There are VCs who do not have any problem 
finding good quality management teams and are happy with the people involved. 
However, there are not enough good managers for all the comparues that currently exist 
and many interviewees state that they usually have to recruit sorne managers from either 
the U.S. or Europe. The latter is very difficult and costly. 
When looking at possible investments, capital supply siders want these companies to be 
world-class; that is, companies that can compete with the U.S . in terms of technology, 
money and management talent. Other biotech companies, such as the big pharmaceutical 
companies, have ready access to more financial resources. Management has to build the 
business model, has to establish strategie partnership relations, and has to raise 
financing. The better management is, the easier it is to raise considerable funds, which 
in turn makes scaling up easier. 
Fin ding a world-class CEO can cost significant amounts of money and take a long tirne; 
nine to twelve months is not uncommon. If the CEO cornes from the U.S., the salary 
must be competitive. On average, the salary prior to adjustment for exchange rate and 
tax differences tends to be a little higher than that of a Canadian CEO. The adjusted 
salary tends to be a large figure. When a Canadian company frrst initiates a search, it has 
to be prepared to offer a package that may be three to five hundred thousand dollars. 
A related problem is that good CEOs want to position themselves with firms that 
possess market capitalization in the 100 to 300 million dollars (CAN$) range. Small 
biotech firms therefore have a hard time, given their limited financial means, in being 
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competitive for top management talent. In Canada, the number of firms in this range of 
capitalization is limited compared to that in the U.S. 
Management needs to co ver a wide variety of skills, and different types of managers are 
needed. Most firms need a multi-disciplinary team, which covers financial management 
and planning, marketing, commercialization and strategie planning. The interviewees 
unanimously consider that lack of sales and marketing skills is a major problem in 
Canada. In this respect, Canada lacks the human resources who know how to establish 
the potential of a given market as weil as how to exploit it. These kinds of skills matter 
greatly for small and new firms. These firms are often not able to adopt a direct 
commercialization strategy and have to adopt a licensing mode or strategy. This 
difficulty is complicated by the fact that the choice of the most appropriate strategy has 
to be made early in the strategie planning of the firm. Depending on this choice, very 
different human resources and approaches are needed. A direct link exists between firm 
size and quality of the management team. Renee, the quality of management hinders a 
more important and fundamental size issue- that there are too many small firms in 
Canada relative to the U.S. Furthermore, even if size does not directly alter the quality 
of science, it is a complicating factor. The quality of management is even more 
important than the quality of science for it is harder to move from pre-start-up to start-up 
and IPO. U.S. VCs perceive Canadian management teams as not being as qualified as 
those in the U.S. Though not specifie to Canada, this is perceived as an important issue. 
For these V Cs, quality of management is based on managers who have long experience 
in the business and the business is successful. It is easier to find managers with success 
in the biotech industry in the U.S. than in Canada. As for the quality of science, a kind 
of critical mass disadvantage to investrnent in Canada exists from the perspective of a 
U.S . VC. Nevertheless, these factors may not be decisive in the decision of these capital 
supply siders to invest in Canadian biotech firms . As seen below, factors that might play 
a more decisive role include existing opportunities in the local market, locus of control 
and time needed to supervise their investrnents, bigger relative size of U.S . firms, and 
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better liquidity of U.S. capital markets. These last two factors are becoming more 
important with the increase in size of many investment funds, and the risk inherent from 
non-domestic investment. Proximity is a very important consideration in the decision to 
invest for it directly affects the locus of control and supervision issues. The further away 
the investment is, the better its potential has to be. Moreover, sorne U.S. capital supply 
siders state that they will not invest unless strong capital support exists locally. 
For many interviewees, the management problem in Canada arises because few CEOs in 
small and young Canadian biotech firms are trained in big pharmaceutical corporations, 
where managers would have been in-company entrepreneurs. Canada has a lack of 
experienced management, managers who have taken products through to market before. 
In Canada, few CEOs have gone through the full range of experience from development 
to clinical trials to product development, commercialization and manufacturing. An 
insufficient number of Canadian CEOs have this variety of experience. Moreover, the 
CEOs who work in the Canadian branches of big international pharmaceutical 
comparues usually have more limited experience than an American CEO. Most of the 
time, the former CEOs have just done Canadian marketing or phase 4 experiences, and 
they have not experienced the difficulties over the full range of clinical trials from 
phases 1 through 4. Stated differently, the level of maturity of management in Canada 
might not reach the level that exists in the U.S . This appears to be particularly the case, 
for example, for the capacity to achieve good market positioning, to make market 
opportunity assessments, and to select the appropriate niche. 
Strategie development that is well adapted to the market is crucial. Many interviewees 
consider that we rarely see firms in Canada that posses this capacity for good 
competition analysis early enough to efficiently reduce risk by adopting such a strategy. 
For the last five to six years, the substantial growth in biotech firms has increased the 
need for good management. 
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Despite this fast growth, many capital supply siders consider the situation as improving 
at all levels, even if many firms could improve their board. Board competencies are an 
important issue for they impact directly on the scientific and development strategies. 
However, there is still a lack of important specifie management resources . For example, 
development is seen as one important issue. Canadian firms are in need of personnel that 
can establish close and persona! links with the big pharmaceutical furns to develop 
contacts and promote strategie alliances. Lack of management in this respect appears 
more problematic as a company maves closer to development and pre-
commercialization. 
• Intellectual property according to the nurnber and the quality of the patents held 
Intellectual property, which is carefully reviewed before investment, is a very important 
issue for the investor. Intellectual property is not seen either as a problem or as a 
Canada-specifie issue by the interviewees. Many patent agents specialize in 
biotechnology IP. Even young biotech companies realize early in their lives that they 
have to partner with leading law firms or intellectual property firms to protect their 
patents. 
Even if IP is not problematic, most interviewed capital supply siders said they are more 
comfortable using U.S. law firms because they have more experience and they know 
their way around biotechnology. From the diligence standpoint, these interviewees are 
more likely to use the U.S. firms . The U.S. law firms are usually more strategically 
focused, and they actually map out the strategy to be implemented, and specify what the 
client should be aware of. 
Canada has experienced a rapid evolution in IP policies during the last ten years. Prior to 
1991 , property laws were not seen as appropriate. Now IP protection is seen as being 
better. The IP culture is not yet seen as being as developed as that in the U.S . but the 
interviewees consider that progress is ongoing. Problems remain and Canada stilllags to 
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a certain extent. For example, start-ups often come from the universities and better 
education about IP is needed at this level. IP issues become more complicated in the 
biotechnology sector because scientists like to publish, which allows them to eam 
money and become known. The problem is that sometimes they publish what is not 
protected. Since many Canadian firms are small and their personnel are relatively 
inexperienced, mu ch is unknown about IP. A reluctance to share property rights and the 
fear to deal with big pharmaceutical firms are also sometimes a concern. 
Thus, in Canada, IP is not a quantitative issue (there are competencies in Canada) but a 
qualitative issue. The difference becomes obvious when it cornes to integrating 
intellectual property into corporate strategy. According to a number of interviewees, 
Canada often lacks the ability to devise and introduce a vision of IP, as weil as a strate gy 
for its development and valuation. To illustrate, the quality of patent agents and experts 
in developing IP strategies is inferior in Canada compared to other countries. Probably, 
the level of diligence put into IP could be greater. This probably reflects less 
sophistication in Canada generally on the selection of an IP strategy using offensive and 
defensive techniques. 
• Scientific due diligence procedures 
This dimension is not seen as an issue in Canada. But many capital supply siders rely on 
a North Arnerican network for their scientific due diligence. While due diligence 
procedures are good in general, their quality can vary from one situation to another. For 
example, at the private placement and institutional investor levels, the quality of due 
diligence procedures varies depending on the managers and the resources available. The 
more experienced funds in biotech do have deep scientific due diligence procedures, 
while the others find it harder to justify analysts to support the manager. In the latter 
situation, the manager is a generalist who relies on outside study. 
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• Major reasons for not providing funding for a project/stage 
Most interviewees cite the lack of management depth and breadth as the major reason 
for not providing financing. Management inability to articulate what they are doing and 
to prepare professional business plans with workable topics is a second (and perhaps as 
important) reason not to provide funding. Very unrealistic expectations and even 
complete naïveté on the part of management about dealing with capital markets occurs. 
Many of these companies do not know how to be a public company and how to deal 
with investors and investrnents. Sorne capital supply siders believe that this also applies 
to sorne groups investing in biotechnologies as they leam by doing. 
Limited breadth of the technology and/or limited market opportunities are other major 
reasons for not providing funding. Even if the capital demand sider has the best 
management team, it will not be able to add any economie value if the technology and 
market are inferior. Most research activities never reach the final product stage. As the 
technology advances in the development process, it becomes easier to estimate potential 
risk, and to mitigate financing difficulties . US. finns have deeper and more advanced 
pipelines than Canadian finns, partly because biotechnology development has taken 
place earlier in the US. This difference should diminish over time as more compounds 
reach the later stages of development. Stakeholders, like the big phannas, also tend to 
limit their alliances to their specialization fields. Since a relatively smaller nurnber of 
therapeutic fields are being developed in the Canadian-based research facilities of the 
big phannas, this becomes a complicating factor if a Canadian finn tries to fund a wide 
range of research activities. Since big phanna research activities are organized globally, 
a small Canadian-based finn might not have access to the proper network as easily as a 
comparable U.S. finn if its compound does not belong to the specialization fields 
already being developed in Canadian-based research facilities . 
Increasing concentration and the creation of consortia are among the most important 
changes observed in the pharmaceutical industry over the last few years. Only four to 
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five major players have survived recent consolidation in the industry. R&D and capital 
needs and capabilities to commercialize products globally are the drivers of this very 
intense M&A activity. Assessing its impact on the funding of research activities, 
especially for (generally smaller) Canadian frrms, is not easy. If bigger players become 
more eager for products, this will facilitate the relative decentralization of research 
activities . However, consolidation may make the development of world-scale Canadian 
firms more difficult since these firms will be more dependent on the international 
distribution network. If the capability to distribute compounds rapidly and efficient! y on 
a global scale becomes more important, this could weaken the position of a small firm 
when negotiating an alliance or the sharing of intellectual property rights. These fim1s 
might see their bargaining position and potential opportunities negatively affected by the 
increased dependence on a more concentrated distribution network. Although the 
direction of the impact is uncertain, it is likely to be fairly important in the future. 
Attracting the attention of U.S. investors is not easy for an average-size Canadian firm. 
While U.S. interviewees are exposed to approximately 600 to 800 hundred deals 
annually, they only conclude between five to ten deals a year. Since they prefer to be 
involved with their financed companies, geographie distance is a factor. As a result, 
these U.S. stakeholders need a strong local co-investor. However, they know few such 
local investors with a good track record of investing in successful companies in the U.S. 
Furthermore, they have a home bias if investment in the same technology is available 
domestically in the U.S. Given this home bias, a Canadian firm must be a supenor 
investment opportunity to attract such a U.S. investor. 
Aspects not related to firms or project-specific characteristics also affect the decision not 
to provide funding. The general investment climate and flavour of the moment are 
detemunants of the decision to provide funding. For some capital supply siders, capital 
markets not only changed dramatically over the past five years but will also change even 
more because of what happened with the dot coms. Since capital markets now prefer to 
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fund more advanced stages of development, ideas no longer get funded. Firms have to 
show that a drug is not only viable, but that it will make money for someone. There is a 
shift to people demanding investments in firms that start making money very quickly in 
order to have early cash value. These investors believe that this signifies that the public 
market is becoming more sophisticated. Their general feeling is that the investment 
climate will enter a more conservative period of unknown length. 
The exposure of U.S. stockholders to Canadian biotech investment is limited to the 
companies that deal with funds that invest in Canada or to firms that have approached 
U.S.-based big pharmaceutical firms to establish alliances with an international 
organization operating in a number of countries. These firms receive many proposais 
from Canada partly because they have a research base here. The second avenue of 
exposure to the Canadian biotech community is through conferences, such as the Bio 
Contact conferences. 
Sorne U.S. capital supply siders believe that the level of Canadian innovativeness is, on 
average, a few months to a year orso behind that in the U.S., and that business models 
and concepts originating from Canada are models that have appeared earlier in the U.S. 
U.S . capital supply siders are talking with a number of very innovative Canadian firms 
because these firms have identified or are developing a very unique technology or drug 
candidate. These U.S. capital supply siders hold similar perceptions about intellectual 
property in Canada. On average, the ideas and concepts presented to them from 
Canadian entities are somewhat behind those presented by U.S. entities but comparable 
to those opportunities presented by European entities. 
Periods of intense biotech financing occur in Canada. A three- to four-year quiet period 
followed a large number of financings in the mid-nineties. In late 1999 and 2000, a new 
wave of bio tech financings occurred. Thus, bio tech financing is facilitated during "hot" 
financial markets and the boom part of the general economy cycle. 
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3.3.2 PERCEPTIONS OF RISK AND RETURN 
Differences in perceptions between project promoters and suppliers of capital about 
future performance and risk are important determinants in the probability of obtaining 
financing. The VCs note that most firms believe that they can get to market or to sorne 
other target quicker than they actually can. The project promoters underestimate time 
and cost (i .e., actual time is twice as long and actual cost is three times as much). 
The unpredictability inherent in the biotech sector is an issue. Capital supply siders with 
a long history of investment in biotechnology know the inherent risk of early stage 
teclmology companies. These investors believe that they will benefit from fmancing this 
sector by taking a long-term perspective. 
The gestation time and time to get products (or drugs) to market is linked both to the 
sector and the quality of management. Long gestation times and missed targets for 
deliverables cause difficulties in stakeholder relationships with promoters due to their 
adverse impact on valuations. This is especially a problem in the bio-pharmaceutical 
segment, which is so highly regulated. 
Differences in perceptions about risk and retum in the negotiation process between firms 
and investors are an issue. An entrepreneur usually thinks his or her company is worth a 
lot more than what capital supply siders think it is . In general, the earlier the 
development stage of the company, and the less experienced management is, the wider 
is the value perception gap between the two parties involved. At least in the earlier 
development stages, promoters have poor knowledge about venture capital dealings . 
33 
- ------------ ---
Negative attitudes on both sides of a financing negotiation also play a role. Sorne capital 
supply siders admit that sorne venture capital groups advance term sheets that are tao 
harsh, impose their terms and ask for as much as 60% of the company. Sorne finn CEOs 
have the attitude that capital markets are there to be used and abused, and exist only for 
their convenience. They try to get every last penny that they can for their shares, and 
they do not care if new shareholders make money or not. Most capital demand siders 
tmderstand that investors take significant risks for which they deserve an adequate return 
as compensation for such risk bearing. 
From the viewpoint of investment bankers, it is important that promoters become aware 
of the expected rate of retum required by investors, and about the network value these 
investors bring to a project. Investment in biotechnology stock is associated with buying 
a lottery ticket by many financial analysts. They consider biotech stocks as being the 
second highest risk after mining stocks. Other capital supply siders believe that many 
participants are still unaware of the time and high risk involved in bringing a product to 
market entry. The nature and importance of perception differences vary from one group 
of capital supply siders to another. Venture capitalists by nature consider themselves as 
being set up to take risk. Their perceptual differences with entrepreneurs are not about 
risk but about value. For other supply siders, perception differences arise from 
misunderstandings about investor expectations and/or competitive retums available from 
investment in other capital market sectors. 
Lack of realism about the required market capitalization required, and the difficulties 
involved in successfully listing a stock on NASDAQ are also important issues. The 
market capitalization of the finn must be in the $300 to $400 million range to get the 
attention of U.S . financial analysts. This is a prerequisite to show that a finn has the 
potential and the market capitalization that are necessary to do a public round of 
financing on NASDAQ. Thus, a $50 million finn has a formidable task if it is to be 
ready for a NASDAQ listing within a three-year span. 
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According to sorne capital supply siders, the total misunderstanding of finance by 
promoters causes the problem. Many capital supply siders also consider that the 
Canadian financing environment is too institutional and too protected, when compared 
to the US. According to them, many entrepreneurs do not realize how tough conducting 
business is in such a capital-intensive industry. 
Since the supply of capital differs by phase of development, this is likely to significantly 
affect the relationship between demanders and suppliers of capital. While many capital 
suppliers can finance the initial phases with relative ease, such is not the case for 
subsequent phases. The majority of the VCs invest less than $5 million, and up to $10 
million in very exceptional situations (i.e., longstanding and well-performing projects 
not yet ready for public markets). However, even in the case a drug delivery system that 
costs relatively less, fifty million dollars in financing is needed. This level of financing 
is often difficult to find in Canadian financial markets. Even if the public distribution is 
fully subscribed, the net proceeds will only be thirty to forty million dollars and a 
financing shortfall remains. Thus, capital demand siders need to plan early for a follow-
up equity distribution in the US. financial market. The US. market is very competitive 
with a great number of participants. The Canadian market provides important leverage 
for US. market entry by increasing the capitalization of the Canadian firm. 
Private rounds in the range of $50 to $70 million are possible. With such funding, a firm 
can go to phase II clinical trials. However, to reach phase III, most interviewees believe 
that the firm needs to partner with a big pharmaceutical company. 
Sorne interviewees attribute the differences in perceptions of risk and retum between 
promoters and investors to the small number offund managers in Canada. They perceive 
these managers as not being very experienced due to the limited number of successes to 
date in Canada, although these fund managers are becoming more educated in the length 
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of time that it takes to develop a compound. With increasing sophistication through 
experience, the Canadian fund managers will be able to invest in these companies at an 
earlier stage. 
The situation in Canada is changing quickly. Five years ago, there were no companies 
with billion dollar market caps in the biotech field in Canada. Today, we have about five 
(Biovail, BioChem Pharma prior to purchase, QLT, Angiotech and MDS). A few capital 
supply siders predict that ten or fifteen firms of this size will exist within a year or two, 
which means that sorne investment decisions will have matured and more investors will 
become comfortable with the idea of bearing risk because they will see successes. With 
more successes and more companies with billion dollar market caps, the belief is that 
more investors will be prepared to bear more risk. 
3.3.3 Difficulty in valuing biotech firms 
• Valuation methods for various groups of capital suppliers 
While sorne capital suppliers use formai valuation methods, others perceive valuation as 
being more of an artistic process, especially for projects at the very early stage. Sorne 
VCs use a detailed evaluation process starting with the firm's history, an evaluation of 
the management based on their past successes, and an assessment of the technology or 
products. The state of development of molecules, an estimate of the capital required, 
markets, level of competition, and a complete fmancial analysis of cash flows and pro 
forma financial statements complete the analysis. Risk analysis accounting for the terms 
of shareholder contracts, as well as agreements and subscriptions, is also performed. 
Valuation is more difficult for biotech firms since a significant part of a biotech firm's 
value consists of intangible assets, and regulatory uncertainty. Regulatory authorities 
can modify their position at any tirne, adding costs and delay to the approval process. 
Clinical and development risk and the general competition landscape are difficult to 
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quantify smce few comparables exist. Since value depends upon perceptions, an 
important gap can appear if concepts are not well explained or understood. 
Analysts and investors examine an array of valuation factors such as management, 
science, intellectual property, markets, regulatory context, type of business model, and 
liquidity of the firm's stock. Poor market liquidity can translate into a loss of 10, 15, 20 
or even 50% in value in one day if a large investor disposes of his shares. Value can 
vary by 30 to 40% depending on the clinical stage and business model involved. 
Any valuation process is ultimately a judgment caU whatever the evaluation process 
being used. Sorne analysts say they use a complex evaluation procedure with up to 30 or 
45 items to determine a base risk-adjusted rate ofretum or discount factor, together with 
a weighting scheme for the various factors involved. For example, 30% is a minimum 
base rate of retum for phase I. The existence of long-term plans (five years and over) is 
seen as an important aspect given the ten to fifteen year development process. Priee 
earning ratios or revenue multiples are used only to value more mature firms. Existing 
comparables in the market are important to establish value and estimate risk. Extemal 
validation of the technology also is a consideration. Due diligence and follow up by a 
YC, as well as an alliance with a big pharma, add comfort for investors. Many 
stakeholders stress the importance of remaining critical about these deal s. 
An alliance with a big pharma has risk. If the big pharma is acquired or merged, the 
joint arrangement for development may be shelved if it is no longer a core priority. 
Sometimes big pharmas want to maintain their eamings per share for they fear the 
reaction of analysts if their earnings growth rate falls below a given target. So there is 
pressure to finance R&D and develop molecules so that there is no direct impact on 
eamings per share. 
Valuation methods are tailored to the stage of development. When a firm already has 
products in the commercialization phase, revenues or profit multiples are used. The 
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cliscountecl cash flow method, where cash flows are properly adjusted for the risks 
inherent in the stage of development of the drug, is another method employed. If the 
perceived risk is high, a discount rate, of say 30% per year, is used. If the drug is only in 
phase 1 or in the pre-clinical phase, the expected success rate is low, at say 10%, and it 
could be 50% for a drug already in phase 2. 
At the pre-start-up or start-up VC stages, the valuation method is more of an art than a 
science. Many capital suppliers mention that feelings about management and the 
negotiation process are significant determinants, and that too low of a priee has a 
negative impact on the performance of the promoter. The most commonly used formal 
valuation method uses comparables. Since the valuation process is an inexact process, a 
10% variation in the valuation obtained by a VC is considered to be normal. 
One valuation method consists of choosing an exit scenario, which means determining 
what the company might be worth at an expected future exit date. Then, the initial value 
that provides a 40 or 45% return is calculated. Hybrid valuation methods also are used 
where discounted cash flows models are used for a five to ten year window, and a 
comparable valuation method is used for a 0 to five-year window. 
In all cases, to ensure valuation is not a garbage-in, garbage-out process, assessment of 
the quality of the valuation inputs is critical. To determine valuation inputs, most 
analysts examine a combination of methods in their attempts to madel the value of tho se 
products. 
Sorne analysts arbitrarily select the discount rate depending on where the companies are 
in the development cycle. Sorne analysts use a multiple of the long bond rate or ten-year 
bond rate as a base discount rate and then add a premium depending on the stage of 
development. Sorne analysts determine what multiple the stock will trade at when it has 
eamings three years from now. Sorne analysts make a net present value assumption 
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about quality. This is based on the likelihood that the product will be developed based 
on an examination of the design of the research or trials, and the fmn ' s key people. 
Thus, given the variation in data quality and valuation methods used, value estimates 
can vary substantially. 
Analysts consider the clinical stage reached by the product when predicting its chances 
ofmaking it through. On average, a clinical trial, or even a pre-clinical stage, constitutes 
the only basis for taking a risk. 
The traditional valuation method for biotechnology is discounted cash flow. As 
companies approach maturity in terms of having a product to market, analysts focus 
more on priee earnings ratios. Typical multiples are 20, 25, or 30 times eamings 
depending on where the firm is in the development spectrurn. Valuations change based 
on sentiment but investors and analysts use discounted cash flows for longer investment 
horizons and priee earnings ratios for shorter horizons. For sorne comparues, the issue is 
what they think they are worth compared to what the market thinks they are worth. 
The argument that Canadian valuations are lower than those in the U.S. is no longer 
considered to be true. One interviewee aptly stated this as follows: 
ft used to be that when you showed up with your green sheet, which is the 
document that you market with, and you have used US comparables, they would 
state that we are not paying the premium because those are US comparable 
companies. Now they Jully expect to see US comparables, and they accept the 
pricing of the US comparables for Canadian companies. 
• How do their practices differ from other competitors both domestically and 
intemationally? 
Practices are similar to those of their competitors at least domestically. Capital demand 
siders often argue that Canadian VCs do not evaluate Canadian firms, as do American 
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V Cs. Many reasons could ex plain this alleged difference if it exists. These include a less 
competitive structure for the VC offer, smaller capital amounts because of smaller 
average portfolios in Canada compared to the U.S ., and differences in the quantity and 
quality of companies in the two countries. Sorne interviewed capital suppliers believe 
that similar enterprises are valued less in Canada than in the U.S. Although sorne 
Canadian entrepreneurs think that they should establish their firms in the U.S. , many 
capital su pp liers stress that most of these firms do not have the critical mass to be in the 
U.S. Furthermore, the Canadian company needs to be really different from what already 
exists in the U.S. to attract U.S. investment. The interviewees also note the lack of 
knowledge about Canadian f1rms . Furthermore, due to the sharp market downturn, many 
capital supplier siders have refused new investments because they are maintaining those 
already in progress. Capital supply capacities limit the amount of capital that can be 
invested in new and ongoing ventures. Sorne interviewees suggest that European 
funding may be a more viable option for Canadian firms since Europeans see Canada as 
a port of entry into the U.S. 
The capital supply siders offer many interesting insights about the nature and practices 
of the VC industry in Canada. These comments concem primarily the lack of 
competition or excessive level of inbreeding in Canada, and the relative immaturity of 
the industry in Canada compared to the U.S. This is reflected in the mentality and 
culture of Canadian capital suppliers compared to their U.S. counterparts. Many capital 
supply siders believe that Canadian VCs have much to leam from the U.S . VC industry. 
The interviewees highlight many problems in Canada in the financing process related to 
the maturity and culture of Canadian capital supply siders. They emphasize the negative 
influence of the overly great role played by institutional investors in such financing, and 
the relative lack of maturity and realistic expectations of Canadian entrepreneurs. Many 
capital supply siders also stress the relatively few numbers of "real" risk capital groups 
in Canada. 
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Capital supply and demand siders share the perception that competition is lacking in 
Canada compared to the U.S . Canada has many players but no competitive spirit. Over 
the long-term, this will result in many unsatisfied investors in Canada. In the U.S. , the 
many (generally private) players are creating capital pools (like BioCapital) to manage 
their investments. These investors see a need for more private players on the supply side 
in Canada for ali the rounds from start-up through pre-IPO. In Canada, not many public 
firms have the level of market capitalization that is of interest to institutional investors. 
Since many IPOs by Canadian firms were premature, Canada has a number of firms 
with market caps that are too low. Sorne capital supply siders consider that these public 
firms do not have the necessary liquidity to progress and to give the retum that is 
expected by investors. These public investors have expected holding periods of one to 
three years over which they want to eam expected retums through growth in market cap 
per share. While many of these interviewees perceive NASDAQ as a superior trade 
venue, a firm needs a market cap of over $500 million to do so. Such a market cap is 
usually attained when the firm has products on the market, and the firm needs capital to 
bring its products to market. If a firm succeeds in consolidating technologies and growth 
by finding partners, then it might be possible to list on NASDAQ. Otherwise, a firm 
might be in a liquidity crisis that can last for three to five years. Firms are vulnerable to 
stock market volatility when their shares do not have liquidity. Sorne capital supply 
siders believe that the TSX does not have the appropriate liquidity, contrary to their 
previous beliefs. So they are questioning whether listing on the TSX is still a good step 
prior to listing on NASDAQ. This will remove an important step in the necessary 
progression for institutional investors who are looking for investments with market caps 
of over US$500 million. 
The development of the private risk capital industry in Canada is seen as a necessary 
and important development. Indirect sources of capital, such as Canadian pension funds, 
are perceived as having a very poor knowledge of bio-industries. Furthermore, two 
important factors seriously impinge on their capacity and willingness to invest in 
41 
biotechnology. 
The first is the liquidity of the Canadian financial market, where most public biotech 
companies have relatively small capitalizations (below $500 million CAN). For many 
capital supply siders, lack of liquidity is an important issue for even solid and profitable 
Canadian biotech firms. The rapidly growing Canadian institutional investors are not 
interested in deals of seven (or even ten) million dollars. A pure hase of 25 million shares 
of Axcan (or even Hemosol) represents 30% of the firm. Thus, players that could 
become more sophisticated investors in biotech do not want involvement in small 
capitalization investments. 
Big pension and mutual funds want returns and are looking for safe and liquid value. 
Generally, they are increasing their relative allocation to non-domestic investments. 
They have no interest in significant exposure to small cap biotechs for they do not want 
to hold more than 10% of any one stock. Small investments demand too much 
supervision and management, and one manager cannat follow 40 to 50 stocks. A lack of 
portfolio managers also means that the number of stocks under management must be 
small. Sorne capital supply siders believe that more funds like BioCapital would be 
launched if more qualified and experienced small fund managers were available. Also, it 
is not reasonable to expect that investors will remain captive in a given fund or category 
of funds for more than two years. According to the interviewees, if no specifie and 
effective government measures are implemented to invest in small cap biotechs, 
consolidations will continue to occur. 
Sorne firms go public prematurely. VCs have financed few firms close to a 500 million 
dollar market cap. Capital supply siders believe this will not happen for the next 
generation of firms , and institutional involvement will be necessary. 
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• When funding in stages, what is the timing and the amount of each portion? 
Financing in stages is not seen as being as important as expected. The attitude of VCs 
towards stage (tranche) financing has evolved somewhat. In the early stage, they try to 
limit themselves to only two portions, 60% of the amount being disbursed in the first 
payment since liquidity needs are usually higher. In contrast, the achievement of 
milestones is seen as being essential for investors who monitor their investments 
close! y. 
3.3.4 LEVEL OF OWNER COMMITMENT AND FINANCIAL 
PARTICIPATION IN THE PROJECT 
While it is often seen as relevant in other sectors of activity, financial comrnitrnent from 
the promoters does not play any role in biotech financing. We hypothesize that since the 
financial means of most individuals are relatively small in such a capital-intensive 
industry, this traditional criterion does not provide any credible indication of project 
sucees s. 
3.3.5 DISCLOSURE OF INFORMATION 
While the V Cs rarely see disclosure of information as an issue, this dimension is seen to 
be a major problem from the viewpoint of the financial markets. Disclosure of 
information, for example, about product development, and clinical trial research design 
and results are essential inputs used by analysts to determine value. Although many 
biotech firms do not have a communication strategy aimed at the financial market, this 
deficiency is not perceived as being unique to the biotech industry. 
3.3.6 STRATEGie ALLIANCES AND MERGERS & ACQUISITIONS 
The capital supply siders consider strategie alliances and mergers as important 
strategies, and believe that the current trend to their use continues to be strong. 
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Strategie alliances are critical because it is very rare that a company can be funded 
through to commercialization without bringing in a partner. Furthermore, the bigger 
pharmaceutical comparues can bring in valuable technical expertise for building large 
plants, manufacturing and marketing. Generally, no international sales force needs to be 
established. 
While VCs consider alliances, mergers and acquisitions as essential strategies, they 
acknowledge that they are difficult to accomplish. Alliances can occur at any stage of 
development of a firm with the exception of start-up. An alliance or partnership for 
basic research is usually narrow and specifie, and more meaningful arrangements 
usually occur at more advanced development stages when there is a potential therapeutic 
candidate. Big pharmaceutical company alliance decisions are generally taken in a 
global perspective. Specifie expertise fields play a critical role in this respect. The 
Canadian-based research centres of the major pharmaceutical firms do have alliances 
with biotech firms worldwide. Given the scale of their research activities, sorne research 
centres have more than 300 researchers involved in basic research. Firms are sometirnes 
too small to be of interest for a big strategie partner. When the alliance occurs too earl y, 
it might be sub-optimal from a value creation viewpoint both for the finn and its 
stockholders. For sorne interviewees, strategie alliances are the link between phases 2 
and 3. This link brings comfort to the financial market. 
Many alliances are just window dressing for there is no substantial involvement from 
the big partner, and no real risk taking. The smaller frrm receives little or no money, and 
the transaction is essentially risk-free for the Big Brother. 
VCs follow two development models. The fust model brings foreign firms to establish a 
lab or a facility in Canada directly or via a joint venture. The other model opts for VC 
participation in a small firm to strengthen its bargaining position in negotiation with a 
big potential partner. The VCs also may provide direct support in the form of expertise 
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in these instances. Whether or not the VCs can facilitate alliances through financial or 
tactical means is unresolved. 
Alliances are seen as a positive validation of the technology of the smaller partner, 
especially when the alliance is with a big pharmaceutical company. Alliances are signais 
that convey credibility to fmancial markets. One problem with alliances is that 
sometimes stakeholders like VCs or financial analysts cannet speak directly with the big 
pharmaceutical partners because of confidentiality. This makes evaluating the alliance 
deal more difficult, and hampers the process of signalling its value to investors. 
Acquisition of a Canadian biotech firm by a foreign finn is not perceived as being a 
negative event per se. While mergers do not mean that research centres will move out of 
the country, they do imply that decision and management centres may no longer be in 
Canada. Canadian-based research activities might be exposed to downsizing later if 
additional acquisitions bring in similar capabilities. In spi te of these potential problems, 
many capital supply siders consider consolidation as a must to achieve critical mass for 
Canadian firms that are relatively small. Consolidation is important because many 
capital supply siders believe that the standards to go public in terms of minimum market 
caps are becoming more stringent. However, consolidation does not solve ali financing 
problems, especially when the combined burn rate still exceeds available combined 
financial resources. 
Most interviewees in the M&A business state that the biggest issue usually is who is 
"driving the bus" after the comparues combine. Sorne of the issues deal with aligning 
the interests of management with shareholders. If management is drawing a large salary 
and options annually in a fashion unrelated to firm performance, they may not care 
about the retum to the common shareholders. They may even resist any merger attempt. 
When specialists in alliances or acquisitions at the big pharmaceutical firms generally 
pass on evaluated opportunities, it is because expected costs exceed expected benefits. 
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In these situations, the technology is valued much higher by the firm than by the big 
pharma. Healthy biotech companies have good and sound financial backing from 
investors, and look to the pharmaceutical industry to realize the value of the technology 
they develop. Companies without solid financial backing try not only to realize the value 
of their technology but also to create or fund sorne of their ongoing activities through 
alliances. These firms see alliances as a way of financing, while it should be used 
primarily to get the maximum value out of their research development. For many 
interviewees from U.S . pharmaceutical firm alliances, biotech firms tend to inflate the 
value of the technology. In turn, they approach the big pharmaceutical firms premature! y 
with an umealistic priee tag. As a result, they do not capitalize on their opportunities. In 
other cases, the opportunity may not be interesting for technical reasons. 
The biotech comparues do not realize how their technology fits into the overall scope of 
the drug discovery, and that delivering a target is just the first of a large number of risks 
that the pharmaceutical company has to fmance. The big pharmaceutical firms are not 
willing to pay enormous sums of money for the technology, but they are interested in 
technologies that help or reduce the risk of drug discovery, and irnprove efficiency and 
accelerate the drug discovery process. Pharmaceutical fmns seem less comfortable than 
the VCs in revealing their goals with respect to target rates of return on their 
investments. 
Many pharmaceutical firms have deliberately decided to avoid the valuation of 
technologies because they find such efforts to be very inefficient and inaccurate. The 
value of a teclmology is firm-specific since its value depends on how access to a given 
technology enables the firm to further its own development process. Big pharmas value 
a product-based biotech firm differently from a technology-based company that is 
helping pharmaceutical firms discover new drugs. 
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------- ----------------, 
When pharmaceutical firms are involved in acquisitions, they concentrate first on the 
business opportunities it brings to the table. After assessing the business transaction, 
they evaluate the alliance transaction. This is aptly stated by one interviewee as follows: 
We like to not muddy the situation, we want to make sure that we put the horse 
before the caddie, and that the reas on for establishing the transaction is to 
enhance effectiveness in drug discovery. 
While non-public information about the nature and conditions of deals is unavailable, 
sources of information to evaluate the amount of money that might be coming into 
Canadian firms from alliances or acquisitions with the U.S. -based big pharmaceutical 
firms are available. Usually, specialists in the field use the U.S. figures with the implicit 
assurnption that Canadian activities represent about 1/10 ofthe U.S . figures . 
3.3.7 GOVERNMENT COMMITMENT AND GUARANTEES FOR 
MANAGING RISK 
Few U.S . capital supply siders appear to possess any specifie information about 
government commitment toward biotech fmns in Canada, although they perceive that 
encouragement as being greater in Canada than in the U.S. The Canadian situation is 
perceived as being more like the European situation where government provides many 
incentives both at the state and federal levels, to help young biotech companies to get 
established. U.S. interviewees with knowledge about the existing programs in Canada 
state that they would be tempted to start a firm in Canada because of these incentives. 
They also stress that the Canadian government must place sufficient pressure on biotech 
companies so that only the best and most innovative companies get started. By removing 
the market's natural selection process, companies that may not survive in a competitive 
environment without government assistance may exist for a couple of years in a 
government-assisted environment. They acknowledge that, since Canada does not have 
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an infrastructure as extensive and as mature as the one available within the U.S., 
incentives are justified to sorne extent so that new Canadian biotech firms can compete. 
Sorne capital supply siders do not know the various programs weil or consider that the 
government does not promote these programs aggressively enough. Even those that are 
using ali kinds of programs mention that similar (or as attractive programs) exist in 
others countries like Germany. For them, the program drivers are great management and 
scientists, and not government programs. 
R&D tax credits are seen as an important determinant for high-tech companies locating 
in Canada. Since persona! incarne tax rates are higher in Canada than in the U.S ., the tax 
holiday for foreign nationals helps to alleviate the lack of management. While it is 
unclear whether these incentives are cast-effective from a global economie perspective, 
the industry takes advantage of these tax provisions. Sorne of the higher tax burd en also 
is offset by the lower cast of living in Canada. 
Sorne capital supply siders believe that having programs or fiscal measures that 
encourage bath investment in the biotech sector at the retail level and help to develop 
broader knowledge would certainly be helpful. However, unless an effective screening 
process to qualify or pre-qualify eligible companies is in place before fiscal incentives 
are offered, such a program could put small investor money at risk. Such programs 
could have a big impact on the stock market if the weight of the biotech sector in the 
TSX index was to rise to, say 6%, from its current weight of about 3%. In that case, 
institutional investors could no longer ignore investment in the biotech sector. 
Big investors have sorne difficulties with portfolio diversification if they only invest in 
Canadian biotechnology. Attracting foreign institutional capital to Canadian biotech 
firms could offset this. This is severely hampered by the relative lack of liquidity of the 
Canadian financial markets. 
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Capital supply siders consider that Canada has been extremely proactive but could be 
even more active and biotech-friendly. However, it is important that governrnent be very 
selective about where to invest, and on how those investments are structured. It is 
important not to end up with 500 companies that are too small for IPOs, and that have 
no knowledge about how to obtain the next level of financing. These interviewees 
believe that Quebec has done the best job among the provinces in fostering 
biotechnology through incentives. B.C has a better record for fostering technologies at 
the universities, and this is something that Quebec can leam from B.C. While Ontario 
does not appear to have a coherent strategy, it remains strong partly because of its 
broader market. An important question not broached by the interviewees is the degree of 
cost-effectiveness ofthe various federal and provincial fiscal and tax programs. 
3.3.8 OTHER RELEVANT DIMENSIONS 
In accordance with the viewpoint of many capital demand siders, sorne capital supply 
siders believe that more competition in the venture capital market would be beneficiai. 
Not only do relatively few pools of capital operate at the venture level but the 
competition between these groups appears to be relatively low. 
Capital supply siders note that biotechnology has a relatively low rating in the Canadian 
financial market. This is expected to change as the relative weighting of the biotech 
sector in the TSX index increases further from its recent increase (from approximately 
0.5% to 3 %). 
Capital supply siders find that many Canadian companies do not meet a minimum level 
of capitalization and size of shareholding. Trading volumes are much lower for 
Canadian IPOs versus U.S. IPOs in the biotech field, probably because Canadian issues 
tend to be smaller at US$20 to 30 million compared to the typical U.S. IPOs, which 
averages US$75 million plus. If most issues are floated to institutional investors, there is 
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a real lack of liquidity. Probably only 25% of the $25 million (or about $7 million) is in 
retail hands. Most of the recent group of companies that went public are Montreal-
based. They include firms such as NeuroChem, Nexia, ConjuChem, and Chirotech, that 
trade on average less than 10 thousand shares a day. Thus, venture capital investors at 
earlier stages in these companies cannot exit as expected if little liquidity exists in the 
market place. Thus, new potential Canadian IPOs are either thinking about waiting to go 
to US. markets or to do a bigger Canadian issue, or even doing a late-stage private 
round instead ofthe IPO. 
Since lack of market liquidity is perceived as the nurnber one problem in biotech 
financing, many interviewees feel that Canadian institutions should be educated to better 
support biotech companies earlier in the process so that they can replace the IPO 
fmancing round with a mezzanine round so that they have enough financial resources 
for the next stage of development. They could then postpone the timing of their IPO 
until their market cap and their valuations are such that they can float an issue whose 
secondary trading has liquidity. 
Capital supply siders believe that a number of good V Cs exist, and that for the most part 
they are Quebec-based. They feel that an insufficient nurnber of dedicated biotech funds 
exist relative to the supply of bio tech investment opportunities to create a level playing 
field for sorne biotech companies. They feel that this is especially the case for non-
Quebec-based funds. Since the US. VCs recognize certain parts of Canada as 
containing expertise in biotech, more specialized US. biotech funds are investing or 
planning to invest in Canadian biotech companies. 
A minority of the capital supply siders advocate that the long-term investment model 
used by Canadian VCs no longer applies to biotech investment. They consider the terms 
of funds that range between five to seven years as being too long. They stress th at su ch a 
long holding period, even for an institution, is overly long. They consider the Canadian 
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mindset as being a lagged evolution of the U.S. mindset in biotech but not in industries 
that Canada is very good at. They predict that Canadian VCs will experience major 
problems since returns for the next two or three years will be flat. While the annual 
long-term retum on venture capital is 16%, it has been 45% to 60% arumally for the 
three years prior to 2001. 
Most interviewees agree that it is preferable if companies can develop further using 
private capital before going public. 
Sorne capital supply siders believe that VCs are concentrating more on companies that 
have reached phase II or phase III, and that it is harder to finance firms at the pre-
clinical stages. In others words, these interviewees believe that VCs are becoming less 
risk-tolerant, although they know the area better and they are ready to assume these 
risks . 
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Table 3.2: Quotes of interviewed supply side stakeholders 
1. Business development is the most critical of ali 2. In Canada, a lot offums probably went public long 
management issues facing_ Canadian fmns . before they should have. 
3. Each year at BioContact the entrepreneur meeting with 4. The capital supply structure will have to undergo 
the investment bankers and financial analysts is a major changes. We have more and more fmns going 
reality check. Entrepreneurs are not aware of the hard public that are stuck under a 500 million market 
reality of the fmancial market place. capitalization. 
5. Without a doubt, the majority ofCanadian fums will 6. On Wall Street, there have been very few investrnent 
be acquired by foreigners, be it European or American banks that invested in AgBio given the few priva te 
furns . initiatives outside the large corporations. 
7. GMOs, the whole issue around GMOs controversy is 8. There is a lot ofproblems in Canada with the 
a real negative ... wh ether they 're involved with financing process of the firms. There is a lot of players, 
GMOs at ali. but no competitive spirit. 
9 . In nutraceutics, we are waiting for legislation that 10. The quality of management is the biggest problem 
would confum or validate the market. Nutraceuticals when we are developing a furn . There is a diversified 
and cosmeceutics would expand if appropria te and important need for management people, mostly in 
regulation can draw the line between real science the marketing and sales department in Canada and in 
products and miracle products. Quebec, more specifically. 
11 . ln plant biotechnology a few big fmns can block most 12. Canadian small firm is often too small to be an 
development for they hold ali the patents. interesting alliance partner or could be crunched by 
bigger foreign furns . 
13. Things that are different between the Canadian and 14. Alliance strategy is an area where the Canadian firms 
American fu·rns? Poor management. Poor are very weak in, extremely weak. 
management. 
15 . We invest in only one project out oftwelve or sixteen 16. The depth of liquidity of the markets in Canada is Jess, 
(acceptation rate of 1/12 or 1/16). so that is a constraint. Y ou don ' t have the capital 
access, you don' t have the sophisticated investors, you 
don' t have the ability to list, to geta proper valuation, 
fmancial analysts and so it begins to feed on itself. 
17. One should not believe those who say that they are 18. The single biggest problem is too many comparues 
going to be ready for the NASDAQ in three years. Do with not enough management and not enough breadth 
you know that you will have to go from a market oftechnology. The perception in the U.S . is that there 
capitalization of 50 million to 400 million? Otherwise, is a lot of"one trick porues" and they're comparues that 
fmancial analysts will not follow your company. are very thin on management. The technology may be 
excellent but it's not brought up to build up an entire 
company. 
19. How early a company can go public depends on the 20. Very often it's a Jack of depth and breadth of the 
current market sentiment. Right now it's exceptionally management groups and perhaps as weil, even of a 
difficult togo public for most fmns. Many of the complete naiveté on dealing with capital markets, for 
companies that went public too early last year have example. Many of these comparues do not know how to 
seen their market value drop tremendously. So there is be a public company. And even . . . dealing with 
risk in going too earl y but market place acceptance investors and investments. 
changes ali the time. 
21. Liquidity is a huge issue for people. Many of the 22. Some groups think that an IPO is liquidity. And you 
comparues ... And it is difficult to get the bread th of the say no, IPO is not liquidity. Liquidity comes when you 
share holding one would like. It would be a great are a billion dollars and the new investors can make 
bene fit if comparues could be driven further with money on the IPO. 
private capital before having to expose thernselves to 
the public market. 
23 . Given that the consolidation of the financial sec tor 24. When we look at the company, we like what we see in 
among the investors ' funds has accelerated, it becomes Quebec or in British Columbia. Institutions want to be 
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progressively more difficult for those groups to look at able to get in and out of stocks, bu y and se li them 
smaller comparues. quickly and without disrupting the market by their own 
activities. Therefore they want to invest in very large 
capitalization comparues. 
25 . Cri ti cal mass is a hu ge issue, many of the 26. And there are plenty of comparues that are starving for 
comparues have difficulty getting the critical mass and capital here for good reasons. Y ou don' t have to be 
it's a moving target as we continue to see consolidation Canadian to have that issue. 
on the financial sector and the natural growth offunds. 
It's going to be a higher board for the company to get to 
the IPO stage. 
27 . An investor who's only interested in an economie 28. It's great that Merck is their partner because that means 
return in biotech is looking for this 45 to 50% rate of their science and their IP and everything must be good. 
return. But then the question is what is the cost? So you have 
to balance off the need for validation, which is 
extremely important and the cost of that. 
29. The perception is that it's a lot easier for a very young 30. l'rn irnpressed with everything l've ever seen. l've 
company to get funded in Canada. But then the problem been in conferences in Vancouver, Calgary, Montreal, 
is what happens after. So there has to be consolidation and Toronto and always l'rn impressed. l'rn always 
because a lot ofthese comparues can ' t move forward surprised that the world doesn't know more about that. 
but yet you still see people kicking in a million or two. 
31. And if the TSX and the European markets are 32. Canadian companies that are funded are called science 
sometimes distractions, it could be negative because projects. That is for the sake of the science and they 
you're getting a market that's not liquid and who wants spend too little time building into a business. 
to compete with a market that's not liquid. 
33. 1 think that it probably reflects less sophistication in 34. The whole project management is an issue. 
Canada generally in selecting intellectual property 
strategy and have real offensive and defensive 
techniques. 
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CHAPTER4 
CAPITAL REQUIREMENTS FOR THE THERAPEUTICS SUB-SEGMENT OF 
THE CANADIAN BIOTECHNOLOGY INDUSTRY 
The primary objective of this section is to estimate total capital requirements for the 
therapeutics sub-segment of the Canadian biotechnology industry using an improved 
estimation method, new data about development costs and attrition rates, and a more 
complete and updated state of the pipeline of molecules for Canadian therapeutics 
biotechnology firms . In addition, this section also provides initial estimates of the 
aggregate extemal capital requirements of our Canadian sample. 
The capital requirement estimates are obtained from scenano analyses usmg input 
vectors for five exogenous variables: the aggregate number of molecules in 
development, potential growth of the aggregate pipeline of molecule.s, average time up 
to market entry, development costs, and failure (attrition) rates at each development 
stage. The purpose of the scenario-based analyses is to provide benchmarks over a mid-
term (five-year) planning horizon, a period long enough to develop appropriate 
fmancing policies at finn and govemment levels. The scenario analyses quantify the 
sensitivities of capital requirement estimates to changes in the relevant input variables, 
especially the development cost and attrition rate vectors. 
4.1 GENERAL METHODOLOGY FOR ESTIMA TING CAPITAL 
REQUIREMENTS 
The United States is an increasingly important segment of the world market for 
pharmaceutical products. 3 Since most Canadian fmns want to se li their products in this 
dominant market, the development of a therapeutic molecule is highly influenced by the 
regulatory requirements of the U.S. Food and Drug Administration (FDA). This directly 
3 The United States is the world's largest market for pharmaceutical products, accounting fo r 48.2% of 
worldwide sa les in 2000. ln contrast, Europe and Japan represent 23.7% and 16.2%, respectively, of the 
world market in 2000 (!MS Health, 200 1 ). 
affects the development and testing costs of Canadian therapeutic firms. Since the 
review processes are very similar in Canada and the U.S., the development of a new 
drug typically follows the steps given in Table 4.1. Given the absence of Canadian data 
on development costs and attrition rates, the U.S. data are used herein. 
Table 4.1. The development process for a pharmaceutical drug 
Development Early Pre-clinical Clinical Trials FDA 
stage Research Tes ting Phase 1 Phase II Phase rn 
Test Laboratory 20 to 80 lOO to 300 1000 to 3000 
population and animal IND healthy patient patient volunteers NDA 
studies fi ling volunteers volunteers fi ling 
at at 
Purpose Discover a Assess FDA" Determine Evalua te Confrrm FDAb Review 
drug safety and safety and effectiveness, effectiveness, & pro cess 
candidate biological dosage & look for side monitor adverse and 
activity effects reactions approval 
a D IND refers to InvestigatiOn New Drug. NDA refers to New Drug ApplicatiOn. 
Somce: Spilker (1998). 
Once a new compound is identified ( discovery stage), the molecule enters laboratory 
and animal tests where the safety and the biological activity of the compound are studied 
(pre-clinical stage). After the filing of an Investigation New Drug (IND) application, the 
molecule is tested on humans. These clinical trials involve three phases. In Phase I, 
safety and dosage tests are conducted on a small number of usually healthy volunteers. 
Phase II ex tends the safety control on volunteer patients and assesses the efficacy of the 
drug. Phase III involves a large number of patients in order to statistically confirm 
efficacy and detect any side effects. The company then files for a New Drug Application 
(ND A). If the FDA approves the new compound, the company can begin to bring it to 
market. 
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The development process for a typical drug is very long, costly and risky. Thus, the 
method to estimate capital requirements, which is depicted in Figure 4.1 , is based on 
various scenarios that capture these three features of the drug development process. The 
model accounts for the five development stages from pre-clinical testing to the review 
process. The discovery stage is excluded from the model because the nurnber of 
molecules, failure rates and development costs cannot be estimated objectively for this 
development stage. While up to 5000 compounds per approved drug can be screened at 
this stage, there is usually no reliable public information about the nurnber of molecules 
actually discovered and tested. 
Figure 4.1. Capital requirement estimation procedure 
[
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The output of the estimation procedure used herein is the total amount of capital needed 
to bring existing and future molecules up to market entry. The model does not separate 
the capital required into its two major components, namely, intemally and extemally 
generated capital. An indirect procedure is used to obtain an estimate of total extemal 
capital requirements using those fmns who have publicly indicated an interest in 
obtaining extemal financing. 
We use vanous scenanos about the nurnber of molecules in the pipeline with and 
without new molecule entry into the clinical testing stage of the development process. 
The scenarios, which assume that no new molecules enter the pipeline, are used to 
evaluate the capital required to bring to market only the compounds currently being 
developed within Canadian firms. The sensitivity of the capital requirement estimates to 
the cost and attrition rate assurnptions is tested by using two different data sources, both 
with and without changes in R&D productivity. To assess the sensitivity of the 
outcomes to the nurnber of molecules in the pipeline, we increase the initial nurnber of 
molecules in the pre-clinical stage by 20%. 
The more realistic scenarios allow for the entry of new molecules into the pre-clinical 
stage. All of these scenarios with new molecule entry assume that the nurnber of new 
molecules entering the pipeline remains constant after 2006. The reason is that 
technological uncertainty is too high beyond this five-year planning horizon to make any 
meaningful projections of the subsequent rate of growth in new molecule entry. 
Different growth percentages are used to assess the sensitivity of the capital 
requirements to this determinant. Two data sources also are used to test the sensitivity of 
the capital requirement estimates to the development cost and failure rate assurnptions 
used at each development stage. Input variables and their quantification are presented in 
Appendix A. 
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This estimation procedure has two potential limitations. The first potential limitation is 
that it uses aggregate input data. Durations, costs and failure rates differ across firms and 
therapeutic fields. However, an alternative methodology, which aggregates capital 
requirement estimates made at the individual finn leve!, may not generate better 
predictions. This alternative methodology imposes significant information-disclosure 
burdens on companies, is more costly to implement, and does not benefit from the 
typical error diversification effect achieved from increasing sample size. The second 
potential limitation is the quality of the input data, although the average durations of the 
different development stages often are quite similar across data sources.4 
4.2 CAPITAL REQUIREMENT ESTIMA TES5 
In this sub-section, we present various capital requirement estimates based on the state 
of the Canadian pipeline in 2001 as reported in Table A. 1 in Appendix A. 
4.2.1 CAPITAL REQUIREMENT ESTIMATES USING SCENARIOS WITH 
NO NEW MOLECULE ENTRY 
The capital requirement estimates for the four base case scenarios with no new molecule 
entry are reported in the second colurnn of Table 4.2. Since no new molecules enter the 
development process in these scenarios, only the total cost of bringing the current 
Canadian pipeline of molecules to market is estimated. Since the average duration ofthe 
development process is 8.5 years, ail molecules currently in the pipeline will have exited 
by the end ofyear 2010. 
4 The average duration of each development stage usually varies within a range of plus or minus six 
months, except for the prior clinical test stage. In addition, sorne sources refer to the total discovery and 
pre-clinical testing stage, while other sources account only for the pre-clinical tests. 
5 Ali the values reported in this section are in Canadian dollars, although the input data tables (i.e. Tables 
A.2 and A.3 in appendix A) report U.S. dollars . A fixed exchange rate of 0.635 is used to translate U.S. 
into Canadian dollars . This corresponds to the mean FX rate at the end of October 2001 . 
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Table 4.2 Estimates of the capital required to bring the current Canadian pipeline 
of molecules (lndustry Canada pipeline 2001) up to market entry 
assuming no new molecule entry into the pre-clinicat development stage 
Scenario fo r development cost and Total capital required by 2010 
attrition rate vectors" (billions of CAN$) 
Base case 20% increase in number 
of molecules in pre-clinical trial sb 
1 39.3 41.9 (+6.1 %) 
2 14.7 15.8 (+7.4%) 
3 46 .1 49.2 (+6.7%) 
4 9.1 9.8 (+7.8%) 
"Scenarios 1 and 2 use the development cost and attrition rate vectors before improvements in R&D 
productivity obtained from PricewaterhouseCoopers (1998) and McKinsey (Bhandari et al. , 1999), 
respective! y. Scenarios 3 and 4 are the corresponding vectors after improvements in R&D productivity. 
bThe percentage change over the base case is reported in the parentheses. 
These total capital requirement estimates differ substantially by the source of the cast 
and attrition rate vectors, and for the same source depending on whether or not the cast 
and attrition rate vectors reflect the impact of technological change. To illustrate, the 
capital requirement estimates using development cast and attrition rate vectors that are 
not adjusted for technological change that are obtained from PricewaterhouseCoopers 
and McK.insey are $39.3 billion and $14.7 billion, respectively. These estimates 
correspond to total costs per approved drug of $787 million and $359 million, 
respecti v el y. 
While bath data sources are based on the expectation that the development cast per 
approved drug will decrease by about 25-30%, the direction of the change in the 
resultant capital requirement estimates depends on the data source used. Total capital 
requirement estirnates increase by more than 17% when technological change impacts 
the cast and attrition rate vectors as envisioned by PricewaterhouseCoopers. In their 
methodology, the fall in the total cast per approved drug is more than offset by the 
increase in the individual cast per compound tested at every stage but the first (see Table 
4.2). Moreover, while the cumulative attrition rate over the whole drug development 
process drops, this eventually leads to an increase in the nurnber of molecules reaching 
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the market. In turn, more capital is required to develop these additional molecules that 
would have been eliminated during the previous process. In contrast, total capital 
requirement estimates decrease by 38% when technological change impacts the cost and 
attrition rate vectors as envisioned by McKinsey. Under the McKinsey methodology, the 
drop is due almost entirely to reductions in clinical development costs. While it is 
difficult to choose between these two contradictory views of the net impact of 
technological change on development costs, our initial capital requirement estimates 
suggest that the common belief that R&D productivity and capital requirements are 
positively related is suspect. 
The sensitivity of the capital requirement estimates to changes in other important 
determinants depicted in Figure 4.1 is examined next. Based on the capital requirement 
estimates, which are presented in the last colurnn of Table 4.2, a 20% increase in the 
number of molecules in pre-clinical trials (i.e., a 8.7% increase in the total number of 
molecules in the pipeline) increases the capital requirement estimates from 6.1% to 
7.8% depending on the scenario examined.6 Based on results not reported to save space, 
an increase in the duration of the total development process from 8.5 years to 11 years 
only increases the capital requirements marginally (by about 0.1 %). Thus, as expected, 
the choice of development cost and attrition rate vectors appear to be the most important 
determinants of capital requirement estimates. 
4.2.2 CAPITAL REQUIREMENT ESTIMATES ASSUMING NEW 
MOLECULE ENTRY INTO THE PRE-CLINICAL DEVELOPMENT 
STAGE 
The capital requirement estimates for the aggregate pipeline of Canadian firms existing 
in 2001 for the four sets of scenarios with entry of new molecules are presented in Table 
4.3 on a total and average annual basis over the entire period and over the first five 
6 The robustness of the estimation procedure is verified by increasing the number of molecules by 20% for 
each development stage. As expected, tllis, results in a 20% increase in expected capital requirements . 
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years. 7 Each set of scenarios includes five different rates of growth in the entry of new 
molecules into the pipeline over the next five years; namely, 0%, 10%, 15% (the base 
case), 20% and 30%. The 0% growth rate can be viewed as a pipeline (sample) with 1-
for-1 molecule replacement as a molecule leaves the pre-clinical development stage. In 
contrast, the assumption in the previous section was 0-for-1 in that each molecule in the 
pre-clinical development stage is not replaced as that molecule migrates to the next 
development stage or fails . Similarly, a 15% growth rate signifies a 1.15-for-1 
replacement rate, or that 1.15 molecules entry the pre-clinical development stage for 
each migrant from that development stage. 
7 Note that the capital requirement estimates do not account for the time value of money. Consequently, 
the yearly annual capital requirement estimate is simply obtained by dividing the cumulative estimates by 
the relevant number of years. 
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Table 4.3. Capital requirement estimates for the current Canadian pipeline of 
molecules (lndustry Canada pipeline 2001) for varions new molecule 
entry rates into the pre-clinical development stage 
Scenario• Growth rate Cumulative capital requirements A vera ge an nuai 
(%) in new {billions of CAN$) for: 
molecule entry 2001- 2006- 2011- Total Full15 First 5 
(first 5 years) 2006 2011 2016 years years 
0 46.9 45.7 45.9 138.5 9.2 9.3 
10 48.9 62.1 73.2 184.1 12.3 9.8 
1 15 49.9 72.3 91.0 213.3 14.2 10.0 
20 51.1 84.0 112.2 247.4 16.5 10.2 
30 53 .7 113 .0 166.4 333.0 22.2 10.7 
0 21.6 20.8 20.8 63.1 4.2 4.3 
10 23 .0 29.5 33.4 86.0 5.7 4.6 
2 15 23.8 35.1 41.7 100.6 6.7 4.8 
20 24.7 41.5 51.5 117.7 7.8 4.9 
30 26.7 57.4 76.6 160.8 10.7 5.3 
0 67.4 63 .6 63 .0 194.0 12.9 13 .5 
10 73.0 90.3 100.5 263 .8 17.6 14.6 
3 15 76.3 107.3 125.0 308.5 20.6 15.3 
20 79.8 127.1 154.0 360.9 24.1 16.0 
30 87.6 176.9 228.4 492.9 32.9 17.5 
0 15 .5 14.4 14.4 44.2 2.9 3. 1 
10 16.9 21.0 23 .1 61.0 4.1 3.4 
4 15 17.7 25.3 28.8 71.7 4.8 3.5 
20 18.5 30.2 35.6 84.4 5.6 3.7 
30 20.5 42.7 53 .0 11 6.2 7.7 4.1 
• Scenarios 1 and 2 use the development cost and attrition rate vectors before improvements in R&D 
productivity obtained from PricewaterhouseCoopers (1998) and McKinsey (Bhandari et al. , 1999), 
respective! y. Scenarios 3 and 4 are the corresponding vectors after improvements in R&D productivity. 
The corresponding estimates per stage of molecule development are presented in table 
4.4 below for the fourth scenario. 
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Table 4.4 Scenario 4*: Breakdown of capital requirements per stage of 
development for various new molecule entry rates into the pre-clinical 
development stage 
Growth rate in Cumulative capital requirements Average anou al 
new molecule Development (billions of CAN$) for: 
entry (first 5 stage 
years) 2001- 2006- 2011- Total Full15 First 5 2006 2011 2016 years years 
Pre-clinical 5.4 5.4 5.4 16.2 1.1 1.1 
Phase I 3.4 3.5 3.5 10.5 0.7 0.7 
0% Phase II 2.4 2.1 2.1 6.6 0.4 0.5 
Phase ill 4.2 3.3 3.3 10.7 0.7 0.8 
Approval 0.1 0.1 0.1 0.3 0.02 0.02 
Pre-clinical 6.5 8.6 8.7 23.8 1.6 1.3 
Phase I 3.7 5.4 5.6 14.8 1.0 0.7 
10 % Phase II 2.4 3.0 3.4 8.8 0.6 0.5 
Phase III 4.2 3.9 5.2 13.3 0.9 0.8 
Approval 0.1 0.1 0.1 0.3 0.02 0.02 
Pre-clinicat 7.1 10.7 10.8 28.7 1.9 1.4 
Phase 1 3.9 6.6 7.0 17.5 1.2 0.8 
15% Phase II 2.4 3.5 4.3 10.2 0.7 0.5 
Phase III 4.2 4.3 6.5 15.0 1.0 0.8 
Approval 0.1 0.1 0.2 0.4 0.03 0.02 
Pre-clinical 7.8 13 .2 13.4 34.4 2.3 1.6 
Phase I 4.0 8.0 8.7 20.7 1.4 0.8 
20% Phase II 2.4 4.2 5.3 11.9 0.8 0.5 
Phase III 4.2 4.7 8.0 16.9 1.1 0.8 
Approval 0.1 0.1 0.2 0.4 0.03 0.02 
Pre-clinical 9.3 19.7 20.0 49.0 3.3 1.9 
Phase I 4.4 11.5 13 .0 28.9 1.9 0.9 
30% Phase II 2.5 5.7 7.9 16.0 1.1 0.5 
Phase III 4.2 5.7 11.8 21.7 1.4 0.8 
Approval 0.1 0.1 0.3 0.5 0.03 0.02 
* This scenario uses the development cost and attrition rate vector after improvements in R&D 
productivity obtained from McKinsey (Bhandari et al. , 1999).· 
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A companson of the capital requirement estimates when only one determinant is 
allowed to vary at a time indicates that the annual, sub-period and total period capital 
requirement estimates differ substantially by the source of the cost and attrition rate 
vectors, by whether or not the cost and attrition rate vectors adjust for the expected 
impact of technological change, and on the choice of the expected rate of growth of new 
molecule entry into the Canadian pipeline of molecules. Thus, for the base case rate of a 
15% growth in new molecule entry, the total capital requirement estimates range from 
$17.7 billion (scenario 4) to $76.3 billion (scenario 3) over the next five years, and from 
$71.7 (scenario 4) to $308.5 (scenario 3) over the entire 15-year estimation horizon. The 
corresponding average annual capital requirement estimates range from $4.8 billion 
(scenario 4) to $20.6 billion (scenario 3) over the next five years, and from $3.5 billion 
(scenario 4) to $15 .3 billion (scenario 3) over the entire 15-year estimation horizon. 
Doubling the growth rate of the number of molecules entering pre-clinical trials over the 
next five years from 15% to 30% increases the total capital requirement estimates by 
about 60% on average over the total time period, and by only about 13% on average 
over the next five years. Sirnilarly, a comparison of the scenarios with 0% and 15% 
growth rates in molecule entry fmds that capital requirement estimates for the higher 
growth rate are about 59% and 11% higher over the entire period and the first five years, 
respectively. 
A comparison of the average annual capital requirements for each of the three five-year 
sub-periods indicates that the capital requirements are expected to be most acute during 
the five-year period 2006-2011. Due to the long duration of the drug development 
process, initial growth in the pipeline of molecules is captured with a lag. 
One can argue that these capital expenditures are underestimated. If most comparues 
incorporate the technological revolution in their new drug development process over the 
next five years, clinical testing expenditures will decrease but basic research and pre-
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clinical testing expenditures will increase. However, firrns will still incur large capital 
expenditures to complete clinical trials on drugs that were already under development. 
Bath of these two capital expenditure enhancers would drive up the capital requirement 
estimates over the period, five to ten years hence. 
The sensitivity of the capital requirement estimates for scenarios with new molecule 
entry to an increase of 2.5 years in the duration of the drug development process is 
examined next. This necessitates an increase in the estimation horizon by two years, or 
up to 2018.8 Unlike the corresponding estimates for the scenarios with no new molecule 
entry, an increase of2.5 years in the duration ofthe drug development process decreases 
total capital requirement estimates by 15% (see Table 4.4). Everything else held 
constant, the two-year extension in the estimation horizon is not sufficient to 
compensate for the fewer number of molecules that are developed by the end of the 
extended estimation horizon when the duration of the development process is 2.5 years 
longer. 
8 Total capital requirements are divided by 15 (and not by 17) to ens ure the comparability of the estima tes. 
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Table 4.5 Sensitivity of the capital requirement estimates for the current Canadian 
pipeline of molecules to various changes in development duration for 
various new molecule entry rates into the pre-clinical development stage 
Scenario" Growth rate Cumulative capital 
(%)in new requirements, 2001-2018 
molecule entry _{Qillions of CAN~ 
(first 5 years) Cumulative A vera ge annual 
0 118.9 7.9 
1 15 180.1 12.0 
30 278.6 18.6 
0 54.2 3.6 
2 15 85.3 5.7 
30 135 .7 9.0 
0 167.4 11.2 
3 15 263.6 17.6 
30 419.1 27 .9 
0 38.0 2.5 
4 15 61.2 4.1 
30 98.8 6.6 
•scenarios 1 and 2 use the development cost and attrition rate vectors before improvements in R&D 
productivity obtained from PricewaterhouseCoopers (1998) and McKinsey (Bhandari et al. , 1999), 
respectively. Scenarios 3 and 4 are the corresponding vectors after improvements in R&D productivity. 
4.2.3 CAPITAL REQUIREMENT ESTIMATES FOR THE CANADIAN 
PIPELINE OF MOLECULES PUBLICLY SIGNALLING THE NEED 
FOR EXTERNAL FINANCING 
As noted earlier, the total capital requirements for the pipeline of products for the sub-
set of finns listed in the Recombinant Capital online database also are estimated. This 
estimate is used as a proxy of the total capital requirements that will need to be raised 
extemally to finance development of the pipeline of molecules for the Canadian 
therapeutics sub-segment. 
The capital requirement estimates for the aggregate pipeline of this sub-sample of 
Canadian finns for the four sets of scenarios with new molecule entry are presented in 
Table 4.5 on a total and average annual basis over the entire period and over the first 
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five years. While the total number of molecules in this restricted pipeline is about one-
half of that in the full sample, the various capital requirement estimates for the base case 
growth rate of 15% in new molecule entry for this restricted pipeline of molecules is 
about one-third of those estimates for the fu ll pipeline of molecules presented earlier in 
Table 4.2. 
Table 4.6 Capital requirement estimates for the current Canadian pipeline of 
molecules publicly signalling the need for external financing 
(Recombinant Capital database 2001) for varions new molecule entry 
rates into the pre-clinical development stage 
Scenario" Growth rate Cumulative capital requirements Average an nuai 
(%)in new (billions of CAN~ for: 
molecule entry 2001- 2006- 2011- Total Full15 First 5 
(first 5 years) 2006 2011 2016 _years years 
0 19.5 12.4 12. 1 43 .9 2.9 3.9 
10 20.0 16.7 19.3 55.9 3.7 4.0 
1 15 20.3 19.4 24.0 63.6 4.2 4.1 
20 20.6 22.5 29.5 72.6 4.8 4.1 
30 21.3 30.1 43 .8 95.1 6.3 4.3 
0 8.2 5.5 5.5 19.2 1.3 1.6 
10 8.6 7.8 8.8 25 .2 1.7 1.7 
2 15 8.8 9.3 11.0 29.0 1.9 1.8 
20 9.1 10.9 13 .5 33.5 2.2 1.8 
30 9.6 15.1 20.2 44.9 3.0 1.9 
0 25 .5 17.5 16.6 59.6 4.0 5.1 
10 27.0 24.6 26.4 78 .0 5.2 5.4 
3 15 27.9 29.0 32.9 89.8 6.0 5.6 
20 28.8 34.2 40.5 103.6 6.9 5.8 
30 30.9 47 .3 60.1 138.3 9.2 6.2 
4 0 5.6 3.8 3.8 13 .2 0.9 1.1 
10 6.0 5.6 6. 1 17.6 1.2 1.2 
15 6.2 6.7 7.6 20.4 1.4 1.2 
20 6.4 8.0 9.4 23.8 1.6 1.3 
30 6.9 11.3 13 .9 32.1 2.1 1.4 
"Scenarios 1 and 2 use the development cost and attrition rate vectors before improvements in R&D 
productivity obtained from PricewaterhouseCoopers ( 1998) and McKinsey (Bhandari et al. , 1999), 
respectively. Scenarios 3 and 4 are the corresponding vectors after improvements in R&D 
productivity. 
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4.3 CONCLUDING REMARKS 
The capital requirement estimation method presented herein uses input data about 
molecule mix across stages, drug development costs, attrition rates, and development 
stage durations. This method is used to estimate the capital needs for various pipelines 
of molecules in the therapeutics sub-segment. These include the pipelines for all 
Canadian firms and all Canadian firms publicly signalling an interest in extemal 
financing. 
The above analysis has two major findings. First, capital requirements are very sensitive 
to the chosen drug development cost and attrition rate vectors. Total capital 
requirements can be increased by a factor of 3 simply by using one data source over 
another, or by using vectors that account or do not account for the effects of 
technological changes and associated productivity gains on these input vectors. Second, 
whatever inputs are used, annual capital requirement estimates for the next five years 
represent several billon Canadian dollars . This implies a huge increase in capital 
requirements over amounts historically raised in the biotech sector during the recent 
past. 
Even if our estimates overstate capital needs, since they assume that all molecules in the 
pipeline are actively being developed, these huge capital requirements should invoke a 
debate about whether or not financial markets have the capacity to finance the large 
number of molecules currently under development in the Canadian therapeutics sub-
segment. Moreover, since our estimates show that technological changes do not 
necessarily reduce capital requirements, another interesting issue is whether the demand 
si de of the drug market will accept to pa y the priee for tomorrow' s medicine. Indeed, if 
a significant part of the molecules currently tested are introduced into the market, global 
healthcare budgets may grow significantly. If this is considered along with population 
ageing, the cost oftomorrow's medicine may be very difficult to bear. These results also 
raise a debate about the high level of regulation in the drug development process since 
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capital requirements are strongly and positively related to the stringency of the 
regulatory process. 
Many issues are not accounted for in our capital requirement estimation procedure. For 
example, our procedure does not directly address the impact of the genornic revolution 
on the revenue structure of bio tech firms. As it becomes harder to develop blockbusters, 
a lower market share is expected for each individual drug. Market saturation for 
therapeutic molecules may limit the economie incentives to develop new molecules. In 
tum, this may encourage a partial migration of development capacities towards other 
less regulated biotechnology segments or sub-segments, such as nutraceuticals or ag-
biotech, with supposedly higher risk-adjusted prospects for profitability. This suggests 
that regulatory policy may have an uneven impact on the development of the various 
biotechnology segments, and especially on the relatively more regulated therapeutics 
sub-segment. 
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CHAPTER5 
CAPITAL POTENTIALLY AVAILABLE TO CANADIAN COMPANIES 
Two main approaches are used to determine the capital potentially available to Canadian 
companies. The first approach is an empirical documentary approach that describes the 
amount of capital obtained by Canadian firms in recent years from each of the main 
sources of fmancing. The second approach uses a probabilistic madel with various 
macroeconomie, market, and sector- and [mn-specifie variables. 
5.1 EVALUATION OF RECENT CAPITAL SUPPLY TO CANADIAN 
BIOTECH FIRMS 
In this section, we examine the amount of capital obtained by Canadian finns in recent 
years from each of the main sources of fmancing; namely, private investors and capital 
markets, investment in clinical research by large pharmaceutical comparues, alliances, 
ftmds from Teclmology Patinership Canada (TPC), ftmds from Genome Canada 
programs, tax credits for research and development, and grants from different levels of 
government (federal and provincial). The data is obtained from various databases and 
press releases. 9 
5.1.1 MAIN FINANCING SOURCES 
Capital for early stage and start-up fim1s cornes primarily from public sources (research 
grants and other federal or provincial funding programs), various venture capital 
sources, and from alliances and joint ventures with large phannaceutical comparues. At 
the discovery phase, grants and tax incentives are often perceived as the most important 
sources of funding . 
Later-stage companies with products in their pipelines have better access to capital from 
private investors and capital markets. These firms are actively engaged in pursuing 
merger and acquisition (M&A) activities . Even if financing is not the main focus of 
these M&A strategies, they often help to preserve or improve present and future 
financing and liquidity. 
Venture capitalists (VCs) play a pivotai role in driving the Canadian biotechnology 
industry. VCs are an important source of equity for start-up biotech firms. Canadian 
VCs are generally private partnerships or closely held corporations funded by private 
and public pension funds, corporations and institutional investors. Unlike the U.S. , 
many Canadian VCs are government or labour-sponsored. The role ofVCs is not lirnited 
only to providing funding. VCs generally are active investors, who guide, lead and 
nurture the companies they have invested in. Among the most well-known VCs in 
Canada are MDS Capital (the leading VC lender to the biotech sector in Canada), 
Ventures West, CDP Sofinov, and the Canadian Medical Discoveries Fund with capital 
under management of over $2.5 billion. 
Institutional investors, corporations and banks also have pools of capital available for 
the Canadian biotech sector. They are important entities that seek to diversify their 
portfolios into this asset class. They invest directly or through affiliated subsidiaries. 
They are primarily concemed with expansion stage financing to attract a merger or 
acquisition with another company, or to enter the public market. Sorne institutional 
investors specialize in the acquisition, tumaround or recapitalization of public and 
private companies that represent favourable investment opportunities. They may have 
billions of dollars invested globally, and their primary objective is long-term capital 
appreciation. The most popular investors in this category in biotech are the 
Development Bank of Canada, CDP Capital, and the Royal Bank. 
Another important source of capital for biotechnology comparues are alliances and 
M&A activities. Big pharmas often fund a newer cash-deficient biotech company to do 
9 The main sources of data include Compustat, Recap, Contact Canada, Statistics Canada, BioCentury, 
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long-tenn risky research activities. For example, a recent alliance was formed between 
Vancouver-based QLT Inc. and Novartis Ophthalmic to perform a phase III clinical trial 
with a light-activated drug Verteporfin. This is a drug against skin cancer and other 
dermatological conditions first discovered by QLT. Novartis is financing the 
development of Verteporfin to a maximum of $15 million, and the two companies will 
share development costs beyond $15 million equally. The merger between Xenon 
Genetics Inc., a privately owned V ancouver-based clinical genomic company, and RGS 
Genome, a privately-owned Montreal-based clinical genomic company, brought 
together two leaders in the Canadian medical research industry to create a clinical 
genomic company that can compete intemationally. Under the terms of the agreement, 
Xenon acquired all of the outstanding shares of RGS in ex change for cash and shares in 
Xenon. Xenon also established and funded a research centre in Montreal to further 
advance the research programs of the two comparues. 
Capital markets have also been an important source of financing for biotechnology in 
Canada. Canadian companies are accessing U.S. equity markets, and they commonly 
pursue dual listings in Canada and in the U.S . An IPO provides capital for companies as 
well as an incentive for VCs to invest in the company. Venture capitalists and owners of 
a finn seek to exit the investrnent within three to five years of their initial investment. 
The exit usually occurs through a merger or acquisition of the company by either the 
original founders or another company, or through an IPO. An IPO is considered as the 
most glamorous and visible type of exit. 
In 2000, the most significant IPOs by Canadian biotech companies are Dynacare Inc. 
with net proceeds ofUS$46.4 million on the NASDAQ and the TSX, and CRYOCATH 
Technologies Inc. and Nexia Biotechnologies Inc. with net proceeds of $40 million each 
on the TSX. 
Venture One, and MacDonald & Associates. 
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Federal and provincial governments develop initiatives to foster an environment in 
which biotechnology companies can succeed and grow. These initiatives address the 
specifie needs of biotechnology companies, which include strong academie research 
institutions conducting basic research in the biosciences, access to early-stage capital, 
and a stable and supportive public policy structure. Generous tax incentives and grants 
have motivated many biotech companies to move to Canada. The most involved federal 
departments in biotech are: Industry Canada, Agriculture and Agri-Food Canada, 
Environment Canada, National Research Canada, Health Canada, Department of 
Foreign Affairs and International Trade (DFAIT), and Fisheries and Oceans Canada. 
The most involved agencies are: Genome Canada, Canadian Institutes of Health 
Research (ClliR), National Research Council (NRC), National Science and Engineering 
Research Council of Canada (NSERC), Social Sciences and Humanities Research 
Council (SSHRC), and Canadian Food Inspection Agency (CFIA). 
5.1.2 CAPITAL OBTAINED BY CANADIAN FIRMS FROM EACH OF THE 
MAIN SOURCES OF FINANCING 
VENTURE CAPITAL 
According to Macdonald & Associates, the life sciences industry raised $618 million 
from the Canadian VC industry in 2001 compared to $813 million in 2000. As shown in 
the table below, despite the decrease in the amount invested in the life sciences, the 
latter saw an increase of more than 1% from its 15.2% share of2001. 
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Table 5.1 VC investments in Canada 
Life sciences in VC for ali sectors % of life sciences 
Period Canada in Canada within total VC 
(Millions of CAN$) (Millions of CAN$) investments in Canada 
1997 374 1647 22.7 
1998 329 1528 21.6 
1999 431 2637 16.4 
2000 813 5337 15.2 
2001 618 3732 16.6 
PRIVATE INVESTMENT 10 
Institutional investors, corporations, banks, and mutual funds are important sources of 
capital for the biotech sector that mainly target later-stage companies. For 2001, the life 
sciences industry raised about $956 million. This amount is comparable to VC 
investment but is far above federal financing. 
Financing from financial businesses, banks, insurance companies and other institutions 
is made mainly through equity, secondary offerings for existing public companies, 
convertible bonds, and through debt. For debt and new equity offerings, figures 
compiled by Dundee Securities Management Company are used. 
ALLIANCES AND M&A 
Biotech firms raise considerable capital through alliances, strategie acquisitions and 
mergers . Funds come from pharmaceutical comparues that may be willing to replace the 
patents that are going to expire or simply want to acquire late-stage or marketed 
products to fill in their pipeline gaps in order to benefit from economies of scale or to 
expand their revenue bases. Funds also come from top-tier biotech firms looking to 
expand their capabilities by poo ling resources with another biotech finn. 
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Private Canadian biotech comparues can always approach public biotech finns and 
phannaceutical comparues for collaborations and equity injections. MethylGene, for 
example, has licensed the rights for its lead drug to MGI Phanna Inc. of Minneapolis for 
up to US$59 million. Caprion and Xenon each raised about $70 million in 2001 from 
partnership deals with Pfizer Inc. , Johnson & Johnson, Sun Microsystems Inc. and 
Oracle Corp. 
Even for public companies, alliances and M&As may be an interesting alternative for 
raising capital when faced with difficult capital markets or weak profits. This was the 
case of the Ottawa-based company, Adherex Technologies Inc. The company floated an 
initial public offering last June at a priee of $1.50, but the stock priee dropped in July 
after Shire Phannaceuticals Group PLC walked away from an accord to develop 
Andherex's anti-cancer drug Exherin . The deal fell apart largely because Adherex was 
unwilling to share in development costs with Shire during the mid-year 2001 weakness 
in capital markets. The drug developer signed a new deal in October to develop its lead 
anti-cancer drug with the giant Astra Zeneca PLC. 
Our estimates of the capital raised by Canadian biotech finns through alliances and 
M&As is based on U.S. data. Experts estimate that Canadian activities represent about 
10% of the sector U.S . total alliances and M&A activities. This figure is consistent with 
that in the Phannaceutical Industry Profile 2001, a report published by the PhRMA 
foundation. 11 This source reports that U.S .-owned research-based phannaceutical 
comparues spent US$451.2 million in Canada in 1999, or about 9.20% of their total 
R&D expenditures abroad. 
10 Other than VC. 
11 Pharmaceutical Research and Manufacturers of America, PhRMA Annual Survey, 2001 , 
www.PhRMA.org . 
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Based on the 10% assumption, the estimate of capital raised by the Canadian biotech 
sector is about $182 million in 2000 and about $66 million in 2001. 
IPOs 
Biotech firms may consider an initial public offering for various reasons, such as to 
expand their businesses, improve market presence or to attract and retain staff and 
enhance the company's profile. Going public can be a pivotai step in the company's 
growth strategy. However, the current state of the financial market can seriously affect 
the capital that can be raised. Canadian biotechnology companies must be well-prepared 
to move quickly, and to get the IPO offering into the market when the market is 
receptive. Well-prepared business models, more investment savvy, and targeting 
specialist investors with a better understanding of the sector are all important 
considerations. When the market sector is hot, momentum buyers become active in the 
sector. While IPOs are a very important source of capital, they are subject to the 
"window of opportunity" phenomenon in capital raising. 
The limited liquidity of the Canadian secondary market for initial offerings is an 
important issue. Firms must set realistic goals and create real opportunities for success 
that preferably do not depend on a single product or clinical trial. 
According to a PricewaterhouseCoopers IPO survey for the year 2001, the gross value 
ofiPOs inlife sciences in Canadian markets declined 89.5% from its last year level. The 
average offer size and the number ofiPOs also fell by 76.8% and 54.5% respectively. 
As is evident from figure 5.1 below, 2000 was an unusually hectic year. The total gross 
value of all successful IPOs in the life sciences was $289.3 million compared to $42.9 
million in 1999. The market behaviour observed in 2000 suggests that the win dow of 
opportunity for initial stock offerings can be short lived. 
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Figure 5.1 Successful IPOs in the Iife sciences industry in Canadian markets 
Lite sciences IPOs in the Canadian markets 
(Source: PricewaterhouseCoopers) 
1997 1998 1999 2000 2001 
GOVERNMENT FUNDING 
According to the 2000 Statistics Canada Survey, the federal and provincial govermnents 
provided 6.4% of the funding for firms performing biotechnology R&D in 1999-2000. 
The estimate of $392 million for the period is an increase of about 22.7% over the 1998-
1999 lev el of $319.5 million, and almost a 50% increase over the $262 million invested 
in 1997-1998. As shawn in Table 5.2, as muchas 97% of all expenditures are directed 
toward R&D activity. The remaining portion is directed toward related scientific 
activities, such as projects to support biotech businesses. 
77 
Table 5.2 Federal government science and technology (S&T) expenditures on 
biotechnology by activity and performer ($000s) 
Activity/ Intramural• Business Higher Performers 
Performer Enterprise Educationb Foreign Otherc Total 
Panel A: 1999-2000 
R&D 177.855 34.577 164.521 628 1.922 379.503 
Related scientific 6.696 922 4638 250 12.506 
activities (RSA) -
Total 184.551 35.499 169.159 878 1.922 392.009 Expenditures 
Pane l B: 1998-1999 
R&D 137.997 15 .14 1 152.468 533 2.916 309.055 
RSA 4.967 1.041 4.081 233 100 10.423 
Total 142.964 16.182 156.549 766 3.016 319.477 Expenditures 
Panel C: 1997-1998 
R&D 113 .074 6.379 132.142 507 1.612 253 .714 
RSA 3.425 980 3.634 230 10 8.279 
Total 116.499 7.359 135.776 737 1.622 261.993 Expenditures 
""Intramural activities" are inside federal government departments and agencies. 
bThe "Higher Education" sector includes universities, colleges and other post secondary institutions. 
0
"0ther performers" include Canadian non-profit institutions and provincial and municipal 
governments. 
Source: Statistics Canada, Biotechnology Scientific Activities in Selected Federal Government 
Departments and Agencies, 1999-2000, Catalogue 88-001 -XIB, vol. 25, no3 . 
Based on Table 5.3, $185 million or 47% of the $392 million spent on science and 
teclmology in the biotechnology sector in 1999-2000 was spent within the federal 
government departments and its related agencies. The expenditures of the National 
Research Council (NRC) and Agriculture and Agrifood Canada are $103 million and 
$55 million, respectively. The remaining $27 million is spent by eight other government 
departments or related agencies. 
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Table 5.3 Federal government R&D expenditures on biotechnology activities by 
selected department or agency, and by performer, 1999-2000 ($000s) 
Department/ Business Higher Performers Intramurala A geney Enterprise Educationb Foreign Otherc Total 
Agriculture and 55.479 - - - - 55.479 Agrifood Canada 
Environment 572 435 342 - 40 1.389 
Fisheries and 2.600 2.600 Oceans - - - -
Health Canada 4.751 - 5 - 42 4.798 
Industry Canada 3.324 29.354 55 - - 32.914 
Medical Research 
Council (now 
Canadian Institutes 5.837 - 127.800 - - 133.637 
of Health Research 
or ClliR) 
National Research 103 .030 5.000 600 108.630 Council - -
NaturalResources 7.071 230 144 40 7.485 Canada -
NSERC 1.800 300 39.900 800 1.200 44.000 
SSHRC 86 - 914 78 - 1.078 
Total 184.551 35.499 169.159 878 1.922 392.009 Expenditures 
""Intramw·al activities" are inside federa l government departrnents and agencies. 
bThe "Higher Education" sector includes universities, colleges and other post secondary institutions. 
c"Other performers" includes Canadian non-profit institutions and Provincial and municipal governments. 
Source: Statistics Canada, Biotechnology Scientific Activities in Selected Federal Government 
Departrnents and Agencies, 1999-2000, Catalogue 88-001-XIB, vol. 25, no3 . 
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Higher education institutions are the second-largest beneficiaries of federal R&D 
expenditures in the biotechnology sector. These institutions account for $169 million or 
43% of the total R&D expenditures by the federal government. These expenditures are 
mainly effected through the Canadian Institutes of Health Research (ClliR) and the 
National Sciences and Engineering Research Council (NSERC). Thus, higher education 
institutions receive 82% of the $207 million extramural spending by the federal 
government during 1999-2000. 
Biotechnology firms received $35 million or 9% of the federal biotechnology 
expenditures in 1999-2000, with most of this funding being granted by Industry Canada. 
This departrnent provided 90% ofits $33 million in science and technology expenditures 
in the biotechnology sector directly to Canadian enterprises. Such expenditures more 
than doubled over the 1998/99-1999/2000 period, and do not include the $300 million 
allocated to Genome Canada. 
Based on Table 5.3, the four major federal government fund distributors are the MRC 
(34%), NRC (28%), Agriculture and Agrifood Canada (14%) and NSERC (11%). 
The annual values discussed on financing of the biotech sector in Canada by major 
funding source are surnmarized in Table 5.3 for the three-year period, 1999-2001. 
Table 5.4 Financing in the Canadian biotech sector: An evaluation ($ million) 
Y ear/Source 2001 2000 1999 
Venture capitala 618 813 431 
Private investments 956.6 1178.4 1353 .2 
other than vcb 
Alliances and M&A 168.96 182.01 158.3 
activitl 
IP0s0 30.3 289.3 42.9 
Federal governmente 483.6 392 319.5 
a MacDonald & Associa tes 
b Canadian Health Care Financing Database - Dundee Securities 
c Estimation based on 10% ofU.S. alliance and M&A activities 
d PricewaterhouseCoopers surveys on Initial Public Offerings in Life Science in Canada 
e Estimation based on Statistics Canada data 
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We provide a description and a comparative analysis of the financial data of Canadian 
and US. public firms in Appendix B. 
5.2 EVALUATION BASED ON A PROBABILISTIC MODEL FOR THE 
SUPPLY OF FUNDS 
5.2.1 CONTEXT 
There is no straightforward and simple method to estimate the capital available to 
Canadian biotech firms. Many factors can affect the amount of capital available from 
various sources, and past experience tends to demonstrate that many of these factors are 
subject to high volatility. Despite the inherent stochastic nature (random movements) of 
the fundamental factors affecting the supply of funds to any high-tech sector, robust 
models and methodologies do exist to establish the probability distributions that can 
properly describe or capture the supply generating process resulting from the complex 
interactions between the various relevant factors affecting supply. Obviously, the supply 
generating process will follow a stochastic process over time to a large extent. 
Several stochastic models can be used to model the supply generating process. Thus, the 
first step is to determine the most appropriate model to start with. For example, one 
question that arises is whether the supply generating process follows a Markovian 
process, a "no-memory" process in the sense that future values do not depend on past 
values. Brownian motion and the Poisson process are two examples of this class of 
process. However, the so-called "Markov chain" type of models may better describe the 
supply generating process. A Markov chain has several states, all of which depend on 
certain other random variables. These other variables affect the change from one state to 
another. In biotech financing, there are several practical concems depending on the 
source of financing. These include the experience of the investment manager that makes 
the decision, the valuation criteria used, and the other criteria used to make the financing 
decision. The choice of the specifie model to be used in the analysis is based on 
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empirical testing and observed correlations between the relevant variables that are 
expected to be associated with the supply of capital to the biotech sector. 
5.2.2 SELECTION AND BEHA VI OUR OF THE KEY VARIABLES 
AFFECTING THE SUPPLY OF FUNDS AND THE VALUATION 
PROCESS 
This section identifies the relevant variables that are expected to affect the flows of 
funds to biotechnology companies. The choice of relevant variables is based on both the 
literature and an examination of the historical correlation matrix. Usually many 
variables are tested using historical data and then selected for the model, based on the 
goodness of the statistical fit obtained from the corresponding series of historie data. In 
this study, an alternative approach is used. We first try to identify a few key variables 
and then build a parsimonious model that incorporate these variables in order to produce 
future distributions of potential capital supply. 
The key variables to be used in the model are the following: 
Two macroeconomie variables; namely: the level of economie growth and the level 
of interest rates in the Canadian economy; 
Market and sector variables, such as market risk premium, competitive industries 
retums and substitute products observed for other high-tech companies, retums of 
the biotech sector as a whole, past and forecasted, and perceived risk in the biotech 
technology markets, proxied by observed failure rates; 
Global availability of funds in recent years; and 
Firm-specific variables, such as average size and the s1ze of the product 
development pipelines. 
The levels of both economie growth and interest rates have clearly been identified as a 
significant and important determinant of the supply of risk capital in a free market 
economy. Therefore, it is an obvious choice (see, among others, Feen et al., 1995; 
Gompers et al., 1998 and 1999). 
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It is clear that competitive returns offered by the other high-tech sectors and substitute 
products may have an important influence on the supply of funds to the biotech sector. 
Basic economie reasoning suggests that the biotech sector has to be fairly competitive in 
arder to attract risk capital, particularly when one considers the relatively longer product 
development time in this sector ( especially in the therapeutics sub-segment) compared 
to other high-tech sectors. The failure rates observed in the biotechnology industry are 
also likely to be a key determinant of capital supply, for they proxy for the specifie risks 
associated with biotech investments. 
Global availability of funds also has to be considered for it defines the leve! of 
development reached by the Canadian venture capital industry and by other sources of 
capital used to finance a biotech finn. 
The choice of the proposed finn-specifie variables, though selected on a more ad hoc 
basis, tries to capture the evolution in the average stage of development of Canadian 
biotechnology firms. Stage of development is linked to the relative maturity of the 
product development pipelines of Canadian firms. Maturity of the pipelines is certain! y a 
factor one should expect to have a significant impact on the perceived investment risk, 
and thus, on the evolution of capital supply through time. 
The identification of the appropriate proxy for each variable and the characterization of 
the behaviour of the relevant variables are obtained by empirical and correlation analyses 
that try to replicate past behaviour of these variables. 
In arder to simulate the amount of capital available from the various sources, sorne kind 
of financial valuation mode! is necessary. Given the general characteristics of biotech 
firms, the use of traditional valuation models or techniques like the discounted 
dividend/cash flow mode!, priee earnings, priee to book or priee to sales offer limited 
83 
possibilities. For example, holding shares of a biotech firm is a contingency claim on 
quite distant and hazardous revenues. Relatively long research and development periods 
(about 12 years for the important therapeutics sub-segment) combined with fairly high 
failure rates complicate any effort to estimate the parameters of the preceding mo dels or 
techniques. 
As we have seen in section 3.3.3, most investors are using a combination of methods 
together with the use of comparables. But given the nature of our simulation approach, 
the only valuation-related variable we need is the distribution of asset priees for the 
whole set of biotech firms. This cornes from the fact that all the firms are in fact 
competing for the same dollar. This implicit hypothesis also can be applied to the whole 
set of high-tech firms. Hence, in the context of our simulation approach, the distribution 
of asset priees, is obtained through empirical modelling as will be shown later. 
The identification and specification of the behaviour of the supply of funds is presented 
in the following section. 
5.2.3 IDENTIFICATION AND SPECIFICATION OF THE SUPPLY OF FUNDS 
The identification and specification of the supply of funds is performed through an 
empirical quantification of the parameters of the model described by equations (1) and 
(2) presented below. The empirical quantification of these parameters relies on the 
following steps : 
Determination of historical individual behaviour and their behaviours in relation to 
all others variables. This quantification is performed based on the specifie historie 
database for each variable described in the preceding section; 
Detennination of the actual state of each of the variables; and 
Simulation of the behaviour of each variable, as explicitly modeled by the equations 
presented in the next sub-section. 
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5.2.4 MODEL CONSTRUCTION AND CALIBRATION AND INITIAL 
VALUES OF THE KEY VARIABLES AND HYPOTHESES 
a. Model construction and calibration 
The purpose of the supply simulation model is to establish, within a certain leve! of 
confidence, the amount of capital that might be available to the Canadian biotech sector 
over the next five years. Although the simulation model presented below could be used 
to generate estimates over a longer time period, the statistical error of the corresponding 
estimates increases rapidly with the time span involved. A five-year period seems 
appropriate in light of the results obtained previously using the capital requirements 
estimation scenarios. Based on these results, the next five-year period seems the most 
critical in terms of potential growth in capital needs. Finally, given the high volatility 
that characterizes the biotech sector, a longer forecasting period would appear to be of 
limited use, since a five-year period is long enough to implement appropriate public and 
private-sector policies. 
The estimation procedure presented in the following paragraphs is defined as a 
stochastic process. It simulates the amount of capital that might be available to the 
Canadian biotech sector based on a mathematical model that integrates the stochastic 
behaviour of each of the relevant variables introduced in sub-section 5 .2.3 of the study. 
As noted earlier, these include interest rates, growth in the economy as a whole and in 
the bio tech sector, as measured by the index of biotech companies and risk premium in 
capital markets. The interest rate policy adopted by the Central Bank has a direct impact 
on the availability of finds. For example, high interest rates tend to move capital away 
from the more risky investments. It is also well documented in the literature that 
economie growth has a direct and significant impact on the level of available risk 
capital. Changes in the biotech index and market risk premium are also important for 
they are proxies for investors' perceptions and market sentiment about return and risk. 
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Two main types of stochastic processes are used in the simulation depending on the 
variables chosen. These are a geometrie Brownian motion and a mean-reverting 
stochastic process. The Brownian motion is used to simulate the random behaviour of 
the main financing sources whose initial states have been discussed earlier. For each 
variable, the behaviour of the governing stochastic process is limited to two parameters 
in order to keep the model parsimonious and tractable. They are defined next. 
b. Brownian motion 
In the case of the geometrie Brownian motion, the following model is simulated: 
where 
• dV, is the change in the random variable V at time t, 
• JL is the drift in the random variable, 
• V, is the value that the random variable takes at time t, 
• dt is the time interval between two steps in the simulation (herein, taken to be one 
month), 
• O" is the volatility of the change in the random variable being simulated, and 
• dB1 is the increment of the Brownian motion. 
The Brownian motion is defined in the usual way, and with the following properties: 
_ The process starts at zero, B0 = 0 , 
_ B1 has stationary and independent increments, 
_The path of the Brownian motion is continuous, 
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_ The increments B, - Bs are normally distributed with mean equal to 
zero, and standard deviation equal to ~ , so that: 
for t>-s 
At each step of the simulation, we compute the new value of the stochastic variable 
as well as its increment. 
c. Mean-reverting process 
The other variables, which exhibit less erratic movements, are simulated using 
a mean-reverting process which is defined as : 
dV, = a(b- V,)dt +a-dB, 
where: 
• dV, is the change in value, or the increment, of the random variable V, , 
• V, is the value that the random variable takes at time t, 
• a is the adjustment speed at which the mean reversion takes place (defmed as one 
herein), 
• b is the long-term value toward which the random variable V, moves, 
• dt is the length of time between two steps in the simulation, 
• a- is the volatility factor, or the standard deviation of each of the variables considered 
in the model, and 
• dB, is the increment of the Brownian motion as described earlier 
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d. Initial values of the key variables and hypotheses 
The initial values of the key variables and hypotheses used in the supply simulations are 
presented in Table 5.5. These values are used to simulate the potential supply of funds 
for the Canadian bio tech sector. As mentioned earlier, two classes of variables are used, 
macroeconomic/sector variables, and fmancing source variables. Macroeconomie and 
sector variables are: the real interest rate, the growth rate of the Canadian economy, the 
TSX-biotech index growth rate, and a market sentiment variable (as proxied by the 
market risk premium). Financing source variables are private and public amounts of 
funding, and funding from the federal governrnent. 
Given the flexibility of the simulation pro gram, bath historical data and forecasts from 
existing public sources are used to select the initial values of industry and sector 
variables. For financing source variables, simple armual arithmetic means over the last 
three years, and over the last two years are also used (see Table 5.4 for data on past 
financings). 
Monte Carlo simulations with geometrie Brownian motion are used for the financing 
sources variables, and a mean reverting process is used for the macroeconomie and 
industry variables. A random shock multiplicative factor affecting only the private 
fmancing other than venture capital was introduced at a final step in arder to account for 
the possible multi-period effect of the associated complex decision process for that 
specifie funding source. This random shock factor does not affect the variable path but 
does amplify the variation dV, , from one simulation to another. 
In addition to the initial state of each variable, various hypotheses about the mean and 
volatility of the remaining variables are introduced, with the exception of private 
financing other than VC. Historical means and volatilities that are used in the simulation 
are reported in Table 5.5. 
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Table 5.5 Initial values of the key variables and hypotheses 
Variable Initial Value Mean* Volatility (Standard 
Deviation)** 
Interest Rate 5% 10% 10% 
Economie Growth 1% 3% 10% 
TSX Biotech Index 2% 3% 10% 
Growth 
Risk Premium 135 basis point 200 b.p. 20% 
(b.p.) 
VC, IPO, Alliances 817.3 30% 25% 
andM&A 
Federal Fun ding 481 10% 5% 
Private Fun ding 956.6 - -
Other Than VC 
Random Shock 0.5 0% 10% 
* The mean 1s the long-term value of the vanable 
** Volatility captures the change of the value around its mean over each simulation. 
One thousand simulations are performed using the initial values of the key variables and 
the hypotheses stated in Table 5.5 in order to estimate the supply of capital to the 
Canadian biotechnology sector over the next five-year period. Several sensitivity 
analyses are also performed based on varying the initial set of variables presented in 
Table 5.5. 
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5.2.5 SUPPLY SIMULATION RESULTS 
Only three of the thousand scenarios obtained with the selected initial set of variables 
and hypotheses are used in the paired capital supply and demand scenarios that are 
presented in the following section. These are the minimum scenario, the mean scenario 
and the maximum scenario. Since the supply estimates come from a simulation process, 
only their resulting paired capital demand and supply scenarios are presented and 
analyzed in the next section. The respective supply estimates are presented in Table 5.6. 
The therapeutics share of capital supply is grossly estimated to be 80%. This percentage 
is in line with the observed percentage of capital allocated to the therapeutics segment 
that was reported earlier for the interviewed sample of stakeholders. 
Table 5.6 Canadian cumulative and average supply estimates over the period 2001-
2006 (Biotechnology sector and therapeutics sub-segment, billions of 
CAN$) 
Supply estimate scenarios 
Minimum scenario Mean scenario Maximum scenario 
Cumulative 10.6 18.7 42 
(2001-2006) 
A vera ge annual 2.12 3.73 8.3 
Cumulative to 8.5 14.93 33.3 
therapeutics (80%) 
A vera ge annual to 1.7 3 6.7 
therapeutics (80%) 
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CHAPTER6 
PAIRED SCENARIOS OF CAPITAL SUPPLY AND DEMAND 
6.1 SCENARIO CONSTRUCTION AND PRESENTATION 
The second objective of this study is to evaluate the adequacy of capital supply and 
demand for Canadian companies in the therapeutics sub-segment. Results from the fust 
two steps that are necessary to evaluate capital adequacy were presented in sections 4 
and 5, respectively. They are estimates of the capital required to bring molecules 
currently being developed and to be developed in the product development pipelines of 
Canadian firms, and estimates of the amount of capital potentially available from the 
various supply sources. In this section, we present two paired scenarios of capital supply 
and demand based on the estimates obtained in the previous sections. These paired 
scenarios allow us to draw conclusions about the volume of external capital that must 
come from the capital markets in the U.S . and elsewhere in order to satis:fy any potential 
shottfall obtainable in Canada. Finally, an analysis of any rnismatch between capital 
supply and demand completes this section. 
Three important considerations in tenns of input vectors need to be addressed in order to 
make balanced and well-thought judgment calls about the existence of a potentially 
significant mismatch between capital supply and demand. They are: 
Choice of appropriate cost and attrition rate vectors; 
Choice of the initial state and growth of the Canadian molecules pipeline, more 
specifically, those molecules that are or will be actively developed by the 
Canadian fmns over the forecasting period; and 
Inherent volatility of supply determinants and the resulting stochastic shocks that 
influence their behaviour. 
Several scenarios about potential capital requirements were presented in section 4. In the 
following section, only two estimated demand scenarios are used. Each scenario 
corresponds to the two alternative pipelines of Canadian molecules to be considered as 
being actively developed in the coming years. They are the Industry Canada 2001 study 
full pipeline, and the sample of Canadian molecules reported in the Recombinant 
Capital 2001 database. These capital demand estimates (see the third and the fourth 
scenarios presented in Tables 4.3 and 4.6) are then used to build two different sets of 
paired scenarios of capital demand and supply. In the first set of paired scenarios, 
McKinsey cost and attrition rate vectors are used (Scenario 4, tables 4.3 and 4.6). This 
scenario is used because it is based on costs and attrition rates reflecting the expected 
improvements in R&D productivity, and the scenario uses an annual growth rate of 15% 
in the number of molecules entering the pre-clinical stage (Scenario 4, tables 4.3 and 
4.6). The main justification for choosing a 15% growth rate is that it has been the 
observed historical growth in the number of compounds that entered the pre-clinical 
stage in Canada over the period 1999-2001. Results from the first pairing of capital 
demand and supply scenarios are presented in Table 6.1 and are analyzed below. 
The second pairing of demand and supply scenarios are presented in Table 6.2. They 
differ from those reported in Table 6.1 since they use the less optimistic 
PricewaterhouseCoopers cost and attrition rate vectors ( after improvements in R&D 
productivity) to estimate capital requirements (Scenario 3, tables 4.3 and 4.6). These 
significantly higher cost vectors lead to higher capital needs, and consequently to paired 
capital supply and demand scenarios where more capital has to come from extemal 
capital markets. The capital requirements estimates mentioned above also refer to what 
is considered to be the most probable growth rate of 15% in the number of molecules 
entering the pipeline over the next five years . 
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6.2 ANAL YSIS OF THE MOST RELEVANT P AIRED CAPITAL DEMAND 
AND SUPPL Y SCENARIOS 
In the most probable scenario in Table 6.1 , the average annual capital requirements 
corresponding to each of the previously mentioned pipelines are $3 .5 billion and $1.2 
billion, respectively (Scenario 4, tables 4.3 and 4.6). These average annual figures 
amount to aggregate capital requirements of $17.7 billion and $6.2 billion over a five-
year forecasting horizon for each of the two pipelines considered. The corresponding 
average annual capital requirements (for the PricewaterhouseCoopers cost and attrition 
rate vectors after improvements in R&D productivity), which are reported in Tables 4.3 
and 4.5 (third scenario), are $15.3 billion and $5.6 billion, respectively. These capital 
requirement estimates correspond to an aggregate capital requirement of $76.3 billion 
and $27.9 billion, respectively, over a five-year forecasting horizon. 
The forecasting horizon over which the domestic supply of funds in the sector is forecast 
is lirnited to a five-year period because the variance of the estimate increases in direct 
proportion to the length of the time span that is being used. Longer forecasting periods 
imply wider confidence intervals for our estimates, and thus, may make these estimates 
less useful. The pipeline, which is reported in the Industry Canada study, refers to the 
total number of compounds being developed in Canadian therapeutics sub-segment 
companies. The pipeline drawn from the Recombinant Capital online database 
represents a subset of the Industry Canada pipeline; namely, that subset for which we 
assume Canadian firms or developers are publicly attempting to attract outside investors 
(particularly from the U.S .). 
The initial state of capital supply in the Canadian economy, which was used in the 
simulation of capital supply performed in section 5, is based on estimates of the capital 
raised by Canadian biotech firms over the past three years (see Table 5.4). 
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A detailed analysis of the results for the two pairings of capital demand and supply 
scenarios completes this section. As a cautionary note, we repeat that judgement calls 
about the existence of a significant shortfall of capital supply to meet demand should be 
used prudently. Since many complex and dynamic factors are at play, any forecasted 
shortfall in the supply of funds should not necessarily be interpreted as symptomatic of 
the need for capital rationing by individual biotech firms. For example, we would expect 
that firms are not actively pursuing the development of all the molecules reported in the 
Industry Canada 2001 study. In practice, firms voluntarily prioritize the development of 
their most potentially successful targets. This results from deliberate strategie choices of 
firms, and is not due to capital rationing per se. In other words, decisions not to pursue 
the development of all molecules could occur even without any capital shortfall. For 
example, lirnited existing capabilities may constrain and lirnit the scope of development 
activities of the sector or of specifie individual firms in that sector. Capital availability is 
only one of the many variables that influence the strategie choices of biotech firms. 
Moreover, capital rationing (or the so-called equity gap) exists only when molecules 
offering more than an adequate risk-adjusted return cannot be financed. 
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Average 
a1mual 
Table 6.1: First set of pairings of scenario estima tes of Canadian supply and 
dernand of funds over the period 2001-2006 (Therapeutics sub-segrnent, 
billions of CAN$) 
Supply estirnate scenarios 
Minimum scenario Mean scenario Maximum scenario 
2.12 3.73 8.3 
80% Average 1.7 3 6.7 
rumual to 
therapeutics 
Average 
Average 
Demand estimate scenarios (therapeutics sub-segment) 12 
Industry Recombinant Industry Recombinant Industry Recombinant 
Canada capital sample Canada capital sample Canada capital 
Pipeline Pipeline Pipeline sample 
3.5 1.2 3.5 1.2 3.5 1.2 
Extemal financing estimates for the paired scenarios 
Minimum scenario Mean scenario Maximum scenario 
1.8 (0.5) 0.5 (1.8) (3 .2) (5.5) 
Table 6.2: Second set of parings of scenario estirnates of the Canadian supply and 
dernand of funds over the period 2001-2006 (Therapeutics sub-segrnent, 
billions of CAN$) 
Supply estirnate scenarios 
Minimum scenario Mean scenario Maximum scenario 
Average 2.12 3.73 8.3 
80% 1.7 3 6.7 
Average 
annual to 
therapeutics 
Demand estimate scenarios (therapeutics sub-segment) 13 
Industry Recombinant Industry Recombinant Industry Recombinant 
Canada capital Canada capital Canada capital 
Pipeline sample Pipeline sample Pipeline sample 
Average 15 .3 5.6 15 .3 5.6 15.3 5.6 
Extemal financing estimate paired scenarios 
Minimum scenario Mean scenario Maximum scenario 
Average 13 .6 3.9 12.3 2.6 8.6 (1.4) 
12 Based on the McKinsey cost and attrition rate vectors after improvements in R&D productivity, 
scenario 4 in tables 4.3 and 4.6. 
13 Based on McKinsey costs and attrition rates vectors before improvements in R&D productivity, 
scenario 3 in tables 4.3 and 4.6. 
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Based on the results reported in Table 6.1 for the capital requirements obtained using the 
most probable 15% growth rate in the number of molecules, only the minimum supply 
scenario suggests a substantial need for extemal financing. This is based on the 
hypothesis that 80% of the total $2.12 billion in biotech financing is used for the more 
capital-intensive therapeutics sub-segment. The average extemal financing estimate for 
this minimum scenario is substantial at $1.8 billion over an average $3.5 billion capital 
requirement or demand estimate. For all other scenarios, there is no indication of any 
possible capital shortfall. For example, the mean supply estimate of $3 billion and the 
corresponding $0.5 billion in extemal financing requirements do not appear to be out of 
range with what could be reasonably be expected to be raised from extemal capital 
markets . AU other scenarios, which are associated with the McK.insey cost and attrition 
rate vectors after improvements in R&D productivity and the 15% growth rate in the 
number of molecules, indicate that Canadian supply matches estimated capital 
requirements, even for the probably overstated number of molecules under development 
in the total development pipeline. 
Thus, it seems appropriate to expect that no real capital shortfall will exist if the 
productivity gains and corresponding lower costs associated with the McK.insey study 
are realized. Nevertheless, one should be careful about our interpretation of the results 
for this first set of paired capital demand and supply scenarios. First, serious doubts have 
been raised about the ability of the industry to reduce costs and failure rates and to 
capture potential productivity gains, at least over the short term. As was emphasized in 
section 4, recent data tend to demonstrate that not only have cost reductions not yet been 
observed but that development time is still increasing. Second, while no significant 
capital shortfall exists overall, this does not necessarily mean that supply is appropriate 
at all stages of the financing continuum (i.e., from seed financing to public offerings of 
debt and equity). Finally, the availability of sufficient capital does not mean that ali 
valuable molecules will be fmanced on competitive terms. The matching exercise tells 
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us little about the competitive structure of capital supply, or about the bargaining power 
of the demanders of capital. fu other words, micro-economie factors in the various 
market niches that may not be highly integrated do matter. 
The results for the sets of paired capital demand and supply scenarios reported in Table 
6.2 suggest a fairly different conclusion. When the more pessimistic 
PricewaterouseCoopers cost and attrition rate vectors are used, substantial extemal 
financing is needed for most sets of paired capital demand and supply scenarios, 
especially for those that use the total pipeline of molecules in development (fudustry 
Canada pipiline 2001). Even for the supply mean scenario of $3 billion, an 
overwhelming annual average of $12.3 billion in extemal financing is needed. A 
substantial amount of extemal financing is even needed to fund the much smaller 
number of products under development captured by the Recombinant Capital sample. 
Whether the results for the Recombinant capital mean paired capital demand and supply 
scenario imply that there would exist a significant capital shortfall is debatable. 
However, obtaining $2.6 billion of the total $5 .6 billion total capital requirements 
through extemal fmancing would probably be difficult, since Canadian and U.S. 
macroeconomies factors that affect capital supply are quite highly correlated. Thus, 
based on the results for the paired capital demand and supply scenarios reported in Table 
6.2, a significant capital shortfall would exist unless a very substantial fraction of the 
molecules reported in the total pipeline do not have real economie value and thus, will 
not be developed in practice. 
6.3 EVALUATION OF THE ADEQUACY OF CAPITAL SUPPLY AND 
DEMAND 
The interested reader should consider two additional issues before arriving at a final 
judgrnent about the existence of a significant capital shortfall based on the results 
presented in Tables 6.1 and 6.2 for various paired capital demand and supply scenarios. 
These two issues are: 
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First, are Canaclian cost and attrition rate vectors the same as the U.S . vectors used 
herein, and which of the two input vectors used in the preceding capital requirements 
estimations are the most appropriate proxies for their Canadian counterparts given the 
Canadian pipelines of molecules used in our study? 
Second, what fraction of the total pipeline of molecules reported in the Industry Canada 
study is being actively developed or has real economie value from a risk-adjusted retum 
perspective? 
The following comments provide sorne guidance on the two above considerations. Most 
of the interviewed experts agree that the number of molecules being actively developed 
(and willingly selected as economically more relevant) is significantly lower than the 
total number of molecules that are reported as being under development. It is known in 
the industry that no new investrnent is occurring for many of the reported molecules, 
and this lack of investment does not appear to be based on internai capital rationing. 
Since firms are clearly signalling their search for extemal capital when they list their 
molecules in the Recombinant Capital database, one can hypothesize that this sample of 
Canadian molecules is a lower bound with respect to the number of economically 
relevant molecules. In section 4, we stress that the Canadian molecules reported in the 
Recombinant Capital database account for about one third (33%) of the capital 
requirements associated with the total Canadian pipeline. Thus, the $2.6 billion in 
extemal financing reported in Table 6.2, which relates to the mean paired capital 
demand and supply scenario (PricewaterhouseCoopers input vectors after improvements 
in R&D productivity), is potentially a meaningful lower bound. If the McKinsey input 
cost and attrition rate vectors (after improvements in R&D productivity) are the 
appropriate inputs, then no extemal capital is needed. 
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Most specialists in the field consider the PricewaterhouseCoopers cost vectors to be 
overstated, at least for the ac tu al state of the Canadian pipeline, and given that Canadian 
costs are lower than their American counterparts. Recent presentations in bio-
conferences indicate that development costs do not conform to the McKinsey input 
values, but instead continue to rise with the increase in average development time. 
Renee, the evidence suggests that the more optimistic cost structure is unlikely to 
prevail in Canada in the near future. As a consequence, a potential and significant 
capital shortfall is possible at least over the next five years. What is even more certain is 
that Canadian firms may be very vulnerable to the need to raise substantial funds in 
extemal capital markets, even if only a limited number of the total pipeline of reported 
molecules are developed actively. 
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CHAPTER 7 
CONCLUDING REMARKS 
The intent underlying this research was to characterize the supply of capital for 
Canadian biotechnology finns . This is made following two objectives. The first 
objective is to identify the issues and difficulties of financing biotechnology in Canada 
from the viewpoint of supply stakeholders, and the second objective is to assess the 
capacity of Canadian suppliers of capital to meet the predicted demand of Canadian 
biotech frrms. 
Analysis of the viewpoint of interviewees on the various dimensions that are relevant to 
biotechnology financing led to the following conclusions: 
• While the quality of science in Canada is world-class and has a high credibi lity, 
not many Canadian fmns have a dominant position in tenns of size and pipeline 
development. 
• The lack of management is one of the major problems in Canada not only in 
terms of a limited nwnber of good managers, but also in tenns of the extent and 
variety of experience and skills. Hiring a CEO abroad is often a necessity in spi te 
/ of the difficulties and costs involved. 
• The lack of management does seriously affect the financing process of a bio tech 
firm because it is one of the major reasons for not providing funding by 
investors . As supply siders mentioned, business models and concepts originating 
from Canada are models that have appeared earlier in the U.S. 
• Attracting U.S. investors is not easy for an average size Canadian finn. U.S . 
stakeholders need a strong local co-investor, but they know few such local 
investors with a good track record of investing in successful companies. 
,----------- - ----------
• Investors generally agree that there is often total misunderstanding of finance by 
Canadian promoters and that the Canadian financing environment is too 
institutional and too protected. 
• The development of the private risk capital industry in Canada is then of great 
necessity and importance. Indirect sources of capital, such as pension funds, are 
also to be encouraged to be more involved with the bio-industries. 
• Also, more competition in the Canadian venture capital industry would be 
beneficiai. In fact, not only do relatively few pools of capital operate at the 
venture level but the competition between these groups appears to be relatively 
low. 
• The second major problem with Canadian biotech financing is that firms go 
public very prematurely. Canadian institutions should be educated to better 
support biotech companies earlier in the process so that they can replace the IPO 
financing round with a mezzanine round so that they have enough financial 
resources for the next stage of development. They could then postpone the 
timing of their IPO until their market cap and valuations are such that they can 
float an issue whose secondary trading has liquidity. 
• The lack of market liquidity in Canada is a major problem in biotech financing 
for even solid and profitable firms. Having programs or fiscal measures that 
encourage investment in the biotech sector at the retail level as well as help to 
develop broader knowledge would certainly be helpful. 
Access to appropriate term financing is a critical factor for being in a competitive 
position and exploiting all of the future growth opportunities for the Canadian biotech 
firms. We evaluate the equivalence of the supply and demand of capital for the 
Canadian therapeutics sub-segment by estimating the amount of capital required by the 
sector over a mid-term planning horizon (five years, a period long enough to develop 
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appropriate financing policies at firm and govemment levels) by determining the capital 
potentially available for investment in the Canadian biotechnology industry to finally 
draw a picture of the adequacy of demand and supply. 
• Considering the full pipeline of molecules of Canadian firms belonging to the 
therapeutics sub-segment (Industry Canada study 2001) and the development 
costs and attrition rate vectors after improvements in R&D productivity (see 
tables A.2 and A.3 in Appendix A for details about the development phases), 
aggregate demand estimates range from $16.9 billion and $18.5 billion 
depending on the growth rate of the number of molecules entering the pre-
clinical testing stage each year over 5 years. This corresponds to an annual 
capital need ranging from $3.4 billion and $3 .7 billion if the growth rates 
considered are 10% and 20% respectively. 
• The base case we considered to analyze the adequacy of supply and demand of 
funding assumes a growth rate of new molecules entry of 15%. The need of 
capital corresponding to this growth rate is of $17.7 billion over five years, an 
average annual amount of $3 .5 billion. 
• The capital demand for each stage of development corresponding to the above-
mentioned estimates are: 
Pre-clinical: $7.1 billion 
Phase 1: $3 .9 billion 
Phase II: $2.4 billion 
Phase III: $4.2 billion 
Approval: $0.1 billion 
• These annual capital requirements are greater than the amounts historically 
raised by the Canadian biotechnology sector and are quite sensitive to the 
development cost and attrition rate vectors considered. 
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• Estimates show that technological changes do not necessarily reduce capital 
requirements and that the latter are strongly and positively related to the 
stringency of the regulatory process. This suggests that regulatory policy may 
have an uneven impact on the development of the various biotechnology 
segments, and especially on the relatively more regulated therapeutics sub-
segment. 
• Simulations of the amount of capital potentially available to the biotech sector 
produced estimates ranging from $10.6 billion and $42 billion with a cumulative 
mean of $18.7 billion over the next five years. The therapeutics sub-segment 
share is grossly estimated to be 80%, thus, the supply of funds for this sub-
segment is estimated to range from a minimum of $1.7 billion, a maximum of 
$6.7 billion, and an average of $3 billion annually. 
• Using the most probable 15% growth rate in the number of molecules and 
McKinsey costs and attrition rates vectors after improvements in R&D 
productivity, only the minimum supply scenario suggests a substantial need for 
extemal financing of $1.8 billion for the therapeutics sub-segment. When the 
more pessimistic PricewaterouseCoopers cost and attrition rate vectors after 
improvements in R&D productivity are used, substantial extemal financing is 
needed for all the supply scenarios considered. Note that judgement caUs about 
the existence of a significant shortfall of capital supply to meet demand should 
be used prudently. Since many complex and dynamic factors are at play, any 
forecasted shortfall in the supply of funds should not necessarily be interpreted 
as symptomatic of the need for capital rationing by individual biotech firms. 
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7.1 DEFICIENCIES IN OUR KNOWLEDGE ABOUT THE FINANCING OF 
CANADIAN BIOTECHNOLOGY COMP ANIES 
The interviews conducted in Canada and the United States capture the viewpoints of 
capital suppliers in terms of financing-related issues and difficulties. This study also 
presents a global assessment of the potential match between capital demand and supply 
over the next five years. An analysis of the interviews and the scenarios of capital 
supply and demand provide a better understanding of the structure, workings, and level 
of performance of the financing system and the financing networks used by both users 
and providers ofbiotechnology capital in Canada. 
Many unknowns remain with regard to the possible policies and measures that could be 
implemented to address the various issues we documented. Specifie policy issues 
include: i) whether or not effective public policies can be formulated to alleviate the 
most negative financing consequences resulting from the structural problems that 
characterize Canadian capital markets; ii) how Canadian firms are affected by the trend 
toward consolidation, and the types of actions that can be implemented to assist 
Canadian biotech stakeholders to develop deeper and more mature pipelines; iii) the 
leve! of growth in the development of new molecules that is expected from Canadian 
science during the next five years, iv) the interaction and effect of specifie competency 
problems on the pace of development of Canadian firms, and v) how the natural 
evolution toward more mature finn pipelines combined with science-risk reduction 
resulting from appropriate financing to keep science in the universities longer and 
improvements in technology transfer and finn spin-offs, can significantly reduce 
financing-related difficulties. In turn, this may make venture capital financing and later-
stage financing in Canada more comparable with the risk/return trade off faced by a 
typical U.S. firm. 
Except for the most extreme mismatch scenarios of capital demand and supply (for 
example, one where capital requirements correspond to the PricewaterhouseCooper 
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higher cost vector and the Canadian pipeline is the one from the 2001 Industry Canada 
survey), the total amount of capital needed to be raised from extemal capital markets 
appear to be attainable, if necessary measures are implemented to address the most 
problematic issues. Even if our most probable paired capital demand and supply 
scenarios do not lead towards large equity gaps at the macro level, this does not 
necessarily imply that serious capital rationing will not exist for some firms or at some 
stages of the product development process. Major fmancing difficulties that need to be 
addressed include the limited liquidity of the Canadian capital market, the lack of 
substantial private mezzanine rounds of financing, premature IPO activity by Canadian 
biotech firms, and problems with specifie competencies and size. These problems will 
significantly affect the ability of the Canadian biotechnology sector to create value. 
Thus, while this study significantly contributes to a lessening of our knowledge 
deficiency in biotech financing in a Canadian context, substantial further work remains. 
Avenues for further study include: 
A study of the role and impact of public financings on product development in the 
biotech industry, and on whether or not such financings should be targeted at the early 
or la ter stages of the bio tech product development process; 
A study to determine if there is an optimal firm size for biotech firms, and the role of 
public policy, alliances, mergers and acquisitions in facilitating the achievement of an 
optimal firm size if it exists; 
A study to identify the determinants of the life cycles of individual product 
developments, product development pipelines, biotech firms and the biotech industry, 
and on how these life cycles evolve and interact over time; and 
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A study of the IPOs (initial public offerings) and SOs (seasoned offerings) of biotech 
firms to assess the short-term and longer-term performance of such offerings, including 
after-market liquidity, risk-adjusted returns, value creation, analyst following and 
subsequent offerings. 
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APPENDIXA 
INPUT VARIABLES AND THEIR QUANTIFICATION 
A.l Number of molecules 
The average duration for each development stage is measured in months. The 
distribution of the numbers of molecules over the total duration of a given stage 
accounts for the attrition rate for that stage. 14 The 306 molecules rep01ted in Table A.1 
as being in the 2001 pipeline for the Canadian therapeutics sub-segment represent 171 
public and private Canadian companies (Industry Canada et al. , 2001). The Canadian 
1999 pipeline contained 224 molecules (Investment Partnerships Canada et al. , 1999). 
Although the coverage differs for these two pipelines, 15 the annual growth in the total 
number of molecules tested is 15% over this two-year period. 
Table A.l. Distribution of the molecules in the pipelines for the therapeutics sub-
segment 
Development 
Number of molecu les in the pipeline 
stage For firms (January For firms (April Growth 1999-2001 For Recap firms 
1999) 2001) (%) (November 2001) 
Pre-clinical 92 133 45 35 
Phase 1 63 62 -2 35 
Phase JI 38 69 82 32 
Phase III 31 35 13 25 
Approval N A 7 NA 5 
Tota l 224 306 37 132 
Sources: Investment Partnersh1ps Canada et al. (1999), lndustry Canada et al. (2001 ), Recombmant 
Capita l (200 1 ), and Ernst & Young (200 1 ), respectively. 
The distribution of molecules by development stage drawn from the Recombinant 
Capital online database (website: www.recap .com) also is presented in Table A.l . This 
is a subset of the Canadian pipeline where the molecule developers are publicly 
attempting to attract the attention of outside investors . This sub-sample is used as a 
14 To illustrate, assume 100 molecules ex ist in the pre-clinical stage at time 0, that the duration of this 
stage is 2 months, and that the attriti on rate of molecules that fa il to pass thi s stage is 50%. The monthl y 
attrition rate is 25% if attri tion rates are, by assumption, distributed uniformly over time. If z is the 
number of molecules that entered the pipeline in each of the two prev ious months, z equals 57.14 in z*( l -
50%/2) + z = 100. Th us, 100 molecules in pre-clinical trials attime 0 represent 57.14 and 42.85 mol ecules 
in their first and second month tri als, respecti vely. 
15 The 1999 Canadian survey includes 65 firm s. 
proxy for estimating the extemal capital requirements for the 2001 pipeline for the 
Canadian therapeutics sub-segment. 
A.2 Growth rates in the number of molecules 
The scenarios with new molecule entry are designed to measure the effect of no and 
positive growth in the number of new approved dmgs over the next five-year horizon. 
This effect is captured by increasing the number of molecules entering the pipeline at 
each point in time when the vectors of attrition rates are assumed to be constant over 
time. 16 
The base case annual growth rate is proxied by the past growth of 15% in the Canadian 
pipeline (see Table A.1). To test the sensitivity of the capital requirement estimates to 
this choice of input value, growth rates of 10%, 20% and 30% also are used. While a 
30% annual growth rate appears unrealistic during the next five years, this is the annual 
rate proposed in the literature (e.g., PricewaterhouseCoopers, 1998, p. 2). If a 
phannaceutical company wants to maintain its historical growth rates in R&D expenses 
and productivity, it has to launch four to six times more dmgs than it currently does over 
the following seven years. This corresponds to average annual growth rate of 20% to 
30%. 17 The 0% and 10% annual growth rates are used to capture pessimistic estima tes 
of the expected growth in pipeline molecules. 
A.3 Development durations 
The average development durations are drawn from Bhandari et al (1999, p. 63). They 
are 8.5 years for development, consisting of 18-month periods for each of the pre-
clinical, phase I, phase II and approval stages, and 30 months for the phase III stage. 
Although these average durations are similar to those reported by Spilker (1998) and 
Mclntyre (2000), the sensitivity of the capital requirement estimates to a six-month 
increase in the average durations also is examined. 18 
A.4 Molecule development cost and attrition rate vectors 
The molecule development costs and attrition rates used herein are presented in Tables 
A.2 and A.3. Only the values in Table A.2 reflect the expected improvements in R&D 
productivity of the two sources of this data. The drug development cost data reported in 
these two tables are expressed in terms of cost per approved drug and cost per 
compound tested in a certain stage. The frrst measure is useful for assessing the total 
cost of bringing a new drug to market, whereas the second measure facilitates a 
16 This monthly rate is derived from the annual growth rate g by apply ing the formula 1~1 + g - 1 . 
17 Precise! y, the average annual growth rates are 7../4-1 = 21.9% and ?J6-1 = 29.2% , respectively. 
18 These new development durations do not exceed the maximum values reported in the literature. 
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computation of the total cost per stage. This latter cost measure is simply obtained by 
multiplying the number of molecules being tested in a given development stage by the 
stage cost per tested compound. Since the duration of the development stage always 
exceeds a month, we assume that costs are distributed uniforrnly across time. 19 
Table A.2 Typical development cost and attrition r ate vectors in the 
biopharmaceutical industry before improvements in R&D productivity 
Development Stage Stage cost per: 
Stage fa ilure rate Approved drug Approved drug Tested compound (%) (Millions of US$} (% of total costs) (MiiJions of US$)) 
Panel A: Scenario 1" 
Pre-clinical 50 66 13.2 6.6 
Phase I 30 67 13.4 13.5 
Phase II 55 167 33.4 47.9 
Phase III 15 150 30.0 95 .6 
Approval 25 50 10.0 37.5 
Total 90b 500 100 NA 
Panel B: Scenario 2" 
Pre-clinical 50 59 25.9 5.9 
Phase I 30 37 16.0% 7.3 
Phase II 57 66 29. 1 18.9 
Phase III 33 65 28.5 43.3 
Approval 0 1 0.4 1.0 
Total 90b 228 100 NA 
0 0 
•scenanos 1 and 2 use the development cost and attnt10n rate vectors before 1mprovements m R&D 
productivity obtained from PricewaterhouseCoopers (1998) and McKinsey (Bhandari et al. , 1999), 
respective ly. 
bThis reports the cumulative attrition rate over the entire development process. 
19 A simple example helps to understand this assumption. Assume that the cost at the pre-clinical stage 
per compound tested is equal to $ 6 million . If 100 compounds enter the pre-clinical stage du ring a certain 
ti me period, then the total pre-clinical stage cost for these 100 compounds is $ 600 million. The cost is 
distributed equally across the number of months in the pre-clinical stage. 
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Table A.3 Typical development cost and attrition rate vectors in the 
biopharmaceutical industry after improvements in R&D productivity 
Development Stage Stage cost per : 
Stage failure rate(%) 
Approved Tested % change in stage cost pet· 
drug compound tested compound due to 
(Millions of (Millions of R&D productivity 
US$) US$)) improvements 
Panel A: Scenario 3" 
Pre-clinical 75 140 22.1 +235b 
Phase I 10 50 31.5 +133 
Phase II 30 75 52.5 + 10 
P hase III 0 60 60.0 -37 
Approval 0 45 45 .0 +20 
Total 84c 370 NA NA 
Panel B: Scenario 4" 
Pre-clinical 50 59 5.9 0 
Phase I 44 38 7.7 +5 
Phase II 57 23 8.3 -56 
Phase III 17 36 29.8 -31 
Approval 0 1 1.0 0 
Total 90 c 157 NA NA 
•scenarios 3 and 4 use the development cost and attrition rate vectors after improvements in R&D 
productivity obtained from PricewaterhouseCoopers ( 1998) and McKinsey (B handari et al. , 1999), 
respective! y. 
bThis value is equal to 100 * [(22 .1 from Table A.2 - 6.6 from Table A.l) 1 6.6 from Table A.l] . 
cThis value is the cumulative attr ition rate over the entire development process. 
The attrition rates presented in these two tables represent the percentage of compounds 
that fail to go to the next stage of the development process. In arder to switch from costs 
per approved drug to costs per compound tested, we need to compute cumulative 
attrition rates, or the percentage of compounds that fail eventually to go to market. 20 As 
is the case for costs, the assomption is that total attrition is distributed uniformly across 
development time for each development stage. 21 
20 If rx represents the attrition rate of stage x and n is the total number of development stages in the mode!, 
th en: 
cumulative attrition rate for stage, or x= 1- IT (1 - r;) , x= l, .. . ,n 
21 More precisely, we assume that the number of molecules failing to pass a certain stage is distributed 
uniformly across ti me, and not the attrition rate per se. 
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The development cost and attrition rate data are obtained from sources that draw very 
different conclusions about total drug development costs, and the impact of the 
technological revolution induced by genomics and bio-infonnatics on the development 
cost and attrition rate vectors through the ir favourable impact on R&D productivity. 
These differences are due to major methodological differences between the two data 
sources. The PricewaterhouseCoopers methodology concentrates on changes in the 
product development rnix across development stages. Advances in dmg discovery 
technology can lead to an increase in the number of molecules tested in early R&D 
stages, and thereby increase attrition rates and costs at these early stages. Furthermore, 
elirninating molecules at earlier stages means reduced failure rates in clinical stages, 
where costs are relatively high. Their combined effect leads to an overall decrease of 
26% in the total cost per approved drug. In contrast, the McKinsey methodology focuses 
only on the effects of the genetic revolution on the clinical development process. 
Pharmacogenornics, defined as "the ability to tailor drugs to the genetic makeup of 
individual patients", can reduce costs in advanced clinical phases in three ways 
(Bhandari et al., 1999, p. 58). First, pharmacogenornics helps to detect toxicity problems 
earlier and therefore reduces the number of compounds to be tested in phases II and III. 
Second, this technology enables a better pre-selection of patients elected for trials, 
which leads to a decrease in the number of patients in late clinical trials . Finally, 
phannacogenomics can also reduce the length of trials. 22 Taken together, genetic 
diagnostics can lead to a reduction of more than 30% in total costs per approved drug 
after accounting for the additional phase I costs related to this technological change. 
Although the two sources explain R&D productivity gains in very different ways, they 
both forecast a significant decrease in the total cost incurred to bring a dmg up to the 
market due to expected gains in R&D productivity. Nevertheless, the total cost esti.mates 
by PricewaterhouseCoopers are over 100% higher than tho se by McKinsey both be fore 
and after expected improvements in R&D productivity are reflected in the development 
cost and attrition rate vectors. 23 
22 We do not directly incorporate this last effect into the duration vector, in order to keep our analysis 
comparable across different data sources. For more details about the effects of genetic diagnostic on 
clinical drug development, see Bhandari et al. (1999), pp. 62-65. 
23 These substantial differences are not unique to the data sources used herein. To illustrate, a U.S.$ 194 
million figure (in 1990 dollars) is reported by the U.S. Congress, Office of Technology Assessment (p. 
72), and a value of about U.S.$ 500 million is reported by the Pharmaceutical Research and 
Manufacturers of America. 
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APPENDIXB 
DESCRIPTION AND COMPARATIVE ANALYSIS OF THE FINANCIAL 
DATA OF CANADIAN AND U.S. PUBLIC FIRMS 
We conducted a comparative analysis of various measures of financial condition and 
performance for samples of Canadian and U.S. biotech firms over the five-year period, 
1996-2000. The initial results for six measures of fmancial condition and performance 
are reported in panels A through F of Table B.1. These measures are total assets, annual 
sales, annual R&D expenses, gross margin (%), return on assets (%) and return on 
common equity (%). In the remainder of this section, we concentrate on the mean and 
median values for the various measures of financial condition and performance. The 
mean provides the average value of each measure for each sample of firms, and the 
median provides the value of each measure for a typical fmn in each sample. 24 
Based on the results for the entire tune period reported in panel A of Table B.1 , the 
mean and median total assets, annual sales, R&D expenses and gross margins are 
significantly lower for the Canadian biotech firms. The mean and median returns on 
total assets and on corrunon equity are negative for both samples of fim1s, and not 
significantly different for the Canadian compared to the U.S. biotech firms. While the 
mean and median total assets, annual sales, R&D expenses and gross margins are lower 
for the Canadian biotech firms, only the differences in their mean values are both lower 
and consistent! y significant for the Canadian biotech fmns on a year-by-year basis. 
To make the comparison more meaningful, we ad just for the smaller average size of the 
biotech firms rn the Canadian sample by restatmg the measures of fmancial condition 
and performance on frrst a per dollar of assets basis, and then a per share basis. The 
results on a per dollar of as sets basis for the en tire period and each of the five years from 
1996 to 2000 are reported in panels A through F, respectively, of Table B.2. 
Over the entire time period, the mean and median sales per dollar of assets are 
significantly smaller for the Canadian biotech firms, and the median R&D expenses 
(book value) per dollar of assets are significantly larger (smaller) for the Canadian 
biotech firms. These results are fairly robust on a year-by-year basis. The major 
exception is the differences in the medians for R&D expenses per dollar of assets that 
have the correct sign but are not al ways significant on a year-by-year basis. 
24 The median a Iso is used because the di stribution of va lues for each measure of financial performance 
and condition is not a lways normal. 
-----------------------------------------------------------------------------------------------------
The results on a per share basis for the entire period and each of the five years from 
1996 to 2000 are reported in panels A tlu·ough F, respectively, of Table B.3. Over the 
entire time period, the mean and median per share total assets and per-share sales are 
significantly lower for the Canadian biotech fmns. While both the mean and median per 
share book values and per share R&D expenses are lower for the Canadian firrns , only 
the differences in their respective medians are statistically significant. While both the 
mean and median earnings per share from operations and cash flows from operations are 
less negative for the Canadian biotech fmns , only the differences in their respective 
medians are statistically significant. These results are not robust given the considerable 
variation in the significance of the differences in the means and medians on a year-by-
year basis . 
We now use regression techniques to examine the possible relationship between various 
measures of fmancial condition and performance stated on a per-share basis and the 
stage of development of the product pipelines of the firms. Since we have the state of 
the pipelines for 1998 and 2000, we run a series of pooled tune-series and cross-
sectional regressions for the Canadian sample of biotech firrns . These results are 
swnmarized in Table B.3. Based on these results, variations in per share total assets, per 
share sales, cost of goods sold, liquidity per share, book value per share, eamings per 
share, retum on assets and return on equity are significantly related to the stage of 
development of product pipelines. With the exception of cost of goods sold, the 
estimated coefficients that are significant are usually those for the nwnber of molecules 
in the la ter stages of the product development pipeline. Interestingly, variations in R&D 
expenses are not significantly related to the development of the number of molecules in 
each stage of the product development pipeline. 
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Please note that: 
APPENDIXC 
INTERVIEW GUIDE 
UQAM Chair in Management of Bio-Industries 
School of Management Sciences 
University of Quebec in Montreal 
Adequacy of Demand and Supply for Capital 
in the Canadian Bio-Industries 
Characterization of Supply 
Interview-Guide 
1. The questionnaire is sponsored by the Chair in Management of Bio-Industries 
(University of Quebec in Montreal) on behalf of Industry Canada and Statistics 
Canada. 
2. The purpose of this questionnaire 1s to characterize the supply of capital for 
Canadian biotechnology finns . 
3. Any information collected by this questimmaire will be treated in a confidential 
mann er. 
4. Y our participation is volnntary. 
Thank you for your cooperation. 
Part 1: General Organization Information 
Na me of the organization: ________________________ _ 
Na me of the interviewee: 
Location: D Canada D United States D Public D Private 
Type of stakeholders: 
D Venture Capitalist 
D Bank/Investment Banker (IPO and Stock Issues Specialists) 
D Alliance/ Acquisition Specialist 
D Capital Market Specialist 
D Institutional Investor And Para-Public Entity 
D Canadian Government Officer (Grants, fiscal and tax credits ... ) 
D Labour-Sponsored Group 
D Other (Specify): 
Financial information as of December 31, 2000: 
• Total capital under management: 
• Source of the funds and Amotmt: 
o Public pension funds _____ _ o Individual investors 
o Private pension funds _____ _ o Foreign investors _____ _ 
o Corporations _____ _ o Government _____ _ 
o Insurance companies _____ _ o Other _____ _ 
o Percentage in venture 
capital: 
• Investment policy 
o Percentage invested in biotech 
firms: 
• Total number of investee biotech companies in the po1tfolio: _____ _ 
o Nwnber of Canadian investee companies in the 
portfolio: 
• Total cast of the investee p01tfolio ($million): 
o Cast with Canadian investee portfolio ($million): 
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Target segment*: 
0 Biopharmaceutical & Biomedical 0 AgroAl Biotech 0 Bioenvironmental 
0 Therapeutics 1 Pharmaceuticals 0 Plant 0 Water 
D Diagnostics D Applied D Soils & Sites Biotechnology 
D Biotechology D Bio-Process D By-products 
D Genornics D Genomics 0 Air 
0 Combinatorial Chernistry D Industrial Bio- D Diagnostic Pro cess Equipment 
D Proteomics 0 Bio-product 0 Other: 
0 Gene therapy D V eterinary 
D Bio-Medical 1 Bio-equipment D Animal 
D Dmg Delivery D Applied Biotechnology 
D Clinical Research D Bio-product 
0 Medical Deviee D V eterinary 
0 Other: 0 Other: 
0 Other 
D Bio-informatics D Chemicals D Resources 
D Forest Products D Nutraceuticals 1 D Energy & Mining Cosmeceuticals 
0 Other: 
• See below for a detailed list of activities and for the Glossary 
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Target biotech companies: 
D Start-ups, early-stage compames (R&D and prototype development; Pre-clinical 
phase & Phase I) 
D Late-stage companies ( companies having made significant progress clinically; Phase 
II & III) 
D Later expansion companies, Nearing market launch (The approval phase and/or in 
the commercialization stage) 
D Publicly traded companies 
D Other (Specify): 
Initial and Follow-on lnvestments in Canadian biotechs as of December 31, 2000 
Investee Investee Stage Total $ Type of Co- $Invested by 
company 
Na me: 
City: 
Prov. : 
Name: 
City: 
Prov.: 
Name: 
City: 
Prov.: 
infonnation deal size Invested financing Investors 
0New D D 
D Follow-on If other If other 
specify: specify: 
D Other 
0New D D 
D Follow-on If other If other 
specify: specify: 
D Other 
0New D D 
If other If other D Follow-on 
specify: specify: 
D Other 
• How many deals are you involved with as a leader? 
• How much will you invest in biotechnology within each of the next 
two years? 
• How much in Canadian biotech firms? 
• What is your eut-off desired rate of return? 
Co-Investors 
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Part II: Information about financing issues and difficulties when investing in the 
Canadian biotechnology sector 
Dimensions 
Issues and difficulties will be handled according to the stage of development and the 
following dimensions : 
1. Type of project to finance 
o Quality science and technology 
o Management team: whether they have had any commercial hits before or not. 
o Intellectual prope1ty: according to the nwnber and the quality of the patents 
the firm may have. 
o Scientific due diligence procedures 
o Major reasons why they do not provide ftmding for a project/stage? 
2. Different perceptions of risk and return 
o Unpredictability ofthe biotech sector 
o Gestation time: time to get products (or drugs) on the market 
o Failure to deliver products to the clinic 
o Failure to reach the critical mass necessary for public funding 
o Did you ever ask for special warrant deals or equity at bargain-basement 
priees before investing in Canadian biotech firms ? 
o What are your goals of return on investment? 
3. Difficulty in valuing biotech firms 
o Evaluation methods of various groups of suppliers: How do they determine 
value? 
o How do their practices differ from other competitors (domestically and/or 
intemationally )? 
o When funding in stages, what are the timing and the amount of each portion? 
4. Level of owner commitment and financial participation in the project 
5. Disclosure of information 
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6. Strategie alliances 1 Mergers & Acquisitions 
o Big brothers: whether the bio tech pattners with a big (or international) 
pharmaceutical company or not. 
o Do you ask companies to pursue Mergers & Acquisitions as a requisite to 
future financing? 
7. Government commitment and/or guarantees for managing risk 
8. Other relevant dimensions 
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Detailed activities for the Bio-Pharmaceutical/ Bio-Medical segment 
Biomaterials 1 Tissue Engineering 
Transplants and implants 
Biomechanics 1 Biophysics 
Bio-equipment /Instrumentation 
Medical imagining 
IVIOOe or aamlnlsiraiion ana susialnea 
release medications 
Radiology 
Other 
Allergy 
Cardiology 1 Angiology 
Cytology 
Dermatology 
Gastroenterology 
Genetics 
Genitourinary 1 STDs 
Gynecology /lnfertility 
Hematology 1 Biochemical analysis 
lmmunology 
lnfectiology 
Metabolism 1 Hormones 
1 Nutraceuticals 1 Cosrneceuticals 
Clinical Research 
Cardiology 1 Angiology 
Dietetics 1 Applied nutrition 
Endocrinology 
Gastroenterology 
Gentitourinary 
Hematology 
Hepatology 
lmmunology 
VOl UIUVO;:)l..tUIOI 1 1""\li iCI U~\,C;IC>I Uùl.:l 1 
Dermatology 
Gastroenterology 
Genitourinary 1 STDs 
Gynecology 1 lnfertility 
Hematology 
lmmunology 
Metabolism 1 Hormones 
Neurology 1 Central nervous system 
129 
Detailed activities for the Bio-Agro-AI segment 
1 tplant 
1 Production 
L_JBiotechnologies 
lîHealth animal 
1 Extraction 1 Manufacturing 
IBioproducts 
1 Technical services and analysis 
Laboratory analysis 1 sampling 
1-- Analys is of risk 1 Toxicology 1 Safety 
1-- Bio-equipment 
~ Suppliers 1 Distributors -Biotechnologies 
1 
1 
1 
1 
1 )Animal 
1 Production 
L_JBiotechnologies 
jîHealth animal 
1 
J 
1 Extraction 1 Manufacturing 1 
IBioproducts 
1 Technical services and analysis 1 
Laboratory analysis 1 sampling 
1-- Analys is of risk 1 Toxicology 1 Safety 
1-- Bio-equipment 
~ Suppliers 1 Distributors -Bio technologies 
Detailed activities for the Bio-Environment segment 
1 (Air 
1 Biotechnologies 
lndustria l bioprocesses 
1-- Environmenta l biotechnologies 
1-- Genetic engineering 
1 
1 
1 Techn ical services and analysis 1 
Laboratory ana lysis 1 sampling 
1-- Analysis of risk 1 Toxicology 1 Safety 
1-- Bio-equipment 
1-- Suppliers 1 Distributors -Biotechnologies 
-
1 (Soil and sites 
1 Biotechnologies 
lndustria l bioprocesses 
- Environmenta l biotechnologies 
- Genetic engineering 
1 
1 
1 Technical services and analysis 1 
Laboratory analysis 1 sampling 
- Analysis of risk 1 Toxicology 1 Safety 
- Bio-equipment 
- Suppliers 1 Distributors -Biotechnologies 
-
1 (Water 
1 Biotechnologies 
lndustria l bioprocesses 
1-- Environmenta l biotechnolog ies 
1-- Genetic engineering 
1 
1 
1 Technical services and analysis 1 
Laboratory analysis 1 sampling 
- Analysis of risk 1 Toxicology 1 Safety 
......_ Bio-equipment 
- Suppliers 1 Distributors -Biotechnologies 
-
1 (By-products 
1 Biotechnologies 
lndustrial biop rocesses 
- Environmenta l biotechnologies 
- Genetic engineering 
1 
1 
1 Technical services and analysis J 
Laboratory analysis 1 sampling 
- Analysis of risk 1 Toxicology 1 Safety 
- Bio-equipment 
- Suppliers 1 Distributors -Biotechnologies 
-
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INTERVIEW GUIDE (CONTINUED) 
GLOSSARY 
1 
r.l o--·--· 1\r; ( ~- :::J:::Jr r _ 
A risk factor includes ali variables statistically 
linked to a studied event. Ali these factors 
Analysis Of Risk constitute risk factors. Their more or less 
marked expression is translated by a 
heterogeneous breakdown of a population's 
exposure to risk. 
1 Anti-infectives 
Drugs used to treat infectious diseases; 
includes antibiotics for bacterial diseases and 
antivirals for viral diseases. 
Application of genetic engineering principles to 
various sectors of exploitation ; e.g., ali 
Applied Biotechnologies techniques using parts of or living organisms to produce varieties that improve plants or animais 
(agri-food and resources) to develop micro-
organisms to trap pollution 
Management and development of the potential 
of aquatic resources and environments for the 
Aquaculture commercial production of animal or plant 
species through mastery of their biological 
cycles. 
Discipline encompassing ali aspects of the 
Bio-informatics acquisition of biological information ; i.e. 
storage, treatment, distribution, analysis, and 
interpretation. 
Use of natural (e.g. coral) or synthetic (non-
organic such as Teflon) materials not rejected 
Bio-materials 1 Tissue Engineering by the human body and without undesirable 
side effects to develop implants, prostheses, 
transplants, orto allow the control led release of 
drugs and components. 
1 Bio-mechanics Modelisation study of musculo-skeletal system and the human body and movement analysis. 
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1 
GLOSS;.\?_ '( 
1 Bio-medical 
That which is directly related to medicine as 
weil as biology. Here, we mean it in the context 
of biomedical engineering; i.e., art of building 
equipment useful in biology and medicine. 
1 Bio-pharmaceutical 
Any substance derived from a gene sequence 
or that is in sorne way related and having 
therapeutic properties. 
1 Bio-producls 
Products manufactured with living cells (plant, 
bacteria, or animal) or their components using 
biotechnological processes. 
Use of living organisms to develop new 
products. Can use whole organisms (yeast and 
Bio-technologies bacteria) or natural substances (enzymes) 
derived from organisms. Described as 
processes and genetic engineering 
Everything referring to harvesting the cells of a 
living organism and growing them in the lab. 
Cellular Culture Animal ce li culture differs from th at of 
microorganisms or bacteria by the media used, 
incubation and cellular passage parameters. 
Clinical research is a medical activity 
concerning hu mans th at ai ms to improve 
knowledge of a disease or treatment. ln 
Clinical Research pharmacology, clinical research is 
characterized by studies of the medication 
given to humans in the context of clinical 
stud ies. 
Asexually producing genetically identical copies 
of genome of a living organism. lncludes both 
Cloning molecular cloning (isolating DNA sequence of 
interest and obtaining multiple copies of it in an 
organism) and cellular cloning. 
Development of tools in arder to help doctors 
evaluate a patient's medical history, the 
Diagnostics symptoms and data of a physical examination 
and other tests to associate them with an 
identified disease. 
1 DNA Probe Molecule, usually a nucleic acid marked with a 
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1 
{.'1 CJ ,_. r-• 1\ r; ' ( 
:..:::J ~ ::.;::..; r f _ 
radioactive isotope, colouring agent, or 
enzyme. Used to find the sequence of a 
specifie gene or nucleotide. 
Transfer of the constituents of the solid or liquid 
Extraction 1 Manufacturing phase into another phase or product. 
lncludes wood products (woodworking 
products, windows, doors, kitchen cupboards, 
Forestry Products floor coverings and mouldings) and pulp and 
paper products (packaging, diapers, glossy 
paper, tissue, and fine paper). 
Method consisting of introducing genetic 
material (genes) into an organism's cells to 
Gene Therapy correct pathological anomaly (mutation, 
alteration .. . ). Often includes introducing a 
normally functioning gene into the cell where 
the existing gene has been altered. 
Overall set of techniques to isolate, sample, 
Genetic Engineering characterize, and transfer genes from one organism to another, i. e. modifying the genetic 
baggage of a cell via genetic manipulation. 
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1 
1 
INTERVIEW-GUIDE (CONTINUED) 
DEVELOPMENT STAGES FOR THE BIO-AGRO-AL AND THE BIO-
ENVIRONMENT SEGMENTS 
~ 
.:.h .!J j 'J:JJ n :.J T o develop and check the the ory or the proven scientific 
knowledge in order to examine in the laboratory whether the 
solution is ready; to make complementary studies concerning 
the technical-economic aspects, engineering, the state of the 
market and to take measurements of the parameters 
connected to the micro-conditions of operation. 
-
3J~ ;.;~rJJJ k~ J J !:.;_J.~J, J J To ensure unfolding , on an average scale, cond itions of 
operation by respecting qualitative and temporal standards 
(to establish the proof of the concept, development of 
prototype, to ensure intellectual protection , to specify the 
competing advantages, to determine the strategy of 
commercial valorization) . 
-· 
.~.J,::Jj J l~J l:J~f ~ !.lJJ :.J To show technological reliabil ity under standard conditions of 
operation . 
- -
_;JI ::;- To offer technology to industrial users (commercial 
~ , JJJJJ 2.-1 ~un~:.El!.JJJ profitability is not yet shown oris not proven); to determine 
the commercial interest although technology cannat be 
economically valuable (technology is in conformity with the 
industrial standards in the plan of rel iabil ity and the 
performance). 
-
c;!.J JJJJJ ;JI!::UJ1~-J!.l' 11 To show that technology is marketable and that it can be 
financially profitable. 
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APPENDIXD 
LIST OF SUPPLIERS INTERVIEWED 
1 1 ;.:.cE;lTlQI J : 
I
Aaron Schwimmer IGoldman, Sachs & Co. Financial Analyst- Globallnvestment 
Research 
r~A-Ie-x-an_d_e_r W- . -M-oo-t-- jseaflower ventures !General Partner 
jAndrea Solari jsanderling i-jc-h-ie-f F- i-na_n_c-ia-1 0- ff- ic_e_r-an_d_P_a_rt-ne_r __ 
.-IB_e_rn_a-rd_C_o_u-pa_l ___ T2C2- Transfer Technologies Commercialization IP .d t 
C .t 1 res1 en ap1a 
i-jB-re_n_d_a-lrw- in ____ jBDC Venture Capital j rD-ir-ec-to_r _________ _ 
jBruce Jackson jPacific Horizon jGeneral Partner 
riC_a_m_e_ro_n_L_. G- ro_o_m_e -~National Bank Financial rln_v_e-st_m_e-nt_B_a-nk- in_g_B_i-ot-ec_h_n-ol-og_y_& __ 
Healthcare 
jchris Ehrlich rln-te-rw-es_t_P_a-rtn-e-rs----------~Senior Associate 
r,C-h-ri-s -La-ir_d ____ jVentures West r,R-e-se- a-rc_h_A_s_s-oc-ia-te ______ _ 
jclaude Camiré jDundee Securities Corporation jBiotech Analyst 
lrC-Ia-u-de-Ve_z_e-au--- ~BioCapita l rA-s-so-c-ia-te-, -V-ic-e--p-re-si-de_n_t-ln-v-es-tm_e_n-ts-
ICosme Ordonez jDLOUHYmerchant j1nvestment Analyst, Drugs & Vaccines 
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